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SUMMARY
The role of transforming growth factors type beta (TGF-p) was investigated 
during murine embryogenesis. There are three known mammalian TGF-p 
genes. The developmental pattern of expression of TGF-p1 RNA has 
previously been elucidated by in situ hybridisation and the localisation of 
TGF-pf protein by immunohistochemistry. Based on this data it has been 
suggested that TGF-pf acts in both a paracrine and autocrine role during 
development. The expression of both TGF-p2 and TGF-p3 RNA has been 
observed in murine embryos by Northern analysis. In order to understand 
the role of these two genes, individually, and in relation with each other, 
the developmental regulation of all three genes was investigated by in situ 
hybridisation using mouse specific probes on serial mouse embryo 
sections from 6.5 days p.c. to 16.5 days p.c.. A comparison was made of 
the data concerning the temporal and spatial expression patterns of TGF- 
p1, TGF-p2 and TGF-p3 RNA, and the role of each gene discussed. The 
pattern of expression of each of the TGF-p RNAs was compared with 
available protein localisation data.
TGF-p2 RNA was found to be expressed in the early embryo, where it was 
localised to the myocardium of the developing heart. This pattern of 
expression persisted, although it was regionally restricted to the 
myocardium overlying the presumptive heart valves. TGF-pi RNA had 
previously been localised to the endothelial cells of the heart valves. It was 
suggested that TGF-p2 was providing the signal which induced the 
endothelial cells, overlying the myocardial tissue of the presumptive heart 
valve, to undergo a epithelial/mesenchymal transformation to form valve 
cushion tissue. TGF-p2 RNA was also expressed in prechondrogenic 
blastemae and growth zones of developing long bones. There was also 
widespread expression of TGF-p2 RNA in epithelial cells, including many 
which were undergoing differentiation. These included the nasal, retinal
and otic epithelium. TGF-p2 RNA was also transiently expressed in ventral 
horns of the neural chord at a time of motor neurone differentiation.
TGF-p3 RNA had a more restricted pattern of expression than TGF-p2. 
TGF-p3 RNA was expressed in intervertebral discs anlagen, cartilaginous 
capsules of the ear and nasal septum. TGF-p3 RNA was also expressed 
in epithelial tissue. The medial edge epithelium of the developing palate 
was an abundant source of TGF-p3 RNA both during and after fusion of 
the palates.
The three TGF-p genes were often expressed in the same developmental 
system, but rarely in the same cell or tissue. The lung develops as simple 
endodermal tubes which are induced to branch distally, the lung expands 
as rapid growth occurs at the terminal end buds and in the surrounding 
lung mesenchyme. The epithelial cells that line the respiratory tubes 
change in morphology at defined points, from a columnar to a simple 
cuboidal shape. The simple cuboida! epithelium eventually becomes more 
flattened in shape, forming the alveolar ducts. The change in epithelial 
morphology is marked by a change in expression from TGF-p3 RNA seen 
in the columnar epithelium to TGF-p2 RNA observed in the simple and 
flattened epithelium. TGF-p1 RNA is expressed in the mesenchyme of the 
lung, and TGF-pf protein has been localised underneath the bronchiolar 
epithelium and at the clefts of the bronchioles. This data suggests there is 
close co-operation between the three TGF-p isoforms during 
morphogenetic events.
The role of the TGF-p genes remains unclear. The interactions of TGF-p 
isoforms with a variety of polypeptides in the ECM has been elucidated 
from in vitro analysis, this data, combined with RNA expression and protein 
localisation data, has not clarified the specific roles of the TGF-p isoforms. 
To determine a complete picture of the role of TGF-p isoforms during 
development, dominant-negative mutations were created and analysed in 
vitro.
The dimeric structure of mature TGF-p isoforms lends itself to the 
production of dominant-negative mutations which can bind to wild-type
monomers of TGF-p, resulting in the formation of heterodimers, which 
reduce biological activity of the selected TGF-p isoform.
Mutations of human TGF-p2 were generated which were sub-cloned into 
the eukaryotic expression vector *H3M and analysed in vitro. The first 
mutant was generated by a deletion of part of the human TGF-p2 cDNA 
sequence which encodes the signal peptide sequence at the N-terminal. 
The second mutation was generated by site-directed mutagenesis of the 
human TGF-p2 cDNA sequence which encodes the proteolytic cleavage 
site. The constructs were transiently transfected into COS-7 cells and the 
conditioned media assayed. The biological activity of the mutant 
constructs were compared to biological activity of constructs which 
contained the wild-type human TGF-p2 cDNA. A reduced level of 
biological activity of mutant proteins was detected by growth inhibition 
assay.
Co-transfections of wild-type TGF-p2 and the mutants were done at 
various ratios to determine if the mutant protein could inhibit wild-type 
activity. Growth inhibition assays showed that the mutants did not reduce 
wild-type levels of biological activity generated by the human TGF-p2 
construct. The mutants were also co-transfected with simian TGF-pl33 ( a 
mutation which requires no acid activation but retains wild-type levels of 
biological activity). The mutants did not reduce the biological activity of the 
simian TGF-pf33 protein.
Note: Some of the data presented in this thesis has been published 
elsewhere. Reprints are bound at the back.
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Chapter 1
INTRODUCTION
1.1 Embryogenesis, pattern formation and cell 
fate.
The study of embryogenesis has been underway for a great many years. 
The first embryologists established fundamental questions which still 
remain to be answered. These questions Include: How do differentiated 
cells arise and form tissues and organs? How do cells know the pattern to 
which they must conform? The emergence of molecular biological 
techniques has provided a variety of tools with which to disassemble the 
detailed events of embryogenesis and possibly provide a means to answer 
these questions.
Many genes have now been identified which have been shown to be active 
during embryogenesis. These include peptide growth factors, the 
homeobox-containing genes, pax genes and retinoic acid receptor genes. 
Homologues of these genes are found in a variety of species which 
diverged, in evolutionary terms, a very long time ago. This seems to 
indicate that whatever function these genes possess it must be very 
fundamental to the organism to ensure survival against evolutionary 
pressures. Melton (1991) suggested that a few types of genes are used 
similarly by diverse organisms to specify cell fates during development.
This project set out to examine the expression of two genes, which are 
members of the transforming growth factor type beta (TGF-p) superfamily, 
during embryogenesis. The relationship between these genes and
members of their immediate family, and the superfamily as a whole will be 
reviewed below.
1.2 Transforming growth factor superfamily
The transforming growth factor type p (TGF-p) superfamily consists of an 
extensive number of proteins that exist in a wide variety of species. These 
proteins are all related, the relationship based upon a number of common 
characterisics.
1. The mature regions of all members of the superfamily maintain a degree 
of homology at the amino acid level which ranges from 40% to 80%. The 
degree of homology that exists at the amino acid level, between the same 
mature protein isoforms, across species can be as high as 99%.
2. Each monomer of the superfamily exists as a mature protein region 
bound to a precursor, the latency associated peptide (LAP).
3. The removal of the precursor by proteolytic cleavage is necessary for 
activation of the mature region.
4. All members exists as homodimers.
There are five sub-groups within the TGF-p superfamily all of which are 
described in the following sections.
1.3 Transforming growth factors type (3
DeLarco and Todaro (1978) reported the isolation of a novel growth factor 
from murine sarcoma virus-transformed mouse fibroblasts, which they 
termed “sarcoma growth factor" (SGF). They described the induction of a 
transformed phenotype in normal rat kidney (NRK) fibroblasts by SGF. 
This resulted in a loss of density-dependent growth inhibition, and 
acquisition of anchorage-independent growth, which led to colony 
formation in soft agar. The effect was immediately reversible upon removal
of the factor. SGF was shown to be distinct from epidermal growth factor 
(EGF), but still competed for the EGF receptor (Todaro et al 1980). Moses 
et al (1981) and Roberts et al (1982) later fractionated SGF into two types. 
Only one of these competed for the EGF receptor. The competing and 
non-competing factors were termed a and (3 respectively. These peptide 
growth factors were renamed “transforming growth factors" (Roberts et al 
1980).
In 1985 Derynck and coworkers cloned the human cDNA for TGF-p, (now 
TGF-p1), and revealed its nature (Derynck et al 1985). The mature protein 
represents only a small carboxy terminal fraction, (112 amino acids) which 
is cleaved from a larger precursor. As expected for a secreted molecule, a 
short signal peptide sequence was present at the N-terminus of the 
precursor. As with all TGF-p-related molecules it exists as a dimer and is 
only activated upon cleavage from the precursor portion of the molecule, 
otherwise it remains inactive.
1.3.1 Structure of TGF-p genes and proteins.
There are three known vertebrate TGF-p genes all of which share common 
features in structure. The human TGF-p1 gene contains seven exons 
(Derynck et al 1987). The splice site junctions are conserved in bovine, 
porcine and murine TGF-p1 genes (Van Obberghen-Schilling et al 1987; 
Kondaiah et al 1989; Derynck et al 1987). The position of the intron/exon 
junctions are conserved in TGF-ps 2 and 3, with the exception of the first 
which differs by three nucleotides, suggesting that the various TGF-ps 
evolved from a common ancestor gene by duplication.
It is now becoming evident that TGF-p4, which was originally isolated from 
chicken DNA library and described by (Jakowlew et al 1988a), does not 
exist. Subsequent attempts, by many laboratories throughout the world, 
have failed to find the homologue in any other species. It was noted that 
the TGF-p4 gene was 2 nucleotides short of porcine TGF-pi. When these 
two nucleotides were taken into consideration the sequence was found to 
be iden tica l to that of porcine TG F-p i (David Burt Personal 
communication). This could be explained by a laboratory mix up, as both 
porcine TGF-p1 and chicken TGF-p4 were cloned in the same laboratory.
Further evidence was established by carrying out a variety of Southern 
blots which indicated that TGF-p4 picked up the same bands as TGF-pi, 
but that this was distinct from the pattern seen with either TGF-p2 or 3. 
Southern analysis carried out on DNA from a variety of species gave 
strength to the argument that chicken TGF-p4 was in fact porcine TGF-p1 
(Marion Dickson personal communication). TGF-p5 has been isolated from 
Xenopus, (Kondaiah et al 1990), however little is known about this member 
of the family.
The mRNAs of the TGF-p genes contain approximately 1200 nucleotides 
of coding sequence, however the mRNA species do vary greatly in length 
which is accounted for by variations in 3’ or 5’ untranslated region (UT) 
length and also by alternative splicing. There is evidence for alternate 
splicing in TGF-p1 and p2. The alternatively spliced TGF-p1 mRNA 
transcripts do not generate novel proteins, but the alternatively spliced 
TGF-p2 mRNA does (Kondaiah et a l 1989; Webb et al 1988). No 
alternatively spliced mRNAs have been identified for TGF-p3.
The three TGF-p proteins contain common features.
1. The translated protein can be divided into two 
regions. The latency associated peptide (LAP) makes up the first two thirds 
of the polypeptide. The last third of the protein is the mature region, which 
has to be cleaved from the LAP to become activated.
2. A short sequence of amino acid residues form a 
cleavage site which separates the precursor LAP region from the mature 
form.
3. The precursor sequence starts with a stretch of 
hydrophobic amino acids that correspond to a signal peptide sequence.
4. Only three cysteine residues are conserved in the 
precursor part of the protein whereas all nine cysteine residues in the 
mature region are conserved between the three TGF-p isoforms.
5. All the proteins contain potential sites for N- 
glycosylation, within the LAP, although these are at different locations only 
one being common to all.
6. Both TGF-pi and p3 contain a potential integrin 
binding site which TGF-p2 lacks.
7. The mature domain of each TGF-p polypeptide is 
highly conserved and each is 112 amino acid residues long. As described, 
there is conservation of all nine cysteine residues and a perfectly matched 
C-terminal sequence.
Denhez et al (1989) suggested that the fact that both TGF-pi and TGF-p3 
have a potential integrin binding site, whereas TGF-p2 does not, could 
indicate that TGF-pi and 3 are more closely related, in functional terms, 
than between either of them and TGF-p2. However, there is still greater 
overall homology between TGF-p2 and TGF-p3 and in most biological 
assays each isoform is interchangeable with only a variation in the degree 
of bioactivity.
1.3.2 Alternative splicing of TGF-p2 mRNA leads to an 
unique protein
The murine TGF-p2 gene can be transcribed to give five mRNA species 
which show different patterns of expression during development (Miller et 
al 1989). TGF-p2’s five different transcript sizes identified by Northern 
analysis were 7.0, 6.0, 5.0, 4.0 and 3.5 Kb (Miller et al 1989) with the 
6.0Kb species predominant. O’Reilly et al (1992) described the same 
number of transcripts for TGF-p2 but the sizes described were different, 
5.8, 5.1, 4.0, 3.8 and 2.8Kb. Again the second largest transcript (5.1 kb) 
was predominant. (The difference in size of transcripts described by these 
two groups probably reflects difference in the interpretation of Northern 
blots rather than any genuine difference in transcript size.) Four of the five 
aforementioned transcripts are generated by variation in polyadenylation 
length and give rise to identical proteins, however TGF-p2 is known to 
produce a transcript via alternative splicing, which results in a protein of 
different length (Webb eta! 1988).
Simian and human cDNA clones of TGF-(52 revealed the existence of two 
types of TGF-p2 precursor. One would give rise to the expected 414 amino 
acid protein, the other would give rise to a 442 amino acid long protein, 
which were called TGF-p2:414 and TGF-|52:442 respectively. Webb et al 
(1988) described TGF-(32:442 as having an insertion of 84 bp at the 
Asn-116 codon of TGF-p2:414, which codes for an additional 28 amino 
acids. Comparison of the coding sequences is identical apart from this 
insertion. Webb and colleagues suggested that this could only arrive via 
alternative splicing rather than transcription from a new gene. Further 
analysis of the sequence around the splice-site junctions indicates that this 
short 84 bp fragment is indeed an exon in its own right. Whether TGF- 
p2:442 is differentially expressed was resolved when cells from human 
prostatic adenocarcinoma (PC-3) and a monkey cell line (BSC-40) were 
analysed. The 4.1, 5.1 and 6.5Kb mRNA species were found to be 
expressed in the PC-3 cell line whereas the BSC-40 line only expressed 
the 4.1 and 6.5 Kb mRNAs (de Martin et al 1987). The use of a probe 
based upon the short 84bp sequence showed that the 5.1Kb mRNA 
species encoded the larger precursor. TGF-p2:414 would then be encoded 
by either the 4.1 or 6.5 Kb mRNA species (Webb et al 1988). This 
suggested that there may be tissue specific expression of the exon 
containing the 84bp fragment. Recent data has indicated that there is no 
difference in expression pattern between the mRNA coding for TGF-p2:414 
and TGF-p2:442 in human embryos (Marion Dickson personal 
communication).
TGF-p3 has been cloned from a variety of species including human, 
mouse, chicken and pig (ten Dijke et al 1988; Derynck et al 1988; 
Jakowlew et al 1988b). The mouse cDNA hybridises to a unique 3.5 Kb 
mRNA and is differentially expressed in various mouse organs and 
developmental stages (Denhez et al 1990; Miller et al 1989; Millan et al 
1991; Schmid et al 1991; Fitzpatrick et al 1990; Gatherer et al 1990; Pefton 
et al 1990). At present no other transcript size of TGF-p3 mRNA has been 
reported although alternatively transcribed, or spliced species, cannot be 
ruled out. The mouse TGF-p3 coding region is 1230 nucleotides long and 
codes for a 410 amino acid protein very similar to its human counterpart 
(Derynck et al 1988).
1.3.3 TGF-p gene promoters
It is quite clear that TGF-p gene expression is regulated during 
development and in vitro. The variety of actions attributed to TGF-p 
isoforms have made it important to understand the mechanism by which 
gene expression is controlled, especially during embryogenesis when cell 
fates are being determined.
The three TGF-p gene promoters have all been isolated (Kim et al 1989; 
Lafyatis et al 1990; Noma et al 1991) (Figure 1). Despite high sequence 
homology between the three isoforms in the region of the mature proteins, 
there is no similarity in the promoter regions. However, there is striking 
homology between promoters of the same gene across species which 
implies that the evolutionary pressure on the sequences has been high. 
This is consistent with studies in the mouse and human, which 
demonstrate that the three TGF-p genes do have different patterns of 
expression, both spatially and temporally, during embryogenesis, but that 
these gene expression patterns are maintained across species (Pelton et 
al 1989; Gatherer et al 1990; Millan et al 1991; Schmid et al 1991).
1.3.4 TGF-pi promoter
Kim et al (1989) investigated the promoter activity of human TGF-pi. The 
analysis of the sequence upstream of the initiation site was carried out by 
generating chimaeric genes containing the bacterial reporter gene, 
chloramphenicol transferase (CAT), and variable regions of 5’ flanking 
DNA. They were able to describe five distinct regulatory regions. These 
included a region having enhancer-like activity, two regions with negative 
regulatory activity and two different promoter regions. From analysis of 
CAT activity it is clear that the negative regulatory regions strongly repress 
the potential transcriptional activity. Kim and coworkers demonstrated that 
deletion of the enhancer region prevented the transcriptional activity of the 
upstream TGF-p1 promoter. They concluded that at least 453 bp upstream 
from the first transcription site was required for maximum expression of the 
hybrid gene. A number of consensus sequences were also found in the 
promoter region. These included several CCGCCC motifs in a repeat, 
some in reverse orientation. It is known that removal of such repeats from
Figure 1. Comparison of the 5* untranslated regions of the three human TGF-8 genes.
The major transcription factor binding sites are indicated, transcription starts from arrows 
above the sequence. The TGF-B1 promoter lacks the conventional TATA box. In the 
TGF-B2 promoter the AP-1 she appears not tobe functional; the existence of a second 
transcriptional start is suggested by indirect evidenoe regarding the size of various TGF-02 
transcripts. The SP-1 sites in the TGF-B1 and TGF-B3 promoters and the CRE sites in 
the TGF-B2 and 3 promoter have been demonstrated to be essential for transcription.
Not drawn to scale.
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the SV40 early promoter has a detrimental effect on transcription, the motif 
is known to bind the SP-1 transcription factor (Fromm and Berg 1982). 
TGF-(31 promoter also contains a sequence which can bind NF-1, at sites 
-267 to -254, although in a reverse orientation to that described by 
(Nagata et al 1983). Akhurst et al (1988) have described the induction of 
TGF-p 1 by TPA. Two 7 base pair (bp) AP-1 sequences were found that 
are highly homologous to a common sequence found in the promoter 
region of several genes responsive to TPk. TGF-pi does not possess the 
conventional TATA box.
1.3.5 TGF-p2 promoter
TGF-p2 protein is encoded by multiple mRNA transcripts (5.8, 5.1,4.0, 3.8, 
and 2.8kb) that are expressed in a variety of cells. Some of the size 
differences are due to variation in length of the 5’ untranslated region. The 
human TGF-p2 promoter region has recently been cloned independently 
by jMalipiero eta! 1990; Noma efa/1991). Both reported sequences within 
the upstream region which are found in many promoters. They also 
reported some features unique to cytokine genes. Neither the promoter 
region of TGF-pi nor TGF-p3 (described after this section) had any 
homology with the promoter region of TGF-p2. Noma et al determined the 
requirement for promotional activity by generating chimaeric constructs 
with the CAT gene. They showed that sequences capable of directing a 
high level of activity were contained up to -525 bp from the transcriptional 
start site. Several CRE like elements as well as AP-1, AP-2 and SP1 
elements and a 50 nucleotide region characteristic of Z-DNA have also 
been identified (Noma efa/1991).
Multiple transcription initiation sites for TGF-p2 have also been identified 
(O’Reilly et al 1992). Transcription from one of these sites was dependent 
upon a CRE/ATF like element located 5’ of the TATA box. Although the 
CRE/ATF like element deviated from the consensus sequence it was 
shown to be critical for promoter activity based upon point mutation 
analysis and the ability to form DNA-protein complex in a gel mobility shift 
assay. O’Reilly and coworkers also described different promotional activity 
in a variety of cell types, based on the use of sequences from -778 to -257 
of the transcription start site. They argued that since the cells were from
different tissues then the DNA between -778 and -257 may contain tissue 
specific regulatory sequences.
1.3.6 TGF-p3 promoter
Lafyatis e ta l (1990) cloned the 5’ untranslated region of human TGF-p3 in 
an attempt to define the structure of the promoter. They showed that a 
TATA box existed 21 bp upstream of the putative transcription start site. 18 
bp further upstream a consensus sequence for a CRE/ATF binding site 
was found. Immediately adjacent to this sequence, an AP 2 binding site 
was discovered. Three SP-1 sites were found at -358, -415 and -694 bp. 
The character of the 5’ untranslated region of TGF-p3 was determined by 
the use of chimeric CAT constructs. This once again demonstrated that, as 
in TGF-pi and TGF-p2, there were regions which could either up-regulate 
or down-regulate promoter activity (Lafyatis et a l 1990). They 
demonstrated that the CRE modulated both basal and cAMP-inducible 
activity of the promoter. The fact that the CRE element was in close 
proximity to the TATA box was suggestive of the role of these two sites in 
the formation of a pre-initiation complex which had been previously 
described (Horikoshi et al 1988). The presence of the AP-2 site could be 
important due to the knowledge that retinoic acid increases expression of 
the AP-2 gene. This suggests that retinoic acid may play a role in 
regulating TGF-p3 during embryogenesis via the AP-2 site.
1.3.7 Latency of TGF-p
Most cells grown in vitro are known to secrete TGF-p in an inactive form 
(Delarco et al 1981; Moses et al 1981; Tucker et al 1983). It was 
demonstrated that treatment of conditioned media with acid (pH 3.6), 
followed by neutralisation, activated TGF-p as determined by anchorage- 
independent growth of NRK-49F cells (Pircher et al 1984). However it 
seems fairly unlikely that this is the favoured method of activation in vivo. 
Lyons et al (1988) pursued the mode of physiological activation further by 
investigating the effects of various proteases on latent TGF-p. By analysis 
of the effect of plasmin-treated conditioned media on anchorage- 
independent growth of NRK-49F cells, they were able to speculate that 
activation of latent TGF-p may take place by dissociation, or proteolytic
cleavage, from a precursor molecule or hypothetical TGF-p-binding protein 
(TGF-p-BP).
TGF-p1 is secreted from cells as a latent complex of high molecular 
weight. Since TGF-pi is found universally in vitro, it is thought that 
activation of the latent complex may be a crucial step in the role of TGF-pi. 
Much of the work that has examined the latent complexes of the TGF-ps 
has revolved around TGF-pi. Although it is known that both TGF-p2 and 
TGF-p3 are produced in latent forms, and both can be activated, in vitro, in 
a similar manner described for TGF-pi. The structural characteristics of 
these forms remains unknown. The structure of both TGF-p2 and TGF-p3 
proteins are fully characterised and do closely resemble that of TGF-p1, 
but it is possibly premature, to suggest that what we understand of the 
TGF-p1 latency complex applies in an identical manner in both TGF-p2 or 
p3 (Figure 2).
Miyazono et al (1991) analysed the large latent complex from mature 
platelets which consists of three components. The mature TGF-pi is a 
covalently associated dimer, which is non-covalently associated with a 
disulphide-bonded dimer of the N-terminal remnant of the TGF-p1 
precursor, known as the TGF-pi-latency associated peptide (LAP) (Gentry 
et al 1987). The third element of the large latent complex is the latent 
TGF-pi-binding protein (LTBP). It has been shown that LTBP is not a 
requirement for TGF-p latency, since transfection of Chinese hamster 
ovary cells with TGF-pi precursor cDNA yielded a latent TGF-p1 molecule 
without LTBP. It is understood that the LAP is sufficient to confer latency 
on the TGF-pi molecule. The complex which consists only of the LAP and 
TGF-p1 mature region is termed the “small latent complex" (Wakefield, 
1989; Miyazono efa/1991).
Kanzaki et al (1990) cloned the cDNA coding for LTBP. Initially they 
purified LTBP from human platelets, and although attempts to sequence 
the N-terminal portion of the protein failed, indicating that the protein was 
blocked, sequence data was derived after the protein had been cleaved 
with proteases. Of 27 peptides sequenced, 22 showed similarity to EGF. 
They also found that several contained the consensus sequence for p- 
hydroxylation of asparagine/aspartic residues. These sequences are often
Figure 2. TGF-B exists as a homodimer. The latency associated peptide is covalently 
bound to the mature peptide region. At the N-terminal end of the latency associated 
peptide is a signal sequence. The two monomers are bound to each other by disulphide 
bonds. The mature peptide is cleaved from the latency associated peptide at a cleavage 
recognition site. Inter-subunit disulphide bonds link the mature region to the latency 
associated peptide and prevent It's activation. The mature peptide of TGF-B Is not active 
until released from the latency associated peptide which can be done in vitro by low pH 
or heat. The latent TGF-B binding protein is linked to the latency associated peptide. It's 
exact role is unclear as it is not required for latency. B2-macroglobulin is thought to mop 
up active mature TGF-B.
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found in vitamin K-dependent proteins involved in blood coagulation. 
Although there are many proteins known to have hydroxylated 
asparagines, the exact nature of their function is still unclear, it is thought 
that they may play a role in Ca2+ binding. Kanzaki et al (1990) also 
demonstrated that LTBP does not bind nor inactivate mature TGF-pi. 
Incubation of LTBP with 125l-labelled mature TGF-p1, followed by 
immunoprecipitation of the mixture with a TGF-p1 antibody, resulted in no 
observed binding by LTBP to the labelled mature TGF-pi. However, the 
labelled mature TGF-pi was found to be cross-linked with the large latent 
complex. They suggested that this meant that in the large latent complex 
LTBP is located close to mature TGF-p1 but that LTBP in free form has no 
affinity for mature TGF-pi. They also suggested that if LTBP were to have 
a role in in keeping mature TGF-pi latent it would be expected to interfere 
with the binding of mature TGF-pi to cell surface receptors. Upon 
investigation, they were able to demonstrate that LTBP had no effect on 
the binding of labelled mature TGF-pi to the cell surface receptors. This 
was compatible with th e ir  conclusion that LTBP does not bind and 
inactivate mature TGF-pi.
The role of carbohydrate stuctures in the latency of TGF-p have been 
assessed (Miyazono and Heldin, 1989; Sha eta! 1989). Although mature 
TGF-pi does not have any carbohydrate structures associated directly with 
it, both LAP and LTBP do. The LAP has three potential giycosylation sites, 
all of which are thought to be used (Miyazono and Heldin, 1989; Sha etal
1989). Treatment of LAP with endoglycosidase F leads to a dose- 
dependent activation of TGF-pi (Miyazono and Heldin, 1989). Miyazono et 
al (1991) suggested that LTBP plays a critical role in the assembly and 
secretion of latent TGF-pi. Using pulse-chase experiments with labelled 
TGF-pi they were able to follow the synthesis and secretion of the various 
forms of latent TGF-pi. They found that within 15 minutes of Initiation of 
TGF-pi synthesis, LTBP became associated with TGF-pi, and within 30 
minutes this structure had been secreted. They also found that TGF-pi 
which had not bound to LTBP was localised within the cell and was only 
secreted extremely slowly. Furthermore, the results of partial tryptic 
digestion suggested that this unattached TGF-pi molecule contained 
inappropriate disulphide bonding.
O’Connor and Wakefield (1987) described a latent form of TGF-pi which 
was in a complex with c^-microglobulin found in serum. They proposed 
that this complex may be a method by which excess TGF-pi Is scavenged 
from the serum, possibly to restrict action of active TGF-pi.
Brunner et al (1989) demonstrated that by changing cysteine residues 
present in TGF-pi it is possible to produce molecules which require no 
modifications to become active. By the use of site directed mutagenesis 
they changed two cysteine residues (Cys223 and Cys225) to serine 
residues. When the construct containing these mutations was transfected 
into cells, only monomeric precursor proteins were expressed which 
released bioactive TGF-pi that did not require acid activation. They 
suggested that dimerisation of the precursor pro-region may be necessary 
for latency.
1.4 TGF-|3 receptors
The first TGF-p receptor to be identified, by ligand-directed radioactive 
labelling, was a high molecular weight proteoglycan which was found in 
great abundance in many cell types (Massague and Like, 1985). Since 
then six receptors which bind TGF-ps have been described: types I and II 
(Laiho et al 1990; Frolik et al 1984; Cheifetz et al 1990; Lin et al 1992), 
type III (p-glycan) (Massague and Like, 1985; Lopez-Casillas eta! 1991; 
Wang et al 1991), type IV (Cheifetz et al 1988a), and type V (O’Grady et al 
1991).
The sixth and seventh TGF-p receptors have recently been identified 
(MacKay and Danielpour, 1991). They have been found on a variety of cell 
lines and have distinct molecular weights of 150kDa and 180 kDa. They 
have had no function attributed to them so far.
Receptors Type I,II and III have, been found in all cells examined, except 
for cells derived from retinoblastomas, which lack all three. The lack of 
receptors in these tumour cells is thought to play a specific role in the 
progression of this particular cancer (Kimchi et al 1988). Receptor type IV 
Is limited to cells from a pituitary tumour cell line and is a special case in
itself as It is the only type of receptor which cross hybridises with other 
members of the TGF-p superfamily (e.g. activin). Receptor type V was 
purified from plasma membranes of bovine liver. The 400kDa receptor has 
been identified on cultured cells, including cells reported to lack the type III 
receptor (O’Grady et al 1991). It should maybe be noted that no cell line 
has been found which responds to TGF-p without having at least one type 
of TGF-p receptor present. Receptors Types I, II, and III are best 
characterised so far.
1.4.1 Type I receptor
Type 1 receptor is the smallest at 53 kD (Cheifetz et al 1990). The receptor 
binds TGF-pi with a higher affinity than TGF-p2, whether TGF-p3 binds to 
this receptor is not known. About 8% of type I receptors have N-linked 
carbohydrates. This carbohydrate moiety is not required for integration of 
the receptor into the cell membrane nor is it required for ligand binding. 
However binding stability may be reduced if It is not present since the 
absolute labelling intensity of type I receptor is reduced in response to the 
inhibitor of co-translational glycosylation, tunimycin (Cheifetz and 
Massague, 1989). There are approximately 300 to 4000 type I receptor 
binding sites per cell on the cell surface which is in contrast to the type III 
receptor which has 10,000 sites per cell.
1.4.2 Type II receptor
Type II receptor is an 83kDa protein previously described due to Its ability 
to bind radioiabelled TGF-p (Segarini eta11989). The type II receptor was 
recently cloned (Lin et al 1992). Analysis of the cDNA t  > predicted that 
the type II receptor would possess cysteine rich extracellular domain, a 
single hydrophobic transmembrane domain, and a cytoplasmic 
serine/threonine kinase domain. Lin and co-workers demonstrated that the 
serine/threonine kinase domain was functional, which implicates 
serineAhreonine phosphorylation as an important mechanism of TGF-p 
receptor-mediated signalling. The type II receptor is related to two other 
serine/threonine kinase receptors. One is an activin receptor the other, 
daf-1, is found in C. elegans. Based on this fact Lin et al (1992) predicted
that the ligand for the daf-1 receptor will be a member of the TGF-p 
superfamily.
1.4.3 Type III receptor (p-glycan)
Receptor type III or p-glycan is an integral membrane proteoglycan, 
approximately 200 kD in size (Cheifetz et al 1988b). It is bound by either 
TGF-pi or p2 with equal affinity. Type III also has the distinction of being 
able to bind a heterodimer composed of monomers of TGF-pi and TGF- 
p2. Receptor type III was “expression clonecT very recently (Wang et al 
1991). They determined that the gene coded for an 853 amino acid protein 
with a large N-terminal extracellular domain, containing at least one site for 
glycosaminoglycan addition, a single hydrophobic transmembrane portion 
and a 41 amino acid cytoplasmic tail with no obvious signalling motif. Wang 
et al (1991) demonstrated that overexpression of type III receptor in the L6 
myoblast cell line, which lacks endogenous type III receptor, leads to an 
increase in amount of ligand bound, and cross-linked, to surface type II 
receptors. They suggested that this indicated the regulation of ligand 
binding ability or surface expression of type II receptor by type III receptor. 
The lack of an obvious signalling motif plus the control over type II receptor 
suggests that the type III receptor might function in an entirely different role 
than either type I or type II.
1.4.4 Type IV receptor and others
Type IV receptor was isolated from rat pituitary tumour and is unique 
amongst TGF-p receptors due to its ability to bind activin and inhibin as 
well as TGF-ps (Cheifetz et al 1988a). Type IV receptor was isolated from 
plasma membranes of bovine liver. The 400kDa non-proteoglycan receptor 
was also found on cells, In vitro, that had no type III receptor present. It 
also showed equal specificty for TGF-pi and TGF-p2. The latest two 
receptors for the TGF-ps have been isloated from a variety of cell lines. 
The 150 and 180kDa glycoproteins were found to only bind TGF-pi and 
did not bind TGF-p2 (MacKay and Danielpour, 1991). The role of these 
other receptors has not, as yet, been defined. MacKay and Danielpour 
suggested that the 150 nand 180 kDa receptors may be involved in
maintaining a pool of TGF-pi, or may be involved in the presentation of 
TGF-pi to other receptors.
None of the receptors type I, II and III described above bind the latent form 
of TGF-ps, which is probably a mechanism by which binding is prevented 
from occuring in the golgi bodies during the production and excretion of the 
molecules (Fanger et al 1986). The affinity of TGF-p3 binding has not been 
determined, as thoroughly as for that of TGF-pi and p2, for the receptors 
in many cell types but it is already known that TGF-p3 has a variety of 
effects on cells which probably reflects the binding affinity of TGF-p3 to 
these receptors, or other specific receptor(s), not yet identified.
1.4.5 Receptors modes of action
The multifarious effects of TGF-ps on cells is fairly well established (see 
section 1.6). However, it is still unclear as to how the TGF-p receptors 
mediate their response. It has been suggested that type I and type li 
receptors are involved in signal transduction (Laiho eta! 1990). Laiho et al 
(1990) based their suggestion on the evidence gained from analysing two 
mutant mink lung epithelial cell lines (MvlLu). The first mutant had a 
normal profile of receptors type I, II and III but had lost the normal growth 
inhibitory response to TGF-ps (mutant S). The second class of mutants 
were also resistant to TGF-ps but they had selectively lost functional 
expression of receptor type I (mutant R). The lack of type I receptor and 
the phenotype of mutant R cells, in combination, led Laiho and co-workers 
to suggest that it was involved in trans-membrane signalling whereas the S 
mutants were suggestive of defects in some central component of the 
TGF-p transduction system. Laiho et al (1991) demonstrated the ability of 
the MvlLu cell mutants to be rescued by the formation of hybrids 
expressing the wild type receptors. Full responsiveness to TGF-p was 
produced as measured by inhibition of DNA synthesis, as well as 
stimulation of fibronectin and PAI-1 production. Their results suggested that 
R mutants may encode a normal type I receptor whose functional 
expression is rescued by the presence of a normal type II receptor 
provided by R cells in the hybrids. Their results provided evidence for an 
interaction between TGF-p receptor types I and II. They also demonstrated
th a t, in Mv1 Lu cells, expression of both receptor types is required for 
mediation of biological responses to TGF-p1.
It has been proposed that cell surface proteoglycans may function as 
anchors for extracellular matrix molecules such as fibronectin and 
collagen, or as receptors for circulating molecules. This could implicate 
type III receptor as a port for activated TGF-ps thus removing it from 
circulation (Cheifetz et al 1988b). Induction of cell adhesion protein 
expression is an action of all TGF-p isoforms, and it has been suggested 
that this operates via the type III receptor based on the fact that this 
receptor binds to all TGF-ps equally well (Cheifetz eta! 1988b).
Cheifetz et al (1990) showed that the same receptors and signalling 
pathways were utilised by TGF-p3, as by TGF-p2 and TGF-p1, at least in 
one cell line. Using one of the mutant MvlLu cell lines previously 
described, it was noted that, none of the three isoforms could inhibit the 
growth of the cells. They concluded that TGF-p3 did not have its own 
receptor/signalling pathway in this cell type. Although all three TGF-p 
isoforms inhibited growth in the parental MvlLu cell line, with similar 
concentrations producing a half maximal effect, there was still a 10 fold 
difference in receptor binding between the three isoforms, which could be 
physiologically important (Cheifetz et al 1990).
An important question, which arose from the investigations described 
above, is the apparent paradox observed in MvlLu cells. These cells are 
growth inhibited to an equal extent by each TGF-p, but it is clear that TGF- 
p2 binds less avidly than either TGF-pi or TGF-p3 to the available 
receptors (Cheifetz et al 1990). How could TGF-p2 act via these receptors 
if its ability to bind them is much lower than that of either TGF-pi or p3? 
This question was answered by identification of a subset of types I and II 
receptors which had high affinity for TGF-p2. The ability of TGF-p isoforms 
to compete with radioligands of TGF-p1 and TGF-p2 was examined. It was 
noted that although TGF-p3 and TGF-pi competed successfully for binding 
with the type I receptor, at a concentration of 10pM, TGF-p2 minimally 
effected the binding of radiolabelled TGF-pi to type I receptor, even when 
at high concentration (500pM). The same was true for the type II receptor, 
except that TGF-p3 had half the potency of TGF-pi. However TGF-p2 did
compete successfully against radiolabelled TGF-p2. Both TGF-pi and p3 
competed strongly for this apparent subset of high affinity receptors.
The combination of different TGF-ps binding a variety of receptors on a 
single cell multiplies the complexity of the effect of TGF-ps on the cell. It is 
therefore vital to elucidate the consequences to the cell after TGF-ps have 
bound to the receptor, and whether the combinations of receptor binding 
do affect the cell in a contrary way. Wakefield, (1987) demonstrated that 
binding of TGF-p to various cell types was not altered by heterologous 
agents which are known to effect the cellular response of TGF-p. These 
included EGF and PDGF, which are required for TGF-p to induce colony 
formation in soft agar. They demonstrated that EGF and PDGF caused a 
20% and 0% reduction in binding, of TGF-p to receptors, respectively. 
Based on this evidence they suggested that modulation of TGF-p binding 
to its receptor may not be a primary control mechanism in TGF-p action.
1.5 Members of the TGF-|3 superfamily
There are five other gene sub-groups which are related to TGF-ps and 
each other, by dint of homology, at the amino acid sequence of the mature 
coding region.
1.5.1 Mullerian Inhibiting Substance
During male embryogenesis, the Mullerian duct, which would develop into 
the female reproductive tracts, regresses. Although testosterone, produced 
later in male sexual development, is responsible for the differentiation of 
the vas deferens, seminal vesicles and epididymus from the Wolffian duct, 
complete male sexual development is not possible without the regression 
of the Mullerian duct. The existence of a Mullerian inhibitory substance 
(MIS) was postulated to explain the phenomenon of Freemartin calves 
which are masculinised females of a heterosexual twin pair, whose 
Mullerian ducts have been obliterated (Lillie, 1916). It wasn’t until over half 
a century later, that MIS was isolated and shown to be localised to the 
Sertoli cells of the testis (Josso, 1992; Blanchard and Josso, 1974) and 
was found to exist in the calf testis some considerable time after birth
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(Donahoe et al 1977). MIS not only has a role in development but has 
been demonstrated to inhibit growth of tumours derived from tissues 
related to the Mullerian duct (Donahoe et al 1979; Fuller et al 1982).
MIS is thought to be a dimer of disulphide linked subunits with a total 
molecular weight of 140kDa (Budzik et al 1983). The dimer is made up of 
two monomeric units which differ slightly in molecular weight (70kDa and 
74kDa). Cate et al (1986) suggested that the smaller polypeptide is a 
proteolytic product of the larger polypeptide, or that they undergo different 
forms of post-translational modification. Since the molecular weight of 
mature MIS protein is deduced to be 58kDa from the amino acid sequence 
it is obvious that MIS undergoes extreme post-translational modification.
A comparison of the bovine and human MIS protein shows a remarkable 
degree of homology (78%) with 108 of the last 112 amino acids being 
conserved. The conserved C-terminal region is a distinct domain with 
significant homology to the mature forms of the TGF-ps.
1.5.2 Decapentaplegic-Vgr related group
The decapentaplegic-Vgr related group (DVR) is an amalgamation of the 
bone morphogenetic proteins, the Xenopus Vg gene, and the mammalian 
homologue Vgr-1, plus the drosophila gene dpp. Previously these 
members of the TGF-p superfamily were considered distinct, recently 
(Lyons and Moses, 1990) has suggested grouping them together as they 
are more closely related to each other than to other members of the TGF-p 
superfamily.
1.5.2.1 Decapentaplegic gene
The Drosophila gene, decapentaplegic (dpp), cloned by Padgett et al 
(1987) is a member of the TGF-p superfamily. The C-terminal 110 amino 
acids of the dpp polypeptide show extensive similarity to the comparable 
regions of the vertebrate TGF-p family members. The dpp polypeptide 
contains seven of the nine cysteine residues conserved in the C-terminal 
region as well as three arginine-arginine dipeptides which are the potential 
site of proteolytic cleavage (Gelbart 1989). An analysis of amino acid
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homology shows that mammalian BMP-2A and BMP 2B are very strong 
candidates for vertebrate analogues of dpp (Gelbart, 1989). It seems that 
the presence of a transforming growth factor-p-related-molecule, dpp, can 
specify the positional fate of cells through the regulation of homeotic genes 
in Drosophila. Panganiban et al (1990) demonstrated that dpp can regulate 
homeotic genes lab and Scr. Reuter et al (1990) also demonstrated that 
dpp, itself, is regulated by two homeotic genes, Ubxand abd-A.
Panganiban et a! (1990) associated three responses during the 
development of the Drosophila midgut that involve homeotic gene 
expression.
The development of the midgut of Drosophila involves the migration and 
stretching of cells in two distinct germ layers to enclose the yolk. The 
double walled tube is then compartmentalised into four morphologically 
distinct chambers and four caeca. The four chambers of the midgut are 
created when three constrictions form at specific positions along the length 
of the migut. The caeca are formed as buds from the anterior end of the 
midgut (described in Panganiban et a /1990).
Four homeotic genes are expressed, in a non-overlapping manner, in the 
developing midgut Scr, Antp, Ubx and abdA. The absence of Scr results in 
abnormal caeca development. The lack of the other three homeotic genes, 
Antp, Ubx, and abdA results in no development of the first, second, 
and third constrictions respectively.
The expression of dpp in the visceral mesoderm of the developing midgut 
makes it an ideal candidate for the participation in the control of midgut 
development.
Expression of both dpp and the homeobox gene Ubx is required for 
development of the midgut. These two genes positively regulate the 
expression of each other. In the absence of Ubx, dpp expression is 
reduced, also the level of expression of dpp is conditional on which Ubx 
allele is present and the lack of dpp causes a reduction in the level of Ubx 
expression, dpp polypeptide was noted to migrate from the visceral 
mesoderm across the endoderm and was thought to induce the expression
of the lab gene in the endoderm cells (Panganiban etal 1990; Reuter etaI 
1990).
Panganiban etal (1990) suggested that the significance of these regulatory 
relationships to morphogenesis by dpp is best indicated by the fact that 
mutations in dpp alter the same structures in the midgut of the Drosophila 
which are affected by mutations in two of the homeotic genes regulated by 
dpp. That dpp functions as a secreted molecule, similar to TGF-p, is 
illustrated by its negative regulatiop of a third homeotic gene, Scr, across 
germ layers. dppshv mutants, a series of mutations that affect 5’ 
regulatory sequences that result in embryos with normal dorsal-ventral 
polarity but which cannot survive beyond larval stages, due to mutations in 
internal organs (originally described by (Segal and Gelbart, 1985). The 
domain of the homeobox gene Sc/'s expression is extended anteriorly to 
include those cells that normally express dpp. The ectopic expression of 
Scr in these cells may prevent them from evaginating as caeca. 
Alternatively, ectopic Scr expression by itself may not be sufficient to block 
development of the caeca but may serve as an indicator that the cell fate at 
the anterior end of the midgut is changed in the absence of dpp. The actual 
mechanism by which the suppression of Scr occurs still remains to be 
determined (Reuter etal 1990).
This example of a member of the TGF-p superfamily reciprocally 
interacting with a homeobox gene during development may be significant 
in terms of the general role played by TGF-ps in cell fate and patterning in 
vertebrate embryogenesis.
1.5.2.2 Bone Morphogenetic proteins
Many growth factors have been implicated in bone growth and repair. 
Fibroblast growth factor (FGF), TGF-p and platelet-derived growth factor 
(PDGF) have been found in bone, and have been shown to have 
multifarious effects on bone and cartilage cells in vitro . However none 
have been shown to induce cartilage or bone formation in vivo. Urist (1965) 
demonstrated that extracts from demineralised bone, if implanted into 
ectopic sites in rodents, could induce new bone to form. Mesenchymal 
cells invaded the implant and were observed to differentiate into cartilage-
forming cells. Bone cells then appeared at the site. These were 
responsible for the gradual removal of cartilage and the deposition of new 
bone in its place. The active component in the bone extract was identified 
as being of protein in nature and named bone morphogenetic protein 
(BMP). It was still unclear as to whether this effect could be attributed to 
just one protein or a combination of many, acting concordantly.
In 1988 Wozney and colleagues cloned four human BMP cDNAs (BMP 1, 
BMP 2A, BMP 2B and BMP 3) (Wozney et al 1988). It was shown that 
three of the BMP’s (BMP 2A, 2B and 3) were related to members of the 
TGF-|3 superfamily of proteins based on their extensive homology at the 
protein level with the dpp gene product. Comparison of BMP 1 with other 
known sequences led Wozney et al (1988) to speculate that it was a novel 
unrelated protein and will therefore be discussed no further. Recently a 
further three BMPs have been isolated but as yet, like there immediate 
relatives, little is known about their expression patterns or role during 
embryogenesis.
Each of the BMP’s tested in vivo induced cartilage formation. Interestingly 
neither TGF-pi nor TGF-p2 were able to induce cartilage formation in vivo. 
Despite the fact that both were originally isolated as molecules which 
induce formation of cartilage specific molecules by fibroblasts in vitro 
(Seyedin efa/1986).
The expression pattern of BMP-2 RNA has been described (Lyons et al 
1990). A number of sites of expression of this gene overlap with 
expression patterns described for other TGF-p superfamily expression 
patterns. The potential for coordinated interaction between various 
members of the TGF-p superfamily will be discussed later.
1.5.2.3 Vg1 and related proteins
Weeks and Melton (1987) reported that Vg1, a maternal mRNA isolated on 
the basis that it is localised to the vegetal hemisphere of frog eggs, 
encodes a member of the TGF-p superfamily. Lyons etal (1989) isolated 
the mammalian equivalent of Vg-1 and termed it Vgr-1 (for Vg-related).
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A putative, though unproven, function of Vg-1 in Xenopus laevis is a role in 
the induction of mesoderm. In an effort to explain how different cell types 
are produced from a fertilised egg it has been suggested that there are 
diffusible factors present which regulate gene expression in the very early 
embryo. It has previously been demonstrated that mesoderm, the third 
embryonic germ layer, arises by an inductive interaction between the 
prospective endoderm and ectoderm (Nieuwkoop, 1969; Sudarwati and 
Nieuwkoop, 1971; Dale etal 1985; Gurdon, 1987). Although many growth 
factors have been shown to be effective in inducing mesoderm formation in 
Xenopus eggs, all were from external sources. However, this does point to 
the possibility that the natural inducer(s) of mesoderm induction share 
many properties with growth factors.
Weeks and Melton (1987) investigated the role of Vg-1 as an inducer of 
mesoderm for a variety of reasons. Firstly the RNA is synthesised during 
oogenesis, is inherited by eggs and persists in the cleaving embryo. After 
the blastula stage the RNA is generally degraded. Secondly, Vg-1 RNA is 
localised in a tight crescent at the vegetal end of mature oocytes. 
Therefore, because Vg-1 RNA is temporally and spatially limited to an area 
known to provide the mesoderm inducing signal, it appears to be a likely 
candidate for that special role. However there is still no functional evidence 
for this role. TGF-p1, in association with FGF, and TGF-p2 have both been 
found to be capable of inducing mesoderm (Rosa et al 1992; Kimelman 
and Kirschner, 1987).
1.5.3 Inhibins and Activins
The final members of the TGF-p superfamily that I will describe are the 
activins and inhibins. These proteins are gonadal hormones which act 
upon the mammalian pituitary to inhibit or stimulate the release of follicle 
stimulating hormone (FSH), respectively (Mason et al 1985; Ling et al
1986). Inhibin is a heterodimer of an a subunit with one of two possible p 
subunits (represented as apa and apb). The two p chains are closely 
related to TGF-p at 46% and 38% homology. The a chain is also related 
but much more distantly. Activin molecules are heterodimers of the two p 
subunits of inhibin. Activin A (PaPa) is identical to erythroid differentiation 
factor described by (Murata et al 1988). Activin B (pbpb) has been shown to
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be the mesoderm inducing factor (MIF) described by (Slack et al 1989), 
and has been isolated from the Xenopus XTC cell line (Smith, 1987; Smith, 
1989a; Smith et al 1989b). Meunier et al (1988) reported the expression of 
inhibin a, p* and pb in a variety of tissues in the rat. These included; the 
placenta, pituitary and adrenal gland, bone marrow, kidney and brain. They 
observed that the expression of an inhibin subunit could vary by several­
fold in a tissue-specific fashion. Meunier et al (1988) concluded that the 
dimers of inhibin possessed diverse functions and may act as growth 
and/or differentiation factors as well as hormones. Petraglia et al(1989) 
demonstrated that inhibin and activin modulated the release of 
gonadotropin-releasing hormone, human chorionic gonadotrophin and 
progesterone from cultured human placental cells. They also noted that 
TGF-p itself was unable to induce this response. The results described by 
Petraglia et al (1988) support the hypothesis that activins and inhibins play 
a role in regulating hormone release during pregnancy. Spencer et al
(1990) described the dose dependent inhibition of fetal adrenal cells in vitro 
by activin A. They demonstrated that activin A inhibited epidermal growth 
factor-stimulated fetal zone cell proliferation, but did not alter basic 
fibroblast growth factor stimulated growth.
Of the TGF-p superfamily, the activins and inhibins, are the only other 
group to have had receptors isloated (Matthews and Vale, 1991; 
Nishimatsu et al 1992). The receptors identified were all serine/threonine 
kinase, which indicates a protein phosphorylation signalling pathway.
1.5.4 Recent additions to the TGF-p superfamily
Growth/differentiation factor (GDF-1) was recently described, having been 
isloated from an 8.5 day p.c. mouse cDNA library (Lee, 1991). Northern 
analysis has indicated that there are two transcripts, 1.4Kb and 3.0Kb, of 
this novel member of the TGF-p superfamily, which show distinct temporal 
and spatial patterns (Lee, 1991). The 3.0Kb transcript is exclusively 
expressed in the brain of embryonic mice. This expression continues into 
adulthood (Lee, 1991). Burt, (l992) determined that GDF-1 is a member of 
the BMP group of proteins, and is related to Xenopus Vg-1 protein. 
Another member of the BMP group is OP-1 which encodes an osteogenic 
protein (Ozkaynak et al 1990). This novel protein was isolated from
- 3 5 -
enriched bovine osteogenic protein preparations, due to its sequence 
homolgy to dpp and Vgr-1. Little else is know about this gene.
The newest member of the TGF-p superfamily, 60A, was isolated from 
Drosophila (Doctor et al 1992). This gene is also a member of the BMP 
family (Wharton etal 1991). The first detectable level of expression of 60A 
RNA, and localisation of its protein, was noted at the onset of gastrulation, 
mainly in the mesoderm of the extending germ band. 60A RNA and protein 
continue to be detected in cells of the developing foregut and hindgut 
(Doctor etal 1992).
1.6 Action of TGF-(3s in vitro and in vivo
The effect of TGF-ps on cells in vitro has been extensively investigated 
(reviewed by (Lyons et al 1990; Moses et al 1990)). It should be borne in 
mind that much of the early work did not distinguish between TGF-p 
isoforms, therefore when describing data from these papers the phrase 
“TGF-p” could refer to one, two or all of the isoforms. Where possible the 
specific isoform will be mentioned and comparisons made.
A generalisation which could be made of these investigations would be that 
TGF-p acts on epithelial cells as a growth inhibitor, and on mesenchymal 
cells as a growth stimulator/inhibitor (Barnard etal 1989). In some systems 
it is known that the extent of the growth response of the cells to TGF-p can 
be determined by its concentration (Battegay et al 1990). However, the in 
vivo observations of TGF-p action tend not to support these findings.
b
Qualitative differences in TGF-pi activity can be determined by quantitaive
A
differences in TGF-pi concentration. For example TGF-pi is thought illicit 
a chemotactic response in vivo. Cells migrate towards a local source of 
TGF-p1, once the cells have reached higher concentrations, TGF-p1 no 
longer elicits a chemotactic response and the cells become stationary. The 
cells can begin to be influenced by other factors to differentiate, as well as 
being influenced by the high concentration of TGF-pi which inhibits their 
proliferation (Moses et al 1990).
1.6.1 Effect of TGF-p isoforms on the extracellular matrix
One important area of action of TGF-ps is on the extracellular matrix 
(ECM). TGF-p is known to galvanise the expression of fibronectin, various 
types of collagen and matrix proteoglycans in many cell types (Ignotz et al 
1987; Keski-Oja et al 1988; Chen et al 1987; Overall et al 1989; Lund et al 
1987). TGF-p initiated the incorporation of fibronectin and type I collagen 
into the ECM of pre-adipocytes (3T3-L1) via the increased expression of 
cell adhesion protein receptors (Ignotz et al 1987). Keski-Oja etal (1988) 
demonstrated that mRNA levels of type I plasminogen activator inhibitor 
(PAI-1) were elevated, in response to TGF-p1, in cell line A549, which is 
derived from a malignant human lung carcinoma, and human lung 
fibroblasts (WI-38). They suggested that TGF-p may be regulating the 
accumulation of ECM by regulating the synthesis of PAI-1. They also 
suggested that the ultimate goal of TGF-p control of PAI-1 may be in 
control of the conversion of plasminogen to plasmin which is a key enzyme 
in the activation of collagenases and other enzymes. Interestingly, plasmin 
was put forward as a candidate protein for the activation of latent TGF-p in 
vivo (Lyons etal 1988). This suggests that TGF-p, PAI-1 and plasmin could 
be involved in a negative feedback loop, which limits TGF-p production and 
ultimately ECM content. More recently it has been demonstrated that, in 
vitro, plasmin only activates approximately 1 % of latent TGF-p (Brown et al 
1990).
The increment in collagen and fibronectin protein levels, in the ECM, were 
shown to be due to an increase in mRNAs of these genes upon the 
application of TGF-p (Varga et al 1987; Keski Oja et al 1988; Ignotz et al
1987). Ignotz and Massague (1986) described the disruption of induction of 
fibronectin, pro-a-1 collagen and pro-a-2 collagen by actinomycin-D, 
suggesting an involvement of transcription. In the case of collagen the 
upregulation is dependent upon the presence of nuclear factor type 1 
(NF-1) (Rossi et al 1988). The promoter region for collagen possesses a 
6bp recognition site for NF-1. Others have demonstrated that TGF-p can 
stimulate the production in fibroblasts of type II collagen (Seyedin et al 
1985), type III collagen (Varga et al 1987), tenascin (Pearson et al 1988) 
and thrombosponin (Penttinen et al 1988). An increase in fibronectin was
also demonstrated in keratinocytes (Wikner et al 1988). Edwards et al
(1987) described the repression of induction of collagen and stromelysin 
but the super induction of tissue inhibitor of metalloproteinases (TIMP), by 
TGF-p in human fibroblasts. They suggested that the control of ECM 
deposition depended on the differential modulation of metalloproteinase 
and TIMP expression. Many other enzymes which are known to degrade 
components of the ECM also have their level of transcription negatively 
controlled by TGF-p. These include elastase (Redini et al 1988), 
transin/stromelysin (Machida et al 1988), and thiol proteases (Chiang and 
Nilsen-Hamilton, 1986). From the accumulated data it seems that TGF-p 
has three main effects upon the consistency of the ECM.
(a) TGF-p stimulates the production of molecules which are constitutive of 
the ECM.
(b) TGF-p inhibits the enzymes which degrade the molecules described in 
(a).
(c) TGF-p stimulates the factors which inhibit the degradative enzymes.
As stated earlier, most of the above experiments only mentioned TGF-p, 
and occasionally were more specific when they talked of the effect of 
TGF-p1. It is only in the last few years that attempts have been made to 
compare and contrast the effects of the three TGF-p isoforms. In the main, 
it seems that they all have similar actions upon the cells investigated, 
although the degree of action does vary. Graycar et al (1989) showed that 
TGF-pi is more potent than TGF-p2, which in turn is more potent than 
TGF-p3, at inhibiting the proliferation of MCF-7 cells. However TGF-p3 is 
more potent than either TGF-p2 or pi in inhibiting DNA synthesis of human 
and mouse keratinocytes (Graycar eta! 1989).
1.6.2 Effect of TGF-p on muscle
The effect of TGF-p on muscle In vitro has been investigated and was 
found to be inhibitory to fusion of myoblasts and formation of 
multinucleated myotubes (Florini eta! 1986; Olson etal 1986; Massague et 
al 1986; McCaffrey et al 1989; Lafyatis et al 1991). This was characterised 
by the inhibition of expression of the muscle specific genes, creatine
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kinase and acetylcholine receptors (Olson et al 1986). The effect of TGF-p 
could be reversed by the removal of TGF-p from the culture conditions 
(Olson et al 1986; Massague et al 1986; McCaffrey et al 1989). McCaffrey 
et al (1989) demonstrated that heparin potentiated the action of TGF-p 
when applied to smooth muscle cells (SMC). The suggested that the mode 
of action of heparin was to release TGF-p from a2-microglobulin. The 
action of TGF-p3 was investigated by (Lafyatis et al 1991). They found that 
TGF-p3 was able to inhibit myoblast fusion in C2C12 sketally derived cells. 
After fusion of C2C12 cells, TGF-p3 mRNA expression was increased 
eightfold. The expression of TGF-p3 in myoblasts was dependent on 
regions of the TGF-p3 promoter being present at -301 to -47 and also the 
long 5’ untranslated region. Lafyatis and coworkers speculated that the role 
of TGF-p3 in adult myoblasts may be related to the function of it’s, 
electrochemically activated, contractile tissue.
1.6.3 Effect of TGF-p on bone
TGF-p is found in relatively large quantities in bones (>5mg protein/Kg 
tissue) (Roberts et al 1990a; Roberts and Sporn, 1990b). Centrella et al
(1988) has suggested that TGF-p plays a central role in the formation and 
continuous remodelling of mineralised tissues. TGF-p is thought to act on 
mesenchymal precursor cells, chondrocytes, osteoblasts and osteoclasts, 
stimulate cell replication and collagen production in cultured fetal rat bone 
cells (Centrella et al 1988; Centrella and Canalis, 1987), and induce 
chondrogenesis of embryonic rat mesenchymal cells (Seyedin etal 1987). 
Carrington et al (1988) described a time-dependent accumulation of TGF-p 
protein when cartilage is being replaced by endochondral bone. The 
highest concentrations of TGF-p protein were present when the conversion 
from calcified cartilage to bone was taking place, and consequently when 
osteoblasts were present. The extraction and immunohistochemical 
analysis, by Carrington et al (1988), indicated that the TGF-p was tightly 
bound to mineralised matrix of calcified cartilage and bone. They 
suggested that the compartmentalisation of TGF-p in the mineral phase 
may be a mechanism for storing latent or processed protein.
1.6.4 Effect of TGF-p on endothelial cells
Modulation of the response of microvascular endothelial cells during 
angiogenesis has been observed to correlate with changes in the ECM 
(Madri et al 1988). It has been widely reported that TGF-p inhibits 
endothelial proliferation in vitro (Jennings et al 1988; Madri et al 1988; 
Takehara et al 1987; Muller et al 1987). TGF-p was also found to block 
angiogenesis in 2-D cell culture systems (Muller et al 1987; Madri et al
1988). Madri et al (1988) correlated this inhibition with an increase in 
cellular synthesis and deposition of fibronectin. Interestingly, they also 
found that application of TGF-p to endothelial cells growing in a 3-D 
collagen matrix gel provoked the formation of tube like structures which 
they suggested may be mimicking angiogenesis. This supported and 
confirmed the hypothesis that TGF-p is angiogenic (Yang and Moses
1990). Takehara et al 1987 described the inhibition of endothelial 
proliferation and ascribed this to the decrease in number of high affinity 
EGF receptors. They noted that EGF-induced expression of specific genes 
(c-myc, JE, KC) decreased, whereas the induction of c-fos gene 
expression, by EGF, was unaltered by application of TGF-p. Merwin et al
(1991) have demonstrated that endothelial cells respond differently to 
TGF-pi and TGF-p2 in vitro. They analysed the effect of these two 
isoforms of TGF-p on bovine aortic endothelial cells (BAECs), rat 
epididymal fat pad microvascular endothelium (RFCs) and bovine aortic 
smooth muscle cells (BASMCs). In 2-D cell system all three cell types were 
inhibited by TGF-pi. TGF-p2 fully inhibited BASMCs, partially inhibited 
RFCs and had no discernible effect upon BAECs. The variation in receptor 
types found on the surface of these cell types corresponded with the 
observed inhibition patterns. Merwin et al (1991) continued this line of 
investigation by comparing the vascular cell response of TGF-p3 with the 
other two isoforms. In general they found that application of TGF-p3 
generated similar responses to that of TGF-p1.
1.6.5 Effect of TGF-p on epithelial cells
TGF-p suppresses the growth of most epithelial cells in culture including 
keratinocytes (Moses et al 1985; Shipley et al 1986; Coffey et al 1988); 
bronchial epithelial cells (Masui et al 1986) and tracheal epithelial cells
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(Jetten et al 1986). However, there are exceptions to this rule. TGF-p has 
been found to stimulate human mesothelial cells (Gabrielson et al 1988). 
Growth and differentiation are closely linked in epithelial cells. Inhibition of 
proliferation by TGF-p is often accompanied by terminal differentiation of 
the cells. It has been demonstrated that upon application of TGF-p to 
bronchial epithelial cells in culture the appropriate specific markers of 
differentiation are found (Jetten et al 1986; Kurokowa et al 1987). Human 
keratinocytes have been shown to possess functional receptors to TGF-p 
and respond in the same manner as do other epithelial cells in that ECM 
molecules are increased and there is a reversible effect on growth (Wikner 
et al 1988). TGF-p has been shown to selectively reduce the expression of 
certain genes associated with cell proliferation, namely c-myc and KC 
(Coffey et al 1988). It is thought that the control of these genes is at the 
post-transcriptional level. Glick et a /(1990) have described the inhibition of 
DNA synthesis associated with the differentiation of keratinocytes which is 
mediated through the production and autocrine action of TGF-p2.
1.6.6 Expression of TGF-ps during embryogenesis
Many cell lines derived from embryonic material have been investigated to 
determine their relationship to TGF-ps (Hill et al 1986; Anzano et al 1986; 
Robey et al 1987; Seyedin et al 1985). The response of cells to TGF-p is 
dependent upon the presence of receptors on those cells. Rizzino, (1987) 
demonstrated that thefe was a considerable increase in numbers of 
receptors on differentiated cells derived from embryonic stem cells which 
initially had few receptors themselves. Robey et al (1987) described the 
secretion of TGF-p by bovine cells derived from fetal osteoblasts and 
suggested that this could be evidence for autocrine action. Rizzino (1985) 
had previously provided evidence that, in an in vitro assay system, early 
embryonic cells are capable of both synthesising and secreting TGF-p like 
growth factors, implicating the production of these factors in the events of 
early development. Rappolee et al (1988) demonstrated the presence of 
TGF-p mRNA in pre-implantation mouse embryos by the use of reverse 
transcription-polymerase chain reaction techniques. They were also able to 
detect TGF-p antigens in blastocysts and noted that TGF-pi only appeared 
after fertilisation.
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The presence of TGF-p mRNA and protein in the early embryo prompted 
others to investigate later stages of embryogenesis. Initially these 
investigations took the form of Northern analysis, which demonstrated the 
presence of the three TGF-p mRNA isoforms in a variety of tissues and 
different developmental times (Denhez eta11990; Miller etal 1989). Heine 
et al (1987) demonstrated the presence of TGF-pi protein during murine 
embryogenesis by immunohistochemistry, using a polyclonal antibody. 
They described TGF-p expression which correlated with specific 
morphogenetic and histogenetic events. The localisation of TGF-p1 mRNA 
was described, using in situ hybridisation with a riboprobe derived from a 
template for TGF-p1 (Lehnert and Akhurst, 1988). They showed that TGF- 
pi mRNA had a specific pattern of expression in late mouse embryos. The 
pattern of expression described, compared well to that for the TGF-p1 
protein and led Lehnert and Akhurst to suggest that TGF-p1 acted in both 
a paracrine and autocrine manner. TGF-pi RNA and protein wre localised 
in perichondral osteocytes and osteocytes, involved in intramembronous 
ossification, suggesting that the protein produced by the cells was used in 
an autocrine manner. In contrast to this data they noticed that in tissues 
which had both an epithelial and mesenchymal component the TGF-pi 
protein was found in the mesenchymal areas underlying epithelia which 
was expressing RNA. Examples of tissues which were suggestive of a 
paracrine mode of action were the hair follicles, tooth bud, submandibular 
gland and fetal heart (Lehnert and Akhurst, 1988).
The expression of TGF-p mRNA and protein has also been investigated in 
earlier stages of embryos (Akhurst etal 1990b; Slager etal 1991). Slager 
et al (1991) described the use of an antibody to TGF-p2 to determine the 
expression in very early mouse embryos. They examined embryos from 
the four cell stage up to 7.4 days post coitum. Slager et al (1991) showed 
high levels of staining of TGF-p2 protein in the trophoectoderm of the 
blastocyst but that there was no staining in the inner cell mass. During 
postimplantation development the primitive and embryonic ectoderm was 
negative while the visceral endoderm was positive, as was the parietal 
endoderm.
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1.6.7 Role of TGF-(3s during development of the heart
Discrete clusters of cells in the sparse reticulum of mesenchyme, which 
form the precardiac mesoderm, migrate from their original bilateral paired 
regions on each side of the embrionic axis, antermedially up the 
cardiogenic crescent and come to rest, differentiating into the primitive 
heart tube. The heart of the 8.0 day p.c. mouse forms a twisted tube of 
which the wall is , in most places, one or two cells thick. The primitive 
ventricular division, along with the truncus arteriosus, forms a funnel-like 
structure. In the ventricle, endocardium forms attachments, in a number of 
discrete places, with the myocardium. Between these points of attachment, 
the myocardium extends into the lumen, forming convex surfaces, leaving 
relatively large spaces between the attachments to be occupied by cardiac 
jelly. In the truncus arteriosus the attachments are fewer in number, and 
more widely seperated, and the central lumen is small compared with the 
volume occupied by cardiac jelly. In the atrium the endocardium is more 
closely applied to the myocardium. At 9.0 days p.c. there is a constriction 
at the atrioventricular (av) channel, formed by the endocardium backed by 
cardiac jelly, which in turn is enclosed by a wider constriction of 
myocardium. In the ventricle a definite trabecular system has developed. 
As development proceeds the cardiac jelly at the av constriction is 
replaced by mesenchymal cells (Viragh and Challice, 1977; Viragh, 1973; 
Viragh and Challice, 1980; DeRuiter etal 1992).
Expression of TGF-fis are seen in the heart as early as 7.0 days p.c. in the 
cardiac mesoderm (Akhurst et al 1990b). By 8.5 days p.c. TGF-pi is 
restricted to the endocardial cells, which by 9.5 days p.c. is localised in 
those endothelial cells which lie over the cardiac jelly at the atrioventricular 
junction. At the same time TGF-p2 is localised in the myocardium at the 
atrioventicular junction (Millan et al 1991). The process by which the 
endocardial cells transform into mesenchymal cells and migrate into the AV 
valve to replace the cardiac jelly has been studied extensively. It has been 
shown to involve an inductive event which emanates from the myocardium 
(Krug et al 1985; Mjaatvedt et al 1987). Potts and Runyan (1989) 
demonstrated that the epithelial-mesenchymal transformation could be
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mediated by TGF-p and that application of antibodies to TGF-p which block 
this activity.
1.6.8 Interaction of TGF-p with other growth factors
TGF-ps interact with a variety of other growth factors as well as with each 
other. The interaction of TGF-ps with the various growth factors, as so 
often, depends upon the cell type. The specific synergistic interaction of 
TGF-p with EGF/TGFa in the stimulation of anchorage-independent growth 
of NRK49F cells is well documented (De Larco and Todaro, 1978). This 
effect is probably mediated by an increase in EGF receptor levels which 
TGF-p exposure brings about in these cells (Assoian et al 1984). However, 
TGF-p alone inhibits the anchorage-independent growth of NRK fibroblasts 
(Roberts et al 1985). This probably indicates that the rise in EGF receptors 
which was observed, is not the only mechanism by which NRK cells 
transform.
TGF-p acts antagonistically with other growth factors. Inhibition of 
mitogenic stimulation of endothelial cells by FGF was noted (Baird and 
Durkin, 1986). TGF-p also acts as an antagonist to interleukin-, and colony 
stimulating factor-, induced stimulation of cell division in haematopoietic 
and lymphopoietic precursor populations TGF-p acts with bFGF to control 
plasminogen activity (PA). FGF causes a pronounced increase in PA 
whereas TGF-p decreases PA. The control of PA depends entirely upon 
which of the growth factors is added to the cells first (Saksela et al 1987). 
TGF-pi is known to act synergistically with FGF to induce mesoderm in 
Xenopus (Kimelman and Kirschner, 1987).
Many biological effects of TGF-p may be indirect and mediated via the 
induction of PDGF. Low concentrations of TGF-p, which is generally 
percieved as a growth inhibitor, can induce an autocrine PDGF-AA loop 
resulting in connective tissue cell proliferation. However, a necessary 
element of this autocrine PDGF loop, the PDGF receptor a  subunit is 
reduced at higher concentrations of TGF-p, limiting the extent of this 
proliferative response (Battegay efa/1990).
TGF-pi, TGF-p2 and TGF-p3 have been found to be auto-regulated In 
murine fibroblasts and keratinocytes (Bascom et al 1989). Treatment of 
these cell types with TGF-p1 resulted in upregulation of TGF-p1 expression 
very early after induction. Increased expression of TGF-pi was correlated 
with increased TGF-p protein. Neither TGF-p2 mRNA nor TGF-p3 mRNA 
levels were significantly increased, but both appeared to be down 
regulated some time after induction. In contrast TGF-p2 treatment of the 
same cells increased expression of all three TGF-ps but with different 
kinetics. Autoinduction of TGF-p2 occurred later than that seen with TGF- 
pi. Bascom et al (1989) demonstrated that TGF-p2 regulates TGF-p2 and 
TGF-p3 mRNA at the transcriptional level, but that the control exerted over 
TGF-pi by TGF-p2 is at both the transcriptional and post-transcriptional 
level.
1.6.9 Interaction of TGF-p isoforms with other 
developmentally important proteins
The induction of mesoderm in early Xenopus embryos has become a 
model by which many developmental processes hope to be explained 
(Nieuwkoop, 1969). The formation of the basic body plan during early 
amphibian development is believed to result from a sequence of inductive 
interactions between different regions of the embryo (Slack, 1983; Smith et 
al 1989). Dale and Slack, (1987) demonstrated that an inducing agent from 
the vegetal region caused the formation of mesoderm. A portion of the 
vegetal region, the dorsoventral region, induces the formation of the 
Spemann organiser. A signal from the organiser then induces mesoderm 
to be dorsally specified. Those ventrally specified mesodermal regions give 
rise to different tissues such as mesenchyme and blood. Whereas dorsally 
specified mesoderm differentiates to muscle and notochord.
The primary axis of the egg is the animal-vegetal axis which is formed in 
early dogenesis. A peptide growth factor Vg-1 (which is a maternally 
derived mRNA and a member of the TGF-p super family), is synthesised 
during this period of axis determination. Initially it is distributed uniformly, 
later it is found anchored in the presumptive endoderm of what will become 
the vegetal half of the docyte (Melton, 1991). At the early blastula stage,
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vegetal endoderm induces mesoderm in overlying cells. The cells that will 
give rise to ectoderm, mesoderm and endoderm are roughly positioned in 
three layers, top to bottom. It was also demonstrated that FGF could act in 
a synergistic manner with a TGF-p-like molecule to induce mesoderm from 
isolated animal caps (Kimelman and Kirschner, 1987).
The induction of xhox3, a homeobox containing gene, is an early response 
to mesoderm induction, and the level of xhox3 expression marks the 
antero-posterior character of the induced mesoderm (Ruiz i Altaba and 
Melton, 1989). The establishment of antero-posterior polarity requires a 
system of positional information that specifies different fates for 
mesodermal cells according to their position at the end of gastrulation. 
Ruiz i Altaba and Melton (1989) suggested that the system includes a 
diffusible graded signal to account for the observed graded axial 
deficiencies in embryos obtained after perturbation by ultraviolet irradiation, 
gastrulation arrest or xhox3 over expression. They proposed that the 
graded signal is likely to be one or more peptide growth factors and that 
gradients of peptide growth factors could set positional information and 
polarity along the antero-posterior axis in the responding axial tissues by 
regulating the level of homeobox gene expression.
1.7 Molecular mechanisms of TGF-|3 action
Some insights into the mechanisms by which growth factors operate have 
been determined by investigating oncogenesis. Considerable progress has 
been made in the understanding of how genes and proteins act to promote 
normal cell growth, and the discovery that mutant forms of some genes, 
(oncogenes and tumour sppressor genes), participate in the formation of 
various types of tumours. However, it is only in the past few years that 
studies into the molecular elements that act to constrain cell growth have 
been investigated. Negative growth control depends on two types of 
components:
(a) Signals that pass from cell to cell, often carried by diffusible molecules.
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(b) A receptor signal-transducing mechanism that enables a cell to 
recognize and respond appropriately to extracellular signals.
TGF-ps fill all the requirements of a molecule which can pass amongst 
cells, however little is known of how its signal is passed on within the cell 
nor what the signal is passed on to.
1.7.1 Cell cycle and retinoblastoma protein
The mechanism of signal transduction of the TGF-ps has been 
investigated with respect to a few of its known functions, in particular, 
growth inhibition by TGF-p1. Negative growth control by TGF-p has been 
linked to suppression of retinoblastoma protein phosphorylation (Laiho et al 
1990; Pietenpol et al 1990). The retinoblastoma gene (Rb) encodes a 
product with presumptive growth-suppressive activity. This activity has 
been predicted on the basis of the phenotype of human familial 
retinoblastoma, a malignancy in which loss of function, by whatever 
means, of the two Rb alleles is associated with loss of cell growth control 
(Levine and Momand, 1990). TGF-pi seems to exert its effect upon Rb 
anytime during G1 phase of the cell cycle, and that TGF-pi prevents 
phosphorylation of Rb. Rb is known to exert a negative growth control over 
the cell when in an unphosphorylated state and can in fact arrest cell 
growth in G1. Phosphorylated Rb is required before the cell cycle can 
proceed. Kim et al (1991) have demonstrated that TGF-pi, c-fos and c- 
myc can be regulated by Rb via a retinoblastoma control region (RCE). 
Whether the regulation is positive or negative depends upon the cell type. 
Hamel et al (1988) suggested that Rb does not directly regulate c-fos but 
carries out its actions via another factor, possibly E2F, a cellular 
transcription factor. Also it has been suggested that with regards to c-myc, 
another element 5’ of the promoter is essential for the effects of Rb on 
expression (Pietenpol efa/1991).
1.7.2 Signal transduction and G-proteins
It has been determined that retinoblastoma cells have lost types I, II and III 
receptors to TGF-p which are usually present In normal retinal cells 
(Kimchi et al 1988). However, the significance of the lack of receptors for
- 4 7 -
TGF-ps on retinoblastomas may not be great since there is no Rb gene 
product to be phosphorylated. It may be that the loss of receptors is a 
secondary event.
The next question to be answered concerning the molecular action of 
TGF-ps is by what mechanism is the cell informed of the binding of TGF-p 
to one of it’s receptors. Unlike other growth factors (e.g. TGF a, EGF, 
PDGF, FGF, insulin and IGF-1) which act, at least in part, through 
stimulation of receptor tyrosine kinase activity and modulation of inositol 
phosphate/protein kinase C signalling pathway, the signalling transduction 
mechanisms of TGF-ps have not been fully elucidated (Murthy etal 1988). 
Recent investigations have demonstrated that a family of proteins known 
as guanine nucleotide-binding regulatory proteins (G-proteins) participate 
in transduction of polypeptide growth factors such as interleukin, and IGF- 
II. The mechanism by which TGF-ps operate has been investigated by the 
use of a variety of toxins which selectively inhibit the signal transduction 
pathways (Murthy et al 1988; Howe et al 1989). Murthy et al (1988) and 
Howe et al (1989) demonstrated that the substrate for the action of 
pertussis and cholera toxins (PT and CT) were a 41kDa and 45kDa 
proteins respectively. Both groups suggest that these two proteins 
correspond to a  subunits of two G-proteins, Gj and Gs respectively. These 
particular G-proteins modulate the activity of adenylate cyclase. Further 
evidence that G-proteins are responsible for transducing the TGF-p signal 
comes from evidence which demonstrates that TGF-pi -stimulated proto­
oncogene expression, as well as TGF-p-stimulated GTPase activity and 
mitogenicity, are inhibited by PT. Furthermore, Howe et al (1989), 
demonstrated that CT and PT had differential effects on the signal 
transducing pathway. CT was discovered to inhibit TGF-pi-stimulated 
monolayer cell growth, whereas PT was without effect.
1.8 Generation of mutants as a form of analysis 
of gene function
Despite the plethora of data concerning the role of TGF-ps in vitro, their 
exact mode of action in vivo remains unclear. The fact that the individual
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members of the TGF-p family have an effect on cells, peculiar to that 
isoform and cell system, complicates the picture. One method of exploring 
the role of a gene is to knock out the function of that gene. This can be 
achieved by a variety of techniques.
(a) Use of antisense oligonucleotides which bind to the specific mRNA 
preventing translation.
(b) The generation of dominant-negative mutants which eliminate protein 
function.
(c) Finally, disruption or replacement of the gene of interest with another 
(usually a marker) gene by homologous recombination in embryonic stem 
cells.
1.8.1 Use of antisense oligonucleotides or RNA
The use of antisense oligonucleotides has been used quite extensively in 
vitro. Melton, (l 985) injected, antisense oligonucleotide and sense globin 
mRNA into frog oocytes. He demonstrated that an RNA-RNA duplex was 
formed and inhibited translation. These experiments proved that it was 
possible to prevent translation of as much as 500 pg of globin mRNA or the 
equivalent of 1% of the total mRNA in an oocyte. The use of antisense 
oligonucleotides has also been explored with considerable success for a 
variety of genes including: HIV virus genes (Goodchild et at 1988), c-myc 
(Wickstrom et al 1988), c-myb (Anfossi et al 1989), bFGF (Becker et al 
1989). Runyan and Markwald, (1990) demonstrated that an antisense 
oligonucleotide specific to TGF-p3, when injected into heart explants, 
inhibited the epithelial-mesenchymal transformation seen in atrio­
ventricular regions of the heart. Neither antisense oligonucleotides to 
TGF-pi nor TGF-p2 had any effect. Runyan et al (1990) suggested that 
TGF-p3 was providing the message required to induce this event. 
Kimelman et al (1988) demonstrated that Xenopus oocytes contained an 
antisense mRNA transcript from the bFGF gene which coded for a 25kd 
protein. However, they also showed that this antisense mRNA interacted 
with the sense mRNA and suggested it may be involved in regulating the 
stability of the bFGF mRNA.
1.8.2 Dominant-negative mutants
The use of dominant-negative mutants as a tool to knocking out protein 
function is potentially a very powerful weapon in the arsenal of the 
molecular biologist. There are two main approaches which can be utilised.
1. The use of mutated proteins which compete with wild-type proteins in 
the formation of naturally occurring dimers or oligomers. The mutated 
proteins then prevent correct functioning of the protein in question. The 
type of mutation can vary between subtle point mutations which change 
potential N-glycosylation sites, or cleavage sites or gross mutations such 
as the generation of proteins, containing major deletions, which still allow 
them to bind to the wild type but prevent normal processing.
2. The use of anti-sense RNA as a method to inhibit translation of sense 
mRNA thus eliminating the gene function. The use of anti-sense RNA of 
considearble length alleviates the potential problems of specificity.
Mercola et al (1990) demonstrated the use of mutant protein with respect 
to platelet derived growth factor (PDGF). Using site directed mutagenesis 
of a PDGF-A cDNA clone, they identified two domains which are required 
to generate stable, mitogenically inactive PDGF-AA homodimers. The first 
mutant was created by an alteration in the coding sequence of the 
tetrabasic cleavage site of the PDGF gene. The second mutant changed 
one of the cysteine residues, to a serine residue, found in mature region of 
the PDGF protein. The mutants were able to form dimers with wild type 
proteins and negate their function in vitro either by preventing correct 
processing or by upsetting the conformation of the protein. They also noted 
that only the cysteine mutant dimerized with PDGF-B supressing its 
expression. The suppression of wild type activity was specific for PDGF 
and not other secretory proteins. Dimers containing the cleavage site 
mutation, (the only one secreted in detectable amounts) did not compete 
with PDGF-AA for biological activity. Mercola et al (1990) suggested that 
this meant the mutant dimer was very unlikely to bind the PDGF receptor.
Amaya et al (1991) employed a dominant negative mutant FGF receptor to 
analyse the role of FGF in Xenopus mesoderm induction. By generating a
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truncated form of the FGF receptor which lacked the tyrosine kinase 
domainy Amaya and colleagues demonstrated that explants containing this 
dominant negative mutant failed to induce mesoderm in response to 
stimulation with FGF. In whole embryos the mutant receptor caused 
specific defects in gastrulation and in posterior development. They also 
showed that overexpression of a wild type FGF receptor could reverse 
these developmental defects.
The use of dominant-negative mutants lends itself to the analysis of TGF-p 
isoforms as they are active when dimeric.
1.8.3 Homologous recombination
The generation of animals which have had the gene of interest replaced by 
another gene has become a very powerful tool to follow the gene function 
in vivo, examples of which are: Hox 1.1 (Zimmer and Gruss, 1989), Hox 
1.5 (Chisaka and Capecchi, 1991), Hox 3 I (Le Mouelic et al 1992), Hox 
l.b (Lufkin et al 1991). The gene of interest is replaced by homologous 
recombination with another gene (either neor or iacZ) in embryonic stem 
cells. Those stem cells which contain the recombinant can then be used to 
form chimeras. The use of IacZ allows the mutation to be followed in situ 
during embryogenesis. Following the fate of cells affected by the mutation 
is especially important when the disrupted gene is supposed to have a 
regionalizing role during embryogenesis. Furthermore the iacZ gene could 
also be used to monitor the level of activity of the disrupted gene promoter, 
taking into account that integration of the targeting vector has the potential 
to modify activity.
1.8.4 Tissue targeting
The main problem with the methods of gene inactivation described above 
is one of specificity in relation to tissue or cell targeting. Many of the genes 
which are investigated have extensive patterns of expression. This means 
that although you can specifically select a gene to knock out you cannot 
yet target only one cell or tissue type. All of the reported attempts at 
knocking out gene function have concentrated on deleting global 
expression of the gene concerned. This is particularly true when using
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homologous recombination as a method for introducing your mutant gene. 
However the use of dominant-negative mutants and antisense mRNA for 
the introduction of mutants does lend itself to the potential for tissue 
targeting. The appropriate construct would have to be driven by a specific 
promoter and then introduced into the organism by well established 
transgenic techniques. However, although many promoters have been 
isolated they have not been characterised to an extent which would allow 
confident targetting of a specific tissue. It has been suggested that 
inducible promoters such as that which drives the metallothionein gene 
could be utelised (De et al 1989). Unfortunately the metallothionein gene 
product is known to be expressed in a variety of embryionic cells which 
make up the uterus and amnion (De et al 1989). Also it is not clear how 
well controlled transcription from such promoters is and the potential 
problem of “leaky” expression would have to be overcome. This is 
especially significant when utelising mutants which disrupt genes known to 
have very extensive patterns of expression such as the TGF-p genes.
1.9 Aims
1.9.1 A comparative study of TGF-p isoform expression in 
post implantation mouse embryos using in situ 
hybridisation
The aim of this project was to determine the pattern of expression of TGF- 
p2 mRNA and TGF-p3 mRNA during murine embryogenesis from early 
stages up to 18.5 days post coitum. Previously the pattern of expression 
for TGF-pi protein and mRNA had been published (Heine et al 1987; 
Lehnert and Akhurst, 1988). Once the pattern of expression for these two 
genes was determined they could be compared and contrasted with that 
known for TGF-pi mRNA and protein. They could also be compared with 
the pattern of expression for the two proteins when this data became 
available. The method of choice for detection of expression of these two 
genes was in situ hybridisation using mouse specific probes to mouse 
embryos ranging in age from 6.5 days p.c. to 18.5 days p.c.. In situ
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hybridisation has a number of advantages compared to other techniques 
such as immunohistochemistry and Northern analysis.
Riboprobes for use in detecting RNA in mouse embryos can be very 
specific for the genes which you wish to detect. This can be of vital 
importance as many genes, especially growth factor genes, exist in large 
families which are closely related. Prudent choice of insert from which to 
make riboprobes and the ability to alter the stringency of the hybridisation 
conditions can almost guarantee the fidelity of the result. Also compared to 
Northern analysis, which can usually only provide a general picture of 
expression, in situ hybridisation allows the detection of RNA in single cells. 
Immunohistochemical analysis can often lend support to data generated 
via RNA analysis. However, a major problem with data generated via 
immunohistochemical techniques is the specificity of the antibodies 
employed. Particularly in the case of large families of genes where there 
has been a large degree of conservation of amino acids the likelihood of 
cross hybridisation is greatly increased. Evidence for this problem of 
epitope recognition comes from two antibodies for TGF-p1 which although 
raised against the same sequence of amino acids they detect the 
intracellular and extracellular form of TGF-pi (Heine et al 1987).
1.9.2 Approaches to address the function of TGF-(32 in 
vivo
To investigate the role of TGF-p2 in various developmental events a 
dominant-negative mutational approach was undertaken.
There are many sites of the TGF-p2 sequence which are available for 
mutation and which could potentially alter function in a dominant-negative 
fashion. These included the signal peptide sequence, the N-glycosylation 
sites, the cleavage site, or any of the cysteine residues found in the mature 
protein.
The N-glycosylation sites (of which there are three in the precursor region 
of TGF-p2) of TGF-ps are thought to be important for proper secretion from 
the cell (Sha et al 1989). It had also been reported that TGF-pi which has 
the N-glycosylated structures removed may not need to undergo the usual
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activation steps (Allen and Boxhorn, 1989). If this is the case then this 
could generate the opposite result to that required. The presence of three 
N-glycosylation sites meant that there was a possibility of having to carry 
out three seperate site-directed mutagenic steps. For these reasons the 
generation of a mutant which possessed altered N-glycosylation sites was 
dismissed.
The cysteine residues offered a potental target which had proven succesful 
in creating a dominant-negative mutant of PDGF (Mercola et al 1990). 
However, the presence of nine cysteine residues and the length of time 
available made this option not feasible. It was also known that in at least 
two cases the alteration of cysteine residues in TGF-|31 had resulted in a 
fivefold increase in activity (Brunner et al 1989).
A further option was the use of the LAP alone to bind wild-type protein. It 
had been suggested that this inhibited the cleavage of the mature region 
thus creating the required effect. The beauty of this approach is the relative 
ease with which a gross deletion of the mature region can be achieved by 
use of restriction endonucleases. Another possibility was the use of 
antisense RNA generated from hTGF-p2 which had been inserted into the 
appropriate vector in the opposite orientation. Instead of relying upon 
antisense oligonucleotides a piece of antisense RNA ranging in size from 
50 nucleotides to full length cDNA could be generated in an effort to block 
translation of the endogenous wild-type mRNA. Again this type of 
dominant-negative mutation was easy to generate by judicious cloning of 
the human TGF-p2 gene, and was very likely to be specific in its knockout 
effect.
The final two options were mutation of the cleavage site sequence. This 
had proved succesful in the generation of a dominant-negative PDGF 
mutant (Mercola et al 1990) and would only involve one site directed 
mutagenesis step. The second option was the removal of the signal 
peptide sequence. Both these options were investigated. Initial 
characterisation of the mutants and their effect upon normal TGF-p2 (and a 
TGF-pi3 3  mutant provided by A Purchio, Oncogen) expression was carried 
out using an eukaryotic expression system. Conditioned media was 
collected and analysed by growth inhibition assays and Western blot.
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It was expected that once one (or more) of the mutant TGF-p2 clones had 
been fully characterised, and shown to act in a dominant-negative fashion, 
it would be employed in the generation of transgenic mice under the 
control of an appropriate promoter. Aternatively it could be introduced into 
mice via homologous recombination.
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Chapter 2
MATERIALS AND METHODS
2.1 Introduction
All materials used throughout this project were sterilised to prevent 
contamination or degradation of samples. Solutions used in DNA analysis 
were millipore-filtered (0.45^m) and autoclaved and plasticware for use 
with DNA was autoclaved. Gloves were worn at all times. Materials 
employed in procedures which involved the use of RNA were treated as 
follows:
(a) glassware was washed thoroughly, rinsed in Milli-Q water and baked 
for a minimum of four hours at 180°C.
(b) plasticware was submerged in Milli-Q water with freshly added 0.01 % 
DEPC for a minimum of four hours and sterilised by autoclaving.
(c) solutions were millipore-filtered and treated with 0.01 % DEPC (except 
any Tris based solutions and organic solvents) before being autoclaved.
All procedures involving bacterial cultures were carried out using aseptic 
technique. Tissue culture was also carried out aseptically in a flow hood 
see section tissue culture.
A list of the specialist chemicals and enzymes used during the project, 
along with a list of suppliers, can be found in appendix A.
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2.2 Recombinant DNA methods
2.2.1 General
To generate specific gene constructs the DNA inserts of interest were 
subcloned into a variety of vectors, each of which had its own unique 
function and use. This was carried out essentially by the methods 
described by (Sambrook etal 1989) with minor modifications. All steps in 
the various methods employed are described below.
2.2.2 Preparation of phenol and phenohchloroform
Phenol was equilibrated by the addition of equal volume of equilibration 
buffer (0.5M Tris-HCI pH 8.0). The phenol and equilibration buffer were 
mixed thoroughly and allowed to settle. The aqueous phase was discarded 
and this step repeated twice. The pH of the equilibrated phenol was 
checked with pH paper, and 1/10 volume of 0.1 M Tris-HCI pH 8.0 and 
0.1 % hydroxyquiniline added. The phenol was stored at 4°C in a light tight 
bottle. RNA-phenol was prepared in the same manner as described above. 
However, the equilibration buffer used was 0.3M sodium acetate pH 5.5. 
The equilibrated RNA phenol was stored under 0.1 M sodium acetate pH 
5.5, at 4°C, in a light tight bottle.
Phenohchloroform was made by adding an equal volume of 
chloroform:isoamyalcohol (24:1) to equilibrated phenol (pH 8.0). This was 
also stored at 4°C in a light tight bottle.
2.2.3 Ethanol precipitation of DNA and RNA
DNA and RNA was precipitated by the addition of either sodium acetate 
pH5.5 or ammonium acetate pH5.5 to final concentrations of 0.03M and 
2M respectively plus the addition of 2 volumes 100% ethanol (3 volumes 
for RNA precipitation). The sample was incubated on dry ice for 20 minutes 
(-20°C overnight) and the nucleic acid pelleted by centrifugation at 
14,000rpm for 15 minutes. The supernatant was removed and the pellet 
washed twice with 70% ethanol. The nucleic acid pellet was air dried and
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resuspended in an appropriate volume of sterilised dH20  (RNA was 
resuspended in DEPC treated dH2 0).
2.2.4 Preparation of competent bacterial cells
Competent DH5a and MC1016/p3 bacterial ceils (see appendix) were 
prepared by the method described by (Hanahan, 1983). Essentially, the 
two strains were prepared the same way.
The bacterial cells were streaked out from a glycerol stock onto a TYM 
plate (2% Bacto-tryptone, 0.5% yeast extract, 0.1 M NaCI, 10mM MgS04, 
1.5% bacto-agar pH 7.0) and incubated for 12-16 hours at 37°C in an 
inverted position. A single colony was used to inoculate 20ml of TYM broth 
(2% bacto-tryptone, 0.5% yeast extract, 10mM MgS04, pH 7.0) and 
incubated for 12-16 hours at 37°C with vigorous shaking (225rpm). The 
whole culture was transferred to 100ml TYM broth and incubation 
continued until the OD6 0 0  reached 0.5. This culture was then used to 
inoculate 500ml of TYM broth (which had been pre-warmed to 37°C) and 
incubation continued, under the same conditions as before, until the O D ^  
reached 0.6. The culture was gently mixed on ice water to ensure rapid 
cooling. The bacterial cells were harvested by centrifugation at 4000rpm 
for 5 minutes at 4°C in sterile bottles. The supernatant was discarded and 
the pellet of bacterial cells gently resuspended in 100ml of ice-cold Tfbl 
(30mM CH3 COOK, 100mM RbCI2, 10mM CaCI2, 50mM MnCI2, 15% 
glycerol (pH 5.8)) The cells were incubated on ice for 5 minutes then 
pelleted by centrifugation at 4000rpm for 5 minutes at 4°C. The 
supernatant was again discarded and the cells resupended in 2 0 ml of ice- 
cold Tfbl I (10mM MOPS, 75mM CaCI2, 10mM RbCI2, 15% glycerol (pH 
6.5)). The cells were divided into 100pl aliqouts in pre-cooled cryostat 
tubes, using pre-cooled tips, and snap frozen in an ethanol/dry-ice mix. 
The cells were stored at -70°C until required. An aliquot was checked for 
efficiency of transformation. If the number of colony forming units fell below 
107/ug supercoiled DNA, then the cells were discarded and fresh 
competent cells prepared.
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2.2.5 Restriction endonuclease digests of dsDNA
An appropriate quantity of plasmid DNA, not exceeding 200pg/ml, was 
incubated with the restriction enzyme (under the conditions described by 
the supplier), at a concentration of at least 2units/ug DNA, in buffer 
(supplied with the restriction endonuclease). If necessary 0.4mg/ml BSA 
and 0.5mM spermidine were added to aid the reaction. An aliquot of the 
digest was analysed on an agarose gel containing ethidium bromide 
(1ng/ml). Gel loading buffer (0.25% bromophenol blue; 0.25% xylene 
cyanol; 30% glycerol) was added to the aliquot before loading which 
allowed the migration of the DNA to be followed. An appropriate DNA size 
marker was run alongside the aliquot of restricted DNA. The percentage of 
agarose in the gel varied between 0.8% to 2% in 1xTBE buffer (0.045M 
Tris-borate, 0.001 M EDTA pH 8.0). The gel was run at 100V in 1xTBE 
buffer and viewed under UV light.
2.2.6 Filling recessed 3’ termini of DNA fragments using 
Klenow enzyme
DNA, in quantities from Vg-10pg, was end-filled to generate “blunt ends”. 
This procedure was carried out immediately after the completion of the 
restriction endonuclease digest using the Klenow fragment of E.Coli DNA 
polymerase I. If the restriction endonuclease digest had been carried out in 
a volume greater than 20^1, then the DNA was precipitated and 
resuspended in 10^ of dH2 0. dNTPs were added to the completed DNA 
digest to give a final concentration of 2mM followed by addition of 0.5 
units/^l Klenow DNA polymerase. The mixture was incubated for 30 
minutes at 37°C. The filled fragment was purified as described in section 
2.2.12.
2.2.7 Phosphatasing linearised dsDNA
To minimise the number of vector self-ligations, especially if vector ends 
are compatible, the 5’ terminal phosphate groups were removed. 1^g 
Linearised vector was phenol extracted and precipitated with ethanol. The 
DNA was resuspended in 1x calf intestinal phosphatase (CIP) buffer 
OOOmM Tris HCI pH 8 .3 ,10mM ZnCI2). 5 units of CIP were added and the
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reaction incubated at 37°C for 30 minutes, followed by incubation at 6 8 °C 
for 15 minutes to deactivate the enzyme. The reaction mix was subjected 
to phenol (pH 8.0) extraction, at least three times, to ensure complete 
removal of CIP, and finally precipitated with ethanol.
2.2.8 Ligation of DNA fragments into linearised vectors
Ligations were performed with insert DNA in a 9:1 (weightiweight) excess 
to vector DNA (150-500ng insert DNA/ligation in a total volume of 10^ 1). 
Vector and insert DNA were added to ligation buffer (50mM Tris-CI pH 7.5, 
100mM NaCI), and the mixture incubated at 65°C for 3 minutes followed by 
incubation on ice for 5 minutes. 10mM ATP (1^ 1) was added plus 5 units of 
T4 DNA ligase dpi). The ligation was incubated at room temperature for 
16 hours. A further 5 units of T4 DNA ligase was added and the reaction 
incubated for a further four hours. Half of the ligation mix was used to 
transform the appropriate competent bacterial cells.
2.2.9 Transfection of construct into bacterial cells
Transfection of competent bacterial cells with plasmid DNA was performed 
by essentially the same protocol for DH5a and MC1061/p3 bacterial 
strains. Ligation mixture (approximately 6 pl) was added to 50pl of the 
appropriate competent cells and 25pl of Tfbll. The transfection mix was 
incubated on ice for 30 minutes (45 minutes for MC1061/p3) followed by 
heat shock at 37°C for 2 minutes (5 minutes for MC1061/p3). The cells 
were incubated on ice for a further two minutes. 1ml of L-broth (1% bacto- 
tryptone, 0.5% yeast extract, 1 % NaCI pH 7.0, antibiotic free) was added to 
the cells and the culture incubated at 37°C for 60 minutes (90 minutes for 
MC1061/p3) at 225rpm. The transfected cells were plated out onto L-agar 
plates (L-broth containg 1.5% bacto-agar with the appropriate antibiotic(s) 
(ampicillin 50mg/ml, tetracycline 20mg/ml) and left to incubate at 37°C for 
12-16 hours in an inverted position. Control transformations were carried 
out simultaneously. They consisted of competent cells with no DNA and 
supercoiled DNA of known concentration. After overnight incubation 
colonies were picked and the plasmid DNA extracted by the small scale 
preparation method described in section 2 .2 .1 0 .
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2.2.10 Small scale preparation of plasmid DNA
This method was based on that described by (Serghini etal 1989), but with 
minor modifications. A single bacterial colony was used to inoculate 5mls 
of L-broth (1% Bactotryptone, 0.5% yeast extract, 0.5% NaCI) containing 
the appropriate antibiotic(s) and cultured overnight at 37°C at 225rpm. 
1.5mls of the overnight culture was microcentrifuged at 10,000rpm for 3 
minutes. The supernatant was discarded and the pellet of bacterial cells 
resuspended in 100pl Solution I (50mM glucose, 25mM Tris-HCI, 10mM 
EDTA pH 8.0). An equal volume of phenol:chloroform (pH 8.0) was added, 
mixed thoroughly, and microcentrifuged for five minutes at 10,000rpm. The 
aqueous phase was retained and incubated at 37°C for 30 minutes with 
50ug RNAse A. The plasmid DNA was subjected to a further 
phenohchloroform extraction and ethanol precipitated as previously 
described. The DNA pellet was resuspended in 50pl dH20  at a 
concentration of 0.5ug-1ug/pl, which was sufficient to allow diagnostic 
restriction enzyme digests to be attempted.
2.2.11 Large scale preparation of plasmid DNA
Large scale preparation of plasmid DNA was carried out by the alkali-lysis 
method as described in (Sambrook et al 1989). Alternatively plasmid DNA 
was produced using Qiagen columns (Qiagen ™), described after this 
section. The DNA produced from these columns was suitable for dsDNA 
sequencing and eukaryotic cell transfection without further purification.
The bacteria containing the plasmid of interest were streaked onto an L- 
agar plate which contained the appropriate antibiotic(s). The plate was 
incubated overnight at 37°C and a single colony used to inoculate 5mls of 
L-broth containing the appropriate antibiotic(s). The inoculate was cultured 
overnight with shaking (225 rpm) at 37°C. The 5ml culture was used to 
inoculate 500mls of L-broth, containing the appropriate antibiotic, in a 2 
litre flask. The large scale culture was incubated overnight with vigorous 
shaking (225rpm) at 37°C.
Bacterial cells were harvested by centrifugation at 4000rpm for 10 minutes 
at 4°C, in a Sorvall rotor. The supernatant was discarded and the pellet
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gently resuspended in Solution I (50mM glucose, 25mM Tris-HCI, 10mM 
EDTA pH 8.0) (2ml/50ml culture). The cell suspension was incubated on 
ice for 5 minutes. Solution II (0.4M NaOH, 1% SDS made freshly) was 
added (4ml/50ml culture) and the mixture inverted gently until it cleared. 
The mixture was then incubated on ice for 5 minutes. Solution III (5M 
KCH3 COOH, 11.5% glacial acetic acid) (6ml/50ml culture) was added and 
the solution mixed gently until a heavy white protein precipitate formed. 
The solution was incubated on ice for 30 minutes and then centrifuged at 
5000rpm for 10 minutes at 4°C to pellet the white precipitate (bacterial 
chromosomal DNA). At this point the two methods diverged. The crude 
DNA preparation was further purified either by the method of Sambrook et 
al (1989) or by Qiagen™ column.
(a) Alkali-lysis method (Sambrook et al 1989)
The supernatant, containing the plasmid, was filtered through sterile 
gauze. 0 . 6  volume of cold isopropanol was added to precipitate the 
plasmid DNA. The sample was mixed thoroughly and centrifuged at 
5000rpm for 10 minutes at room temperature. The supernatant was 
drained off and the pellet of plasmid DNA washed in 70% ethanol and 
centrifuged (5000rpm) at room temperature. The pellet was resuspended 
in 1/50th volume TE pH 8.0 and incubated at 37°C for 30 minutes with 
50ug/ml RNase A. The plasmid DNA was then subjected to a 
phenol:chloroform extraction and precipitated with ethanol. The pellet was 
resuspended in sterile water (500pl) and the concentration determined by 
spectrophotometric analysis.
(b) Large scale preparation using Qiagen™ columns.
The Qiagen™ column was equilibrated with 10ml QBT (750mM NaCI, 
50mM MOPS, 15% ethanol ph 7.0, 0.15% Triton-X). The supernatant 
containing the plasmid DNA (from (a)) was added to the column and 
allowed to enter by gravity flow. 30ml buffer QC (1M NaCI, 50mM MOPS, 
15% ethanol pH7.0) was added and allowed to pass through. The plasmid 
DNA was eluted with buffer QF (1.25M NaCI, 50mM MOPS, 15% ethanol 
pH 7.0) and the eluant mixed with 0.7 volumes of isopropanol to precipitate 
the plasmid DNA. The mixture was centrifuged at 5,000 rpm for 30 minutes
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followed by one wash in 70% ethanol. The plasmid DNA pellet was 
resuspended in 500pl of dH20  and the concentration determined. The DNA 
produced via this method could be used directly for double stranded 
sequencing or transfections into eukaryotic cells without undergoing further 
purification.
2.2.12 Extraction of DNA fragments from agarose gels
DNA to be purified was run on an 1% agarose gel containing 1pg/ml 
ethidium bromide. The gel was viewed under a long wavelength UV lamp 
in order to minimise damage to the DNA. The DNA fragment of interest 
was excised from the gel using a sterile scalpel blade and purified by 
centrifugation through siliconised glass wool at 6y000rpm for 1 0  minutes as 
described by Serghini et al (1989). Two 1.5ml eppendorfs had their caps 
removed. One had a hole punctured in the base and a plug of siliconised, 
sterile glass wool inserted. The first eppendorf was placed into the second 
eppendorf and the gel slice placed on top of the glass wool. The gel slice 
was spun through the glass wool at 6,000rpm for 10 minutes. The DNA 
fragment was precipitated with ethanol and resuspended in dH2 0.
2.2.13 Purification of DNA using PlasmidQuik™ columns
Small concentrations of dsDNA required for sequencing reactions which 
had not been prepared from the Qiagen column method were purified 
using PlasmidQuik™ columns (Stratagene). The DNA could either be 
purified directly from a 5ml culture or from already existing DNA. Cells from 
1.5ml of the overnight culture were harvested by centrifugation at 10,000 
rpm for 5 minutes. The supernatant was discarded and the cell pellet 
resuspended in 110pl lysis buffer (8 % sucrose, 10mM Tris-HCI pH 8.0, 
50mM EDTA, 0.5% Trito-X-100 plus RNace-IT cocktail). The sample was 
incubated at 100°C for 30 seconds and centrifuged at 10,000rpm for 5 
minutes. The pe i let was discarded and 110pl of loading buffer added (1M 
NaCI, 5mM Tris-HCI pH 8.0, 0.1 mM EDTA pH 8.0). The sample was 
incubated at 100°C for 5 minutes and immediately placed on ice. 
Thereafter the sample was applied to the top of a Plasmidquik™ column 
containing resin and pushed through with pressure applied from a syringe. 
The DNA was precipitated from the eluate by addition of an equal volume
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of isopropanol and washed in 70% ethanol twice. This usually yielded 5pg 
of DNA.
2.2.14 Generation of synthetic oligonucleotides
Synthetic oligonucleotides were designed based upon the sequence data 
for human TGF-p2 (M19154.Embl). The oligonucleotides (P1,P2 and P4) 
were manufactured by Enzymatics of Cambridge (England). 
Oligonucleotides P5 and P6  were manufactured on an Applied Biosystems 
DNA synthesiser™ (E. O’Hare) (Figure 3).
2.2.15 Polymerase chain reaction (PCR) methodology
100ng of plasmid DNA, containing the appropriate insert, was mixed with 
specific sense and antisense primers (50pmoles), 0.2mM dNTP’s and 2 
units TAQ polymerase (Cambio) plus PCR reaction buffer (50mM KCI, 
15mM MgCI2 ,100mM Tris-HCI (pH 8.0)) in a total volume of 100pl. A layer 
of mineral oil was placed on top of the reaction to prevent evaporation. 
PCR was carried out using a DNA Thermocycler (Perkin Elmer Cetus). The 
amplification consisted of the following sequential steps: denaturation 
(95°C for 1  minute), annealing (43-52°C, 1 minute) and elongation (72°C, 2 
minutes). The PCR was run for 30 cycles after which the reaction was 
incubated for 10 minutes at 72°C. 10pl of PCR product was analysed by 
agarose gel electrophoresis on a 1 % gel. The layer of mineral oil was 
removed by extraction with an equal volume of chloroformrisoamylalcohol 
(24:1).
2.2.16 Site-directed mutagenesis by PCR
The generation of the cleavage site mutation was carried out by site 
directed mutagenesis using primer (P4) which contains three mismatches 
with the known sequence and the sense and antisense primers (P1 and P2 
respectively) of human TGF-p2 cDNA by the method described by 
(Stappert et al 1992) (Figure 4).
Primers, P2 and P4, were annealed to single stranded DNA template, 
generated from an M13mp18 vector containing the human TGF-p2 cDNA 
(see section 2.4.4), in a volume of 10pl containing O.lpmole template DNA,
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Figure 3.
All sequences are written 5' to 3'.
Oligonucleotides P1, P2 and P3 were used for generating the cleavage site sequence mutant. 
P4 contains three mismatch bases from the original DNA sequence which disrupt three of the 
five codons which generate the five amino acid cleavage recognition site. P1, P2, P5 and P6 
were also used to prime sequencing reactions. P5 will anneal x bp downstream of the cleavage 
site sequence. P6 anneals y bp downstream of the end of the signal peptide coding sequence.
Oligonucleotides for PCR, sequencing and SDM
P1
5‘ AAT TCA AGC AGG ATA CG
P2
5’ AAC TCT AAG AGT AAG AAT GG
P4
5‘ CAA AGC AAG CTT CTT CTG CAG GTT GG
P5
5' GTA AAG TGG ACG TAG G
P6
5' TCG CCT CGA TCC CTT G
Figure 4.
Site directed mutagenesis by PCR (See text for details). Single stranded human TGF-82 
was generated and primers P2 and P4 annealed. Sequenase enzyme (USB) and T4 DNA 
iigase were added with dNTFs and a double stranded product formed with the mismatch PS 
oligonucleotide incorporated into one of the strands. The heteroduplex is subjected to PCR 
using primers P1 and P2. The products are a mixture of four products. Two fragments contain 
one strand which has the mutated sequence in alternate strands. One fragment contains no 
mutated sequences. One fragment contains the mutated sequence in both strands. The PCR 
product which contains the latter fragment can be detected by restriction endinuclease digestion 
using Hindlll and Pstl which have had two new recognition sites generated by introduction of the
mutated sequence. PCR products which contain products of interest were sub-cloned into piH3M
Site directed mutagenesis by PCR
ssHuman TGF-B2
Anneal P2 
and P4
\
i
P4 P2
/
I
-  -  ^
pi \
i
Extend with 
sequenase and 
/  ligate
i
Anneal P2 
and P1
\
PCR for -----
30 cycles ^
/
+
— 4
*
10x excess of P2 and P4 (500pmoles each) and annealing buffer (20mM 
Tris-HCI pH 7.4, 2 mM MgCI2> 50mM NaCI). The mixture was heated to 
65°C for 3 minutes and allowed to cool to room temperature for 30 
minutes. Synthesis of the complementary strand was done in a volume of 
20pl containing the same annealing mixture plus 2.5 units Sequenase™ 
(from the USB sequencing kit), 1 unit T4 DNA ligase (Pharmacia) and 
synthesis buffer (0.5mM each dNTP, 1mM ATP, 10mM Tris-HCI pH 7.4, 
5 mM MgCI2, 2mM DTT). The reaction was incubated at 37°C for 90 
minutes and stopped by the addition of 10mM Tris-HCI pH 8.0 and 10mM 
EDTA. One fifth of the reaction was amplified by standard PCR using 
primers P1 and P2, as described above.
2.2.17 DNA sequencing
DNA sequencing by the dideoxy chain termination method (Sanger et al 
1977) was performed upon double stranded (ds) DNA using Sequenase™ 
(USB). Prior to performing the sequencing reaction the dsDNA was treated 
in the following manner. Where the DNA had been produced with a 
Qiagen™ column it was not purified further. When, the DNA had been 
produced by the alkali-lysis method (see section 2 .2 .1 1 ), the sample was 
purified with a Plasmidquik™ purification kit (Stratagene) as described 
section 2.2.13.
A final concentration of 0.2M NaOH and 0.2mM EDTA (pH 8.0) was added 
to 5pg of purified dsDNA which was incubated at 37°C for 30 minutes. The 
reaction was neutralised by the addition of 1/10th volume 3M sodium 
acetate (pH 5.5). The samples were ethanol precipitated, washed at least 
twice with 70% ethanol, and the pellets of DNA resuspended in 7pl of 
dH2 0 . The samples were treated exactly according to the protocol 
provided with the Sequenase Kit (USB). 2pl of Sequenase reaction buffer 
was added to the sample along with 1pM of the appropriate primer. The 
sample was incubated at 65°C for 2 minutes and allowed to cool to room 
temperature for 20 minutes. 1pl of 100mM DTT was added plus 2pl diluted 
labelling mix (diluted 1/5 in dH2 0), 1.0pCi of ^S-dATP and 2pl of diluted 
Sequenase enzyme (diluted 1/15 in Sequenase enzyme dilution buffer). 
The samples were incubated at room temperature for 4 minutes. 3.5pl of 
each sample was mixed with 2.5 pi of each ddNTP, in tubes pre-warmed to
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37°C, and incubated a further 3 minutes. 4pl of stop solution was added to 
each reaction. The samples were stored at 4°C until required. Prior to 
running the samples on a gel they were incubated at 80°C for 2  minutes 
and quenched on ice.
2.2.18 Preparation of sequencing gels
Sequencing gels containing 7.2% polyacrylamide were prepared by mixing 
33g urea (Sigma), 13 mis 40% acrylamide (containing 2% bis-acrylamide 
(Sigma)), 0.75 mis 10% ammonium persulphate (BDH), 7.7 mis 10xTBE, 
75pl TEMED (Sigma) and 33mls dH20  and polymerised between glass 
plates 0.4mm apart. Gels were run at 34 Watts for a minimum of 2 hours, 
fixed in 10% methanol, 10% acetic acid for 15 minutes. The gel was dried 
for 45 minutes in a Biorad Gel Dryer at 80°C and exposed to X-ray film at 
room temperature overnight. The gels were read manually.
2.3 M13 recombinant DNA techniques
The M13 series of vectors are a very powerful tool in molecular biology 
because of the ease with which single stranded DNA can be produced 
from them. The analysis of M13 vectors was similar to that of other double 
stranded DNA vectors. dsDNA was sub-cloned into dsM13mp18 under the 
same conditions as described previously. Approximately 150ng DNA was 
used to transfect DH5aF bacterial cells essentially by the same method 
described in subsection 2.2.9. However, after heat shock at 37°C for 2 
minutes, 100pl of an overnight culture of either DH5a or TG1 cells and 3ml 
of top agar (0.5% NaCI, 0.7% Bacto-agar) was added and the mixture was 
plated immediately onto 2XNY agar plates (1% casein hydrolysate, 025% 
NaCI, 1.2% Bacto-agar) containing 20ug/ml X-gal and 25ug/ml IPTG. The 
plates were incubated overnight at 37°C in an inverted position. Blue 
plaques were indicative of the M13 vector religating with no insert present 
Clear plaques, showing integration had occurred, were picked and used to 
inoculate 5ml of 2XNY broth (25% casein hydrolysate, 10% yeast extract, 
2.5% NaCI). The inoculate was grown overnight at 37°C with vigorous 
shaking at 225rpm. Double stranded DNA was isolated by the small scale
plasmid preparation described in subsection 2.2.10. Single stranded DNA 
could be isolated as described in section 2.3.1.
2.3.1 Isolation of single stranded DNA from M13 
recombinants
To retrieve single stranded DNA from an overnight preparation of M13 
DNA, the supernatant produced when harvesting the bacterial cells was 
treated immediately. Alternatively the supernatant could be retained for 
later analysis although in order to maintain viability of the single stranded 
DNA the supernatant was incubated at 70°C for 10 minutes prior to storage 
at 4°C.
To 900pl of each supernatant, 250 pi PEG/NaCI (15% polyethylene glycol 
8000, 2.5M NaCI) was added and the mixture incubated on ice for a 
minimum of 30 minutes. The supernatant mix was centrifuged for 5 
minutes at 1 0 ,0 0 0 rpm, at room temperature, after which the supernatant 
was discarded and the pellet washed with 300pl phenol buffer (0.3M NaCI, 
0.1 M Tris-HCI, 1mM Na2EDTA pH 7.9). The pellet was resuspended in 150 
pi of phenol buffer and subjected to a phenol/chloroform extraction 
followed by ethanol precipitation in 3 volumes of 100% ethanol. The pellet 
was finally resuspended in 20pl of dH2 0 . The purity of the single stranded 
DNA was determined by gel electrophoresis and visualised by ethidium 
bromide staining. The single stranded DNA could then be used as a 
template to generate sequence data or for site directed mutagenesis.
2.4 Genes and vectors
2.4.1 Constructs for generating TGF-(31,2, and 3 specific 
riboprobes
Murine TGF-p 2 and TGF-p3 cDNAs were supplied by F Dehnez and P 
Kondaiah. The murine TGF-p2 probe was a 501 bp Pstl-Sacl fragment 
subcloned into Bluescribe in an antisense orientation with respect to the T7 
promoter (by Margot McKerrell). The fragment coded for amino acids 81 to 
249 of the TGF-p2 LAP. The TGF-p3 specific probe was generated from a
Figure 5.
Diagrammatic representation of the three mouse TGF-B isoforms. The solid tine underneath each 
represents the template of DNA which was used to produce anti-sense RNA, and to show the
region of protein which It encodes. (A) Mouse specific TGF-B1 template is GOObp and enoodes amino acidis 
68-268 of the latency associated peptide (LAP) (Akhurst et al 1990). (B) Mouse specific TGF-B2 
template is 501 bp and encodes amino acids 81 -249 of the LAP. (C) Mouse specific TGF-B3 template 
is 738bp and encodes amino acids 8-251 of the LAP. (D) Each of the templates was sub-doned 
into transcription vector which has the bacterial promoters T3 and T7 either side of the multiple cloning 
site. The construct were linearised with respect to the promoter which would generate anti-sense 
RNA. X«Xbal, H-Hindlll.
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738bp PCR fragment which had been sucloned into Bluescript KS II (by 
Paturu Kondaiah and Fabienne Denhez). The fragment coded for amino 
acids 8  to 251 of the TGF-p3 LAP and was orientated in Bluescript such 
that the T3 promoter generated antisense RNA. For in situ hybridisation 
analysis, a gene specific mouse TGF-pi cDNA described by Akhurst et al 
(1990) was used. This consisted of a 600bp Kpnl -  Apai fragment 
subcloned into Bluescribe (Stratagene) in an antisense orientation with 
respect to the T3 promoter. The fragment was derived from full length 
murine cDNA, (Derynck et al 1986), and corresponded to the region of the 
latency associated peptide (LAP) between amino acids 6 8  to 268. The 
three riboprobes shared between 35 to 47 % homology (See Figure 5).
2.4.2 Preparation of human TGF-|S2 mutant
To investigate further, the role of TGF-p2 during embryogenesis, the 
generation of dominant-negative mutants was attempted as described in 
the Introduction. This involved the alteration of the coding sequence of 
human TGF-p2, and expression of the mutants proteins in an eukaryotic 
expression system. The analysis of the mutants generated required the 
use of a suitable vector and vector expression system. The vector chosen 
was xH3M which has a number of advantages compared to other vectors 
when expressing eukaryotic genes (see Figure 6 ).
Two constructs of kH3M containing simian TGF-pi which had been 
mutated at cysteine residues 223/225, and cysteine residue 33 (Brunner et 
al 1989), were provided by Dr A F Purchio (Oncogen). These mutants had 
been shown to produce five times and normal levels of activity 
respectively. The jtH3M-TGF-pi-(cys33) (TGF-pi33) construct was used as 
a starting point for the generation of a series of further constructs that had 
the TGF-pi cDNA replaced with human TGF-p2 cDNA (hTGF-p2) 
(provided by Dr G Bell). The *H3M-TGF-pi3 3  construct was also used as a 
positive control. The hTGF-p2 cDNA was in a Bluescribe vector.
Firstly, the TGF-pi3 3  was removed from the SH3M-TGF-P13 3  construct. 
The construct was digested with the restriction endonuclease Pstl. The 
linearised construct had the recessed 3’ termini filled in, by method 
described in section 2.2.6, to generate blunt ends. The construct was then
Figure 6
fH3M SV40-based expression vector.
The direction of transcription from the eukaryotic promoter is indicated by the arrow. The vector is 
composed of seven segments. Segment 1 is the pBR322 origin of replication (pIVX). Segment 2 is the 
M13 origin of replication. Segment 3 is the supF gene (the selectable marker). Segment 4 is a chimeric 
cytomegalovirus/human immunodeficiency virus promoter. Segment 6 contains splice and polyadenytatidor 
signals. Segment 7 contains the SV40 origin of replication (M. Kriegler 1990). Not drawn to scale.
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digested with EcoRI which isolated the vector from the TGF-pi3 3  cDNA. 
This left the linearised xH3M vector with one blunt end and one EcoRI 
compatible end. The digested construct was run on a 1% agarose gel and 
the linearised vector excised as described in section 2 .2 .1 2 .
The Bluescribe vector which contained a 2.3Kb fragment of hTGF-p2 was 
digested with the restriction enzymes EcoRI and Hhal which generated a 
1.966Kb fragment. The 1.966Kb linearised fragment of hTGF-p2 had one 
EcoRI compatible end and one blunt end. This could be ligated into the 
xH3M vector in a directional sub-cloning step as described in section 2.2.8. 
The construct xH3M-hTGF-p2 was used as a starting point for the 
generation of the signal peptide sequence mutant (Figure 9 and 10).
2.4.3 Generation of signal-peptide sequence mutation
The signal peptide mutant was generated from the *H3M-hTGF-p2 
construct by digestion with the restriction enzyme Espl. Espl cuts the 
hTGF-p2 gene at two sites, either side of the signal peptide coding 
sequence, and not at all in the vector. This resulted in the generation of 
two linearised DNA molecules (5.931Kb and 35bp). The digested construct 
was run on a 1 % agarose gel and the 5.913Kb band removed from the gel 
and purified as described in section 2.2.12. The 35bp band, which 
contained most of the sequence which encodes the signal peptide was 
discarded.
The linearised construct, missing the 35bp of signal peptide coding 
sequence, could not be directly religated for two reasons. Firstly, this would 
have caused the sequence to jump out of frame (Fig 5). Secondly, it was 
not directly possible as the Espl restriction endonuclease recognition site is 
GC/TNAGC. The Espl sites were GC/TGAGC and GC/TCAGC 
respectively and were therefore did not produce compatible ends (Fig 7). 
The linearised construct was purified and the recessed termini end filled as 
described in section 2.2.6. The blunt ended construct was religated to 
produce the construct which coded for the signal peptide mutation ((32e) 
(Figure 7).
Figure 7.
Diagram showing steps in the generation of the signal peptide mutation. (A) The first 21 amino 
acids make up the signal peptide sequence for hTGF-62. The solid lines under the DNA 
sequence are the locations of the Espl sites. (B) After restriction endonuclease digestion with 
Espl the two termini! are not compatible. (C) The two termini! are end-filled and can be ligated 
together. (D) The ligation of the two terminii result in the creation of a new amino acid residue x. 
The sequenoe has remained in frame with 5 of the original signal peptide residues still present.
Generation of signal peptide mutation
(A)
1 2 3 4 5__  6__7___ 8____  17_18__19__20__ 21___
ATG CAC TAC TGT GTG CTG AGC GCT--/--GTC GCG CTC AGC CTC 
TAC GTG ATG AC A CAC G AC TCG CGT--/--CAG CGC GAG TCG GAG
Espl Espl
(B) 1 2 3 4  5 20 21
ATG CAC TAC TGT GTG C TC AGC CTC
TAC GTG ATG ACA CAC GAC T CG GAG
(C)
(D)
20  21
ATG CAC TAC TGT GTG CTG A TC AGC CTC
TAC GTG ATG ACA CAC GAC T AG TCG GAG
_ 1___ 2_ 3 4  5___ 6___ x _  20 21
ATG CAC TAC TGT GTG CTG ATC AGC CTC 
TAC GTG GTG ACA CAC GAC TAG TCG GAG
2.4.4 Generation of cleavage site sequence mutant
The generation of the second hTGF-p2 mutant involved the mutagenesis 
of the proteolytic cleavage site. This was attempted by PCR directed 
oligonucleotide mutagenesis (Stappert et al 1992) (Figure 4). Human 
TGF-p2 cDNA, isolated from the pBS construct described above, was 
subcloned into M13mp18 in such an orientation that single stranded DNA 
prepared from the M13 construct would be of the sense strand.
M13mp18 was digested with EcoRI and Hindi. This generated a linearised 
M13mp18 vector with one EcoRI compatible end and one blunt end. The 
EcoRI/blunt fragment of hTGF-p2 generated for ligation into the *H3M 
vector (described above) was ligated into the M13mp18 vector. Single 
stranded DNA was generated from the M13-hTGF-|32 as described in 
section 2.3. Site directed mutagenesis was carried out on the ssDNA by 
PCR as described in section 2.2.16 (Fig 4 and 8 ). The mutation of the 
proteolytic cleavage site, by the introduction of 3 new base pairs, was 
confirmed by sequence analysis (Figure 9 and 10).
2.5 RNA analysis
2.5.1 Extraction of cellular RNA
RNA was extracted from a variety of tissues and cultured cells by the 
method described by (Chomczynski and Sacchi, 1987). Mammalian cells 
were cultured in a 75cm2  flask until confluent. The cells were washed twice 
in PBS (Life Technologies) and the flask drained. 1ml of solution D (4M 
Guanidinium thiocyanate, 25mM sodium citrate, 0.5% sarkosyl, 0.1 mM p- 
mercaptoethanol) was added and the cells scraped with a sterile 
"policeman”. A further 2mls of solution D was added and the viscous 
mixture collected in a sterile 30ml polypropylene tube. The following 
reagents were added, 1710th volume 0.2M sodium acetate pH 4 .0 ,1ml of 
unequilibrated phenol, 0.6ml chloroform:isoamylalcohol (49:1). The sample 
was mixed gently after the addition of each reagent and incubated on ice 
for 15 minutes. RNA was pelleted by centrifugation at 10,000rpm for 20
Figure 8
Generation of the cleavage site mutation. Diagram showing human TGF-02 polypeptide 
with normal cleavage site amino acid residues, and DNA sequence which encodes this region.
P4 spans this coding region but contains three mismatch bases (*) in the codon which code for 
the three arginine residues. The result of the site-directed mutagenesis shows the introduction 
of the mismatches which results in the formation of two new restriction endonuclease sites for
Hindlll and Pstl (solid lines above coding sequence). The altered amino acid sequence is shown 
below. The three basic argine residues have been replaced by two leucines and a glutamine residue.
Generation of cleavage site mutation.
Arg Arg Lys Lys Arg
CGG CGG AAG AAG CGT
GCC G C C TTC TTC G C A
Primer 4  GG TTG GAC GTC TTC TTC GAA CGA AAC
★ ★ *
Pst1 Hindlll
CTG CAG AAG AAG CTT
GAC GTC TTC TTC GAA
Leu Gin Lys Lys Leu
Figure 9.
Diagram showing monomers of (A) normal human TGF-B2. (B) Human TGF-B2e with deleted 
signal peptide sequence. (C) Human TGF-S2c with altered cleavage site sequence. The 
length of the polypeptides is given in brackets. The human TGF-B2e polypeptide lacks 23 
amino acids which have been removed from the signal peptide sequence. The cleavage 
site mutant polypeptide will be the same size as normal human TGF-B2 but the five amino acid 
cleavage recognition sequence has been altered by site-directed mutagenesis.
Polypeptides expected from mutant constructs.
SP(29)
Human TGF B2 (414)
C(5)
HB LAP
Human TGF B2f (401)
SP(6) C(5)
1 LAP
Human TGF B2c(414)
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Figure 10
(A) Diagram of human TGF-B2 cDNA above (B) human TGF-B2 protein. The ATG initaition 
start site is indicated along with the in frame stop site. The primers used for sequencing, 
SDM and PCR are drawn below the cDNA in their approximate positions of homology. 
Not drawn to scale. e«Espl, p* Pstl, N-Notl, hUHindlll. s-Sphl restriction sites.
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minutes at 4°C in a Sorvall rotor. The aqueous phase was transferred to a 
fresh tube and 3ml of iso-propanol added. The solution was mixed and 
incubated at -20°C for 60 minutes. The RNA was pelleted at 10f000rpm for 
20 minutes at 4°C and the supernatant discarded. The pellet was 
resuspended in 0.6ml Solution D and an equal volume of isopropanol was 
added. The RNA was precipitated by incubation at -20°C for 60 minutes 
followed by centrifugation at 10,000rpm for 10 minutes. The pellet of RNA 
was washed twice in 70% ethanol and resuspended in DEPC treated 
dH2 0 . This method yielded about 200ug-300^g RNA/5X106  cells.
2.5.2 RNA gel electrophoresis
RNA was analysed on a 1.5% denaturing agarose gel containing, 5.2% 
formaldehyde, IxMOPS buffer (0.2M MOPS sodium salt, 25mM Sodium 
acetate, 2.5mM EDTA sodium salt, pH 7.0). RNA samples (between 
10-30^g RNA per lane at 1pg/^l) had an equal volume of 50% formamide, 
5.2% formaldehyde, IxMOPS buffer added, and incubated at 70°C for 10 
minutes. The samples were quenched on ice and 1/6th volume loading dye 
added (20% Ficoll, 10mM EDTA, 0.25% xylene cyanol, 0.25%  
bromophenol blue). The gel was run in 1XMOPS, which was circulated to 
prevent depletion of ions at the anode. Ribosomal RNA or an RNA ladder 
(Life Technologies) was run alongside the samples as a size marker.
2.5.3 Transfer of RNA to a nitrocellulose membrane
For Northern analysis the samples were prepared and run as described 
above. When the gel had run a sufficient distance (as determined by 
migration of the loading dye) it was washed in Milli-Q water with frequent 
changes for 1  hour to remove formaldehyde. The marker lanes were 
removed from the main body of the gel and stained with ethidium bromide 
(50pg/ml) for 1 hour followed by destaining in Milli-Q water for up to 16 
hours. The markers could then be viewed on a trans-illuminator and 
photographed alongside a scale.
The remainder of the gel was placed on two sheets of 3MM Whatmann 
paper which had been soaked in 10xSSC (1xSSC: 0.15M NaCI, 0.015M 
Na^itrate) and were acting as a wick in a tray containing a reservoir of
10xSSC. A piece of nitrocellulose was cut to the size of the gel and was 
floated on Milli-Q dH20  till wet and then submerged for 5 minutes. The wet 
filter was placed on top of the gel, and care taken to remove any air 
bubbles. Four pieces of dry 3MM Whatmann paper (cut to the same size 
as the gel) were placed on top of the filter followed by a stack of paper 
towels. A small weight (100g) was placed on top of the towels and the blot 
left for 16 hours. The filter was removed from the blot, rinsed in 2xSSC and 
baked at 80°C for two hours.
2.5.4 Random prime labelling of DNA
DNA inserts, to be used as probes, were labelled with a22?  dCTP using a 
random primer labelling kit (Boehringer Mannheim) following their protocol 
exactly. 200ng of double stranded DNA was resuspended in 7pl dH2 0 , 
incubated for S minutes at 100°C and quenched on ice. 100mM (2pl) of 
each dNTP (except dCTP), plus 1710th volume reaction buffer, containing 
random hexanucleotides, 0.5pCi a32? dCTP and 1 unit of Klenow was 
added to the DNA and the reaction incubated at 37°C for 30 minutes. The 
reaction was stopped by incubation at 65eC for 10 minutes. Unincorporated 
nucleotides were removed from the mixture by passing the sample through 
a Nick column (Pharmacia). The specific activity of the probe was 
determined and if this was below 10®cpm/ug then it was discarded. The 
sample was kept on ice until required. Immediately prior to use the 
radioactive probe was incubated at 1 0 0 °C for 1 0  minutes.
2.5.5 Northern hybridisation
The nitrocellulose filter, prepared by method above, was placed on 2xSET 
(0.15M NaCI, 0.03M Tris-HCI pH 8.0, 0.002M EDTA) until wet and then 
submerged for 5 minutes. The filter was placed in a hybridisation bottle, 
with 10mIs of pre-hybridisation mix (50% formamide, 5xSET, ixDenhardts 
(0.02%  BSA (RNase free), 0.02%  SDS, 0.02%  Ficoll, 0.02%  
polyinypyrrolidine (all w/v)), 20mM phosphate buffer and 50ug/ml 
denatured and sheared salmon sperm DNA). The filter was incubated at 
43°C for at least 4 hours. The probe was denatured and added to the pre­
hybridisation mix. Incubation, at 43°C, continued for a further 16 hours.
The percentage of formamide could be altered depending on the 
stringency of hybridisation required.
2.5.6 Northern washes
Filters were washed twice at 65°C in 4xSET, 0.2% SDS for 15 minutes; 
twice at 65°C in 2xSET, 0.2% SDS for 30 minutes; twice at 65°C in 1xSET, 
0.2% SDS for 30 minutes and finally once in 0.2xSET at 65°C for 30 
minutes. The filter was exposed to Kodak X-Omat autoradiographic film.
2.6 In Situ hybridisation
2.6.1 Mouse husbandry
Embryos from 6.5 days p.c. to 18.5 days p.c. were generated from NIH 
males crossed with either Parkes females or NIH/Parkes F1 females. Noon 
on the day the copulation plug was found was considered as 0.5 day p.c.. 
The mice were kept under a 14 hour light to 10 hour dark cycle, the dark 
period from 1900 hours to 0500 hours.
2.6.2 Collection of embryos
Females from timed pregnancies were sacrificed by cervical dislocation. A 
ventral incision was made through the body wall and the uterus withdrawn 
from the body cavity. The decidua was cut from the uterus and placed in 
ice-cold, millipore-filtered PBS (130mM NaCI, 7mM Na2 HP04, 3mM 
NaH2 P0 4 .2H20  pH 7.2). Embryos 10.5 days p.c. or older were dissected 
from the decidua and amnion. Embryos 9.5 days p.c. and younger were 
left in the decidua. All solutions were pre-cooled to 4°C. Embryonic 
material was fixed in filtered 4% paraformaldehyde (PFA) in PBS for 6  to 
24 hours at 4°C with continuous rotation. The embryonic material was 
washed in PBS for 30 minutes; 0.85% saline for 30 minutes; ethanoksaline 
(0.425% saline : 50% ethanol) for 15 minutes; and 70% ethanol for 15 
minutes. The 70% ethanol was replenished and the embryos could be 
stored at this stage for a number of weeks. The embryos were processed 
through a Histokinette automatic processor on a 24 hour cycle. The cycle
included: 100% ethanol; 5 washes in methanol; one wash in 100% ethanol; 
one wash in 50% ethanol:50% chloroform; two washes in chloroform; one 
wash in xylene and finally two washes in paraffin wax. The embryos were 
embedded in paraffin wax and stored at 4°C prior to use.
2.6.3 Preparation of slides and coverslips
Microscope slides for in situ hybridisation were washed at 65°C in a 10% 
Decon solution overnight, rinsed in hot running tap water for at least four 
hours followed by rinsing in Midi Q water. The slides were then baked for a 
minimum of four hours at 180°C, following which they were dipped in a 2 % 
TESPA (Sigma) solution in acetone for 5 seconds followed by at four 
washes in 100% acetone and four washes in Milli-Q water. The slides were 
dried, in a dust free environment, at room temperature. Coverslips were 
treated  in a sim ilar manner although they were coated in 
dimethyldichlorosilane (BDH) solution instead of TESPA.
2.6.4 Cutting tissue sections
Embryos and tissues embedded in paraffin wax blocks were placed in a 
microtome and 5-7uM serial sections cut. These were floated onto water at 
42°C. The sections were picked out with TESFA-coated microscope slides 
and left to dry at 42°C for at least four hours. The sections were then 
stored at 4°C, with desiccant, until required.
2.6.5 Radioactive riboprobe synthesis
To generate ^S-labelled RNA probe, (riboprobe) to a high specific activity, 
Bluescript KSII or Bluescribe (+) vectors, containing the insert of choice, 
were linearised with respect to the orientation of the T3 and T7 promoters 
as described in section 2.4.1. 1ug of DNA template, in 1pl of dH2 0 , was 
incubated at 37°C with the appropriate polymerase in a reaction buffer 
(0.04M Tris-HCI pH 8.0, 8 mM MgCI2, 1mM Spermidine, 0.025M NaCI.); 
plus the following 0.1mM DTT; 1mM of ATP, CTP, and GTP; 7.5uM UTP-S; 
0.3mg/ml BSA (RNAse and DNAse free); 30 units RNA guard (Pharmacia) 
and 75uCi S^UTP (dryHAmersham) in a total volume of 20pl. The reaction 
was terminated by incubation with 0.15 units of DNAse 1 in IxDNAse
buffer (0.1 M NaOAc pH 5.0; 5mM MgCI2; 10mM DTT (added fresh); 50 
units RNA guard and finally 0.05mg Poly A). 50 pi of Orange G was added 
before the reaction mix was centrifuged through G50 sephadex column 
which had been equilibrated with column buffer (0.3M NaOAc pH 5.0; 
10mM Tris-HCI pH 7.5;1mM EDTA pH 8.0; 0.1% SDS; 10mM DTT (added 
fresh)). The column was washed through with 2 volumes of column buffer 
and the eluants pooled. An equal volume of phenol pH 5.0 was added. The 
sample was thoroughly mixed and centrifuged at 10,000rpm for 5 minutes. 
The aqueous phase was retained and subjected to a chloroform:iso- 
amylalcohol (24:1) extraction. Three volumes of 100% ethanol were added 
to precipitate the riboprobe. The riboprobe was pelleted by micro­
centrifugation for 15 minutes at 10,000g, washed twice in 70% ethanol and 
resuspended in 100pl ADB buffer (40 mM NaHC03  pH 10.2; 60 mM 
Na2 C 03; 10 mM DTT). An aliquot was removed from the sample and kept 
on ice prior to analysis on a polyacrylamide gel (see Section 2.6.6). The 
remainder of the sample was digested by controlled alkaline digestion in 
ADB at 60°C. The length of time for the incubation of the riboprobe was 
calculated by the following formula (Cox et al 1984):
Incubation time (minutes) s (Lo -  Li)/(0.11 x Lo x Li)
Lo = Original length of riboprobe (Kb)
Li = Required length of riboprobe (Kb)
After alkaline digestion was completed, 10pl 0.1 M NaOAc pH 6.0, 10pl 
0.5% sodium acetate, 5^10.05mg Poly A and 50 ul 1 mg/ml Orange G was 
added to the reaction before the mixture was separated through a G50 
sephadex column. The sample was washed through with two volumes 
column buffer and the eluants pooled. The sample was extracted with 
phenol (pH 5.0) and chloroform:isoamyla!cohol (24:1) before ethanol 
precipitation. The pellet was resuspended in an appropriate volume of 
50mM DTT such that a 10X stock was equal to 3 x 105  dpm/pl. The 
riboprobe was stored at -20°C for up to two weeks prior to use.
2.6.6 Polyacrylamide gel electrophoresis
Both full length and alkaline-digested samples of each riboprobe were 
analysed on a 6 % polyacrylamide gel. Approximately 105  counts per 
minute (cpm) of each sample were loaded in each lane. The 
polyacrylamide gel solution contained (50% urea, 0.5X TBE, 6.5% 
polyacrylamide stock (acrylamide:bis-acrylamide, 19:1). Polymerisation 
was initiated by the addition of 1 / 1 0 0 th volume of 1 0 % ammonium 
persu lphate plus 1 /3000th  volum e of TEM ED (N .N ’.N ’ .N  
tetramethylethylenediamine). The solution was mixed thoroughly and 
quickly poured between two silanised glass plates separated by 1 mm 
spacers. After the gel had set the wells were flushed out with running 
buffer (0.5X TBE) and the gel was pre-run at 300V for 30 minutes. The 
samples were taken up in loading buffer (98% Formamide, 1% 
Bromophenol blue, 1% Xylene Cyanol), incubated at 80°C for two minutes 
to denature the RNA, and quenched on ice for 2 minutes. The wells of the 
gel were flushed out again and the samples loaded. The gel was run at 
300V for 1 hour, placed on 3MM Whatmann paper, covered in Clingfilm™ 
and finally exposed to autoradiographic film for 16 hours (See Figure 11).
2.6.7 Phosphorylation of DNA to generate radiolabelled 
markers for PAGE
Phosphorylation of DNA allows the replacement of the 5’ hydroxyl group 
with a radioactive phosphate group supplied by t32? ATP (Amersham). The 
double stranded or single stranded DNA (1pg) was incubated in the 
presence of 10 units T4 polynucleotide kinase (Stratagene) with 0.01 M 
ATP and react buffer (0.05M Tris-HCI pH7.6, 10mM MgCI2, 5mM 
drthiothreitol, 0.1 mM spermidine HCI, 0.1 mM EDTA pH 8.0) for 45 minutes 
at 37°C followed by incubation at 65°C for 10 minutes to deactivate the 
enzyme.
2.6.8 Pretreatment of tissue sections
All treatments were performed in 250ml glass troughs using a 20 
microscope slide carrier. The tissue sections were dewaxed twice in 
Histoclear™ for 10 minutes each, followed by rehydration in 100% ethanol
Figure 11.
RAGE gel electrophoresis of riboprobes.
Pre and post-alkaline digested riboprobe samples were run on a RAGE gel. The gel 
was exposed to autoradiographic film overnight. The sizes of the three mouse specific 
riboprobes are indicated at the side of the gel. The post alkaline digested riboprobes 
were determined to be on average *100 nucleotides.
1. premTGF-61
2. post mTGF-61
3. pre mTGF-B2
4. post mTGF-p2
5. pre mTGF-83
6. post mTGF-63
7. pre hTGF-s2
8. post hTGF-p2 
M. marker

twice for 2 minutes each, followed by immersion in an ethanol series (90%, 
80%, 70%, 50% and 30% dilutions). The sections were equilibrated in 
0.85% saline for 5 minutes, followed by PBS for 5 minutes. The sections 
were re-fixed in fresh 4% paraformaldehyde for 20 minutes at room 
temperature, followed by washes in PBS, twice, for 5 minutes each. The 
sections were incubated with proteinase K (40 ug/ml) in PKB buffer (50mM 
Tris-HCI pH 7.5; 5mM EDTA pH 8.0) for 7.5 minutes at room temperature 
followed by a brief wash in PBS before further fixation in 4% PFA for 5 
minutes. The sections were acetylated in fresh 0.2% acetic anhydride, in 
0.1 M triethanolamine, for ten minutes at room temperature. After briefly 
washing the sections in PBS, followed by 0.85 % saline, they were 
dehydrated by immersion in an ethanol series for 2 minutes each (30%, 
50%, 70%, 80%, 90%, 100%). The sections were left to air dry in a dust 
free environment prior to application of the radioactive riboprobe.
2.6.9 Hybridisation of riboprobe to tissue sections
The riboprobe was applied to the sections in a hybridisation mix containing: 
60% formamide; 0.3M NaCI; 10mM Tris-HCI pH 8.0; 5mM EDTA; 10mM 
NaP04  pH 6 .8 ; 10% dextran sulphate; IxDenhardts; 0.5mg/ml yeast RNA; 
0.5mg/ml Poly A RNA; 50mM DTT and 1x riboprobe (3x104  cpm/^l). The 
hybridisation mix was incubated at 80°C for 2 minutes and quenched on 
ice. 6 pl per 1 1  mm x 1 1  mm coverslip of hybridisation mix was placed on the 
section. The coverslip was lowered gently on top and air bubbles removed. 
The slides were placed horizontally in a hybridisation box along with a 
tissue which had been soaked in 4xSSC, 50% formamide. The box was 
sealed and placed in an incubator at 52°C for 16 to 18 hours.
2.6.10 Post hybridisation washes
Microscope slides were placed vertically in a 20 microscope slide holder. 
The sections were then subjected to the following washes: 5x SSC,0.1% 
2-mercaptoethanol for 15 minutes at 50°C; 2x SSC, 50% formamide, 1% 
2-mercaptoethanol for 20 minutes at 65°C; four washes in RNase buffer 
(10mM Tris-HCI pH 8.0, 5mM EDTA, 0.5M NaCI) for ten minutes each at 
37°C followed by a 30 minute incubation in RNase buffer plus 20ug/ml 
RNase A at 37°C; RNase buffer at 37°C for 15 minutes; 2x SSC, 50%
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formamide, 1 % 2-mercaptoethanol at 65°C for 20 minutes; 2x SSC 50°C, 
15 minutes; 0.1 x SSC at 50°C, for 15 minutes. The sections were 
dehydrated by immersion in a short ethanol series (50%, 70%, 100%) for 2 
minutes each and allowed to air dry in a dust free atmosphere. The 
sections were dipped briefly in a gelatimchromalum solution (0 .1 % gelatin: 
0.01 % chromic potassium sulphate) and allowed to dry overnight. This was 
a necessary step to allow the emulsion (Ilford K5) to adhere to the glass 
slide and section.
2.6.11 Autoradiography
Autoradiography was performed under dark room conditions using a Kodak 
904 filter for illumination. Slides were dipped in a solution of Ilford K5 
emulsion and glycerol (50% emulsion:1% glycerol) which had been 
prewarmed to, and maintained at, 45°C. The emulsion was allowed to dry 
for at least 2 hours in a light tight environment. The slides were sealed in 
light tight boxes with dessicant, and stored at 4°C prior to development. 
After the sections had been exposed for the appropriate length of time (3 
days to 2 weeks) they were developed by agitation in 20% Phenisol (Ilford) 
for 2.5 minutes followed by 30 seconds in 1 % acetic acid, 30 seconds in 
water and finally fixed for 5 minutes in 30% sodium thiosulphate. The 
sections were rinsed in cold running water for at least one hour before 
counter staining and mounting.
2.6.12 Staining and mounting
Sections were incubated for 5 to 30 seconds in Harris’ Haematoxylin 
(Sigma), rinsed under cold running tap water for 30 seconds, followed by 
incubation in Scott’s Tap water (20g MgS04, 20g NaHCCtylitre of water) to 
provide an alkaline environment for the haemotoxylin stain. After a further 
rinse in cold running tap water the sections were dehydrated through an 
ethanol series (50%, 70% 100%, 100%, 2 minutes each). The sections 
were then incubated in two changes of Histoclear, 5 minutes each. 
Coverslips were mounted using Gurr’s Neutral Mounting medium and left 
to dry overnight.
The sections were viewed with an Olympus BH2 microscope using 
brightfield and dark ground optics. Photographs were taken using Kodak 
Panatomic X, TMX 100 or PanF film, with a green filter plus LBD-2N filter 
for the brightfield views. Darkfield views were photographed without filters. 
No filters were used for high power (40X) brightfield views.
2.6.13 Alcian green staining
Sections were dewaxed prior to staining (see section 2.6.8), and incubated 
in 1 % Alcian Green stain in 2% acetic acid for 5 minutes. This was followed 
by rinsing with dH2 0. The sections were transferred to a solution of 0.1% 
Nuclear Fast Red in 5% ammonium sulphate for 5 minutes, followed by a 
rinse in dH2 0. Finally the sections were incubated in 0.25% tartrazine, to 
which 2 drops of acetic acid /100ml had been added, and left for 30 
minutes. The sections were dehydrated in a series of alcohols, cleared in 
Histoclear for 10 minutes and then mounted in Gurr’s Neutral Mounting 
medium.
2.7 Tissue culture
2.7.1 Introduction
Cells were maintained at 37°C as subconfluent monolayers in 75cm2  tissue 
culture flasks (Nunc) in 10ml of Dulbecco’s modified Eagles medium plus 
10% foetal calf serum (FCS), 0.7% Na2 HC03, 10mM glutamine, 1% non- 
essential amino acids, 10mM NaOH (DMEM). All tissue culture media 
contained Gentamicin (0.1 mg/ml). Each flask was flushed with 5% C 0 2  
and the cap screwed on tightly. Cultures were usually split every 3-4 days 
by washing cells twice in 10ml PBS (Life Technologies), followed by 
incubation in 2mls of Trypsin (Trypsin EDTA in Puck’s saline) for 2 minutes 
at 37°C. Trypsin was deactivated by addition of 8 mls of DMEM plus 10% 
FCS. Cell numbers were estimated using an “improved Neubauer” 
haemocytometer (BDH) and fresh culture medium was innoculated with 
5-10x105  cells/1 Omls.
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2.7.2 Long term storage of eukaryotic cells
Cells were grown to 80% confluency and trypsinised as described above. 
Trypsin was deactivated by addition of DMEM plus 10% FCS and the cells 
centrifuged for 5 minutes at 1000rpm. The supernatant was aspirated off 
and the cells resuspended in 1ml of 10% dimethyl sulphoxide (DMSO) in 
DMEM plus 10% FCS. The cells were cooled by storage in Nunc cryostat 
tubes, wrapped in Bubblepak™, at -70°C  for two days and then 
transferred to liquid nitrogen stores. Cells which had been frozen by this 
method were thawed quickly at 37°C and added to 9ml DMEM plus 10% 
FCS. The following day the media was aspirated off, the cells were washed 
in PBS and fresh media added.
COS-7 cells and CCL64 cells were maintained, as subconfluent 
monolayers, in DMEM plus 10% foetal calf serum (FCS) (Life 
Technologies). Cells were split every two to three days and seeded out into 
fresh DMEM at 1x106  cells.
2.7.3 Transient transfection of COS-7 cells
COS-7 cells were transiently transfected by the DEAE-dextran method as 
described by Freshney (1987) with modifications. The COS-7 cells were 
seeded out in DMEM plus 10% FCS into 75cm2  flasks (Nunc) at a cell 
density of 1x106  cells/flask and incubated overnight at 37°C. The following 
day the cells were checked to determine their confluency. If the cells were 
between 40-60% confluent they were suitable for transfection.
1 unit of construct *H3M-sTGF-p13 3  (p133) and jcH3M-hTGF-p2 (p2) 
(10pg=1 unit), and 1, 2 and 4 units of constructs jcH3M-TGF-p2e (p2e), 
jcH3M-hTGF-p2c (p2c), and nH3M-hTGF-p2f (p2f) were transfected 
independently into COS-7 cells (see section 2.4.2 for description of various 
constructs). The vector jtH3M (31) was included in all transfections mixes to 
make the total DNA content equal to 50pg. Co-transfections of the two wild 
type constructs with each of the mutant constructs were carried out 
independently in ratios of 1:, 1:2 and 1:4 of wild-type construct to muutant 
construct.
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A transfection mix containing 10ng DNA/ml DMEM plus 10% FCS, 100pM 
chloroquine, 0.04% DEAE dextran was prepared, and made up to 5ml with 
media. While the cells were washed twice with PBS the transfection mix 
was incubated at 55°C. The transfection mix was then added to the wells 
and incubated for 2.5 hours at 37°C. The transfection media was removed 
and 10% DMSO in PBS added to the cells and left for 2 minute at room 
temperature. The DMSO was aspirated off and 5ml DMEM plus 10% FCS 
added and the cells incubated for 48 hours.
2.7.4 Determination of efficiency of transfection
The construct pIRV (Beddington et al 1989) which contains sicopies of 
the bacterial gene p-galactosidase driven by human actin gene promoter 
was used to determine the efficiency of the transfection procedure. 25pg 
pIRV was transfected into the COS-7 cells as described above. The cells 
were rinsed twice in PBS and fixed in 2% formaldehyde, 0.2% 
glutaraldehyde in PBS for 5 minutes at 4°C. The fix was aspirated from the 
cells which were washed twice with PBS. The reaction mix (1 mg/ml X-Gal, 
5mM potassium ferricyanide, 5mM potassium ferrocyanide and 2mM 
magnesium chloride in PBS) was added to the flask and the cells 
incubated for 24-48 hours at 37°C. The cells were examined under a light 
microscope and cells which stained blue counted. A flask of cells which 
had not been transfected with pIRV was examined simultaneously.
2.7.5 Collection of conditioned media
For the collection of conditioned media, transfected COS-7 cells, 48 hours 
post transfection, were incubated in serum-free DMEM after having been 
washed in four changes of PBS. The cells were left to condition the 
serum-free DMEM for 48 hours. The conditioned media was cleared by 
centrifugation at 1,000rpm for 10 minutes and a cocktail of protease 
inhibitors added (1pg/ml aprotonin, leupeptin and pepstatin A). The CM 
was immediately frozen at -20°C or acid dialysed against 0.2M acetic acid 
for 12 hours and lyophilised. Dialysis tubing was treated as described in 
(Sambrook et al 1989). The lyophilised sample was resuspended in water 
and used immediately.
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2.7.6 Preparation of dialysis tubing
Dialysis tubing was cut into 15cm strips and boiled for 10 minutes in 2L of 
2% NaHC03 and 1mM EDTA pH 8.0. The strips were rinsed thoroughly in 
dH20  and boiled for a further 10 minutes in 1mM EDTA pH 8.0. The strips 
were allowed to cool and stored submerged under 1mM EDTA pH 8.0 4°C. 
The strips were rinsed thoroughly inside and out with dH20  prior to use.
2.7.7 CCL64 inhibition assay
The CCL64 (Mv1 Lu cells) assay for TGF-p biological activity was carried 
out according to the protocol of (Danielpour et al 1989). TGF-p inhibition of 
CCL64 epithelial cells was measured by assaying the tritiated thymidine 
incorporation in these cells over a period of time when incubated in 
conditioned media collected as described 2.7.5. A 75cm2 flask of 
subconfluent CCL64 cells were trypsinised and resuspended in DMEM 
plus 10% FCS. The cells were pelleted by centrifugation and media 
aspirated off. The cells were washed in assay buffer (DMEM plus 0.1% 
FCS and 10mM HEPES), and resuspended at 105 cells/ml in assay buffer. 
They were seeded into 24 well dishes at 0.5ml per well. The cells were 
returned to the incubator for one hour. The samples to be tested were 
added to the wells and the plates returned to the incubator for a further 22 
hours. 1.0pCi 3H (80 Ci/mmole) was added to each well and incubated for 
2 hours at 37°C. The assay buffer was aspirated off and the cells washed 
twice in PBS and fixed in 1ml methanol:acetic acid (3:1 v/v) at room 
temperature for 1 hour. The fixed cells were washed twice with 80% 
methanol and finally trypsinised for one hour at room temperature. 0.5ml of 
0.5% SDS was added to each well and the mix transferred to scintillation 
vials containing 10ml of Ecoscint A. All samples were analysed in triplicate. 
Samples were counted in a Texas Instruments scintillation counter.
2.7.8 Lysis of COS-7 cells growing in culture
Subconfluent cell cultures were trypsinised as described previously. The 
cells were harvested by centrifugation at 1 .OOOrprn for 1 minute. The cells 
were resuspended in 100pl PBS and boiled for 10 minutes. The sample 
was sonicated to shear chromosomal DNA and finally centrifuged at
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10,000rpm for 10 minutes at room temperature. The supernatant was 
retained and stored at -70°C until required.
2.8 Protein analysis
Western blot analysis was carried out in order to detect proteins produced 
from the various constructs either from the conditioned media or from cell 
lysates. A detection kit based on alkaline phosphatase staining from 
British Biotechnology (BDK-1) was used. The kit included rTGF-p1 as a 
control.
2.8.1 Preparation of Tris-glycine SDS-PAGE gels
SDS-PAGE gel was made in the same manner as described in section 84, 
but with minor differences. In order to seperate protein bands between 
12-43kDa a 15% acrylamide gel was prepared. A gel mixture containing 
15% acrylamide (29% acrylamide:1% bis-acrylamide w/v), 0.325M Tris-CI 
pH8.8, 0.1% SDS. 0.1% ammonium persulphate and 0.01% TEMED were 
added and the gel mixture poured between glass plates. Butan-1-ol was 
layered on top of the acrylamide which was allowed to set. The butan-1-ol 
was removed and thoroughly rinsed away with dH20 . A stacking gel 
mixture was prepared (5% acrylamide (29:1 acrylamide:bis-acrylamide), 
120mM Tris-CI pH 6.8,0.1% SDS, 0.1% Ammonium persulphate and 0.1% 
TEMED), and poured on top of the acrylamide gel and allowed to set. The 
samples were prepared in 1XSDS gel loading buffer (50mM Tris-CI pH 6.8, 
100mM DTT, 2% SDS, 0.1% bromophenol blue, 10% glycerol). Prior to 
loading the samples were incubated at 100°C for 3 minutes. Any wells 
which had no sample loaded, had 1XSDS gel loading buffer loaded. 
Appropriate molecular weight standards were run simultaneously (Sigma). 
The gel was run in Tris-glycine buffer (25mM Tris base, 250 mM Glycine, 
0.1% SDS pH8.3), at 100V for 1 hour followed by 300V for a further 3 
hours.
- 8 4 -
2.8.2 Transfer of proteins to nitrocellulose
The proteins were transferred to a nitrocellulose filter and probed with 
antibodies to TGF-p. The nitrocellulose was floated on a tray of Milli-Q H20  
and immersed for 5 minutes. Six pieces of Whatmann paper were soaked 
in Transfer buffer (TBS)(39mM glycine, 48mM Tris, 0.037% SDS, 20% 
methanol). The gel was placed in a sandwich between Whatmann paper 
and with the nitrocellulose next to the gel. The whole sandwich was placed 
in a Bio-Rad electro blot tank and a current passed through the gel (200mA 
for 2 hours). The filter was dried at room temperature for 1 hour and stored 
at 4°C.
Prior to detection of the proteins of interest, the molecular weight ladder 
can be detected with Ponceau S stain (Sigma). The dried filter was placed 
onto Milli-Q H20  and submerged for 5 minutes. The wet filter was 
transferred to a tray containing a working solution of Ponceau S stain (1:9 
Ponceau S: Milli-Q H20 ) and incubated for 5-10 minutes with gentle 
agitation. When the bands of the molecular weight ladder bacame visible 
the stain was discarded and the filter washed with several changes of 
Milli-Q H20. The positions of the proteins were marked as the Ponceau S 
stain will wash off during the rest of the detection process.
2.8.3 Detection of TGF*ps on nitrocellulose filters with 
specific antibodies
The detection of TGF-p2 was carried out with a kit supplied by British 
Biotechnology using a chicken polyclonal antibody which detects both 
TGF-pi and TGF-p2. The protocol provided was also used with some 
minor modifications. The stock solution of TGF-p antibody (10mg/ml) was 
diluted in blocking buffer (1/1000) (TBS, 1% EIA grade BSA, 0.05% 
Tween-20 EIA grade)(TBS= 500mM NaCI, 20mM Tris-HCI pH 7.2). The 
membrane was placed on Milli-Q H20  for a few minutes then incubated in 
blocking buffer for 2 hours at room temperature. The blocked nitrocellulose 
filter was incubated with the diluted antibody for 2 hours at room 
temperature in a heat sealed plastic bag. The antibody dilution was 
removed and the filter washed three times in TBS containing 0.05% 
Tween-20 for 5 minutes. Affinity purified, biotin-conjugated anti-rabbit IgG
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was diluted in blocking bufer (1:1000). The filter was then incubated with 
the diluted anti-rabbit IgG second antibody for 1 hour at room temperature. 
The filter was washed as before. Diluted alkaline phosphatase-conjugated 
avidin in blocking buffer (1:500) was incubated with the filter for 1 hour at 
room temperature. The washes were repeated. Finally, the colour solution 
was prepared by adding 66pl of colour reagent A (50mg/ml p-nitro blue 
tetrazolium chloride in 70% N.N dimethyl formamide) to 10ml of AP buffer 
OOOmM Tris-HCI pH 9.5, 100mM NaCI, 5mM MgCI2). 33pl of colour 
reagent B (50mg/ml 5-bromo-4-chloro-3-indoyl phosphate p-toluidine salt 
in N.N-dimethyl formamide) was added and mixed. The filter was 
incubated with the colour solution for several hours. After suitable colour 
development, the colour reaction was removed and the filter rinsed with 
ddH20. The filter was photographed and the membrane dried and stored in 
the dark indefinitely.
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fChapter 3 
RESULTS
3.1 Introduction
At the start of this project it was known that each of the TGF-p isoforms 
was expressed during mammalian embryogenesis. The majority of this 
data was based upon expression analysis by in situ hybridisation and 
Northern blot analysis. Additionally, there was a large body of data 
available on TGF-p1 expression in murine embryogenesis gathered by in 
situ hybridisation and immunohistochemistry. Very little data existed on the 
detailed developmental expression of TGF-p2 or TGF-p3 and what there 
was was based entirely upon Northern blot analysis (Denhez et al 1990; 
Miller etal 1989). To contribute more comprehensive data on the temporal 
and spatial patterns of expression of these two, relatively new, members of 
the TGF-p gene family, global in situ hybridisation studies were performed 
on serial sections of murine embryos, from gestational age 6.5 days up to
16.5 days using mouse gene probes which were specific for TGF-p2 and 
TGF-p3. Dissected skin from 18.5 days p.c. embryos were also examined. 
No expression of either gene was detected in the embryo prior to 8.5 days 
p.c.. However both were expressed in extraembryonic material from 6.5 
days p.c. to at least 9.5 days p.c. (described in section 3.2.9)
One of the first major hurdles to overcome when carrying out in situ 
hybridisation using genes from a conserved family is to minimise the 
amount of cross-reactivity between the riboprobes and other members of 
the gene family. The riboprobe templates were chosen from the region of 
the cDNA which encodes the LAP, which has considerably less homology 
between the isoforms than does the DNA sequence encoding the mature
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region. The riboprobes were between 35 to 47% homologous which, under 
the conditions of the in situ hybridisation employed, ensured that there was 
no cross-reactivity. The TGF-pi -specific riboprobe utilised by Akhurst et al 
(1990) provided a positive control whilst a sense TGF-02 riboprobe was 
used as a negative control. No specific autoradiographic signal was 
observed at any time, when using the sense riboprobe, during these 
experiments (Figure 1 D, H, P. Figure 2 C. Figure 9 C, F, I. Figure 10 C. 
Figure 11 I). To confirm the specificity of the three templates they were 
used to detect total RNA on a Northen blot (Fig ). The TGF-p1 specific 
template detected a band of 2.5Kb. The TGF-p& detected at least two 
bands at 4.0 and 5.0Kb, there may have been other bands hidden by the 
ribosomal RNA. The specific TGF-p3 probe picked up the expected 3.5Kb 
transcript (Figure 12).
3.2 Expression of TGF>(3 isoforms during murine 
embryogenesis
During this stage of the investigation at least three embryos from each 
stage described were studied. 18.5 days p.c. embryos had their skin 
removed and investigated.
3.2.1 Expression during and osteogenesis and 
chondrogenesis
There are two main routes to bone formation. Intramembranous 
ossification is the conversion of primitive connective tissue into bone, 
whereas replacement of cartilage by bone is known as endochondral 
ossification. Cartilage in the embryo arises from condensations of 
mesenchymal cells which form a precartilage blastema in those parts of 
the embryo where cartilaginous elements later develop. In general, the 
formation of bone by endochondral ossification can be considered as a 
model for both types of bone formation. Mesenchymal cells condense to 
form pre-chondrogenic blastema, around which a perichondrium is formed, 
with inner chondrogenic and outer fibrous layers. Chondroblasts give rise 
to chondrocytes and mature cartilage is deposited. The outer fibrous
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Figure 12.
Northern analysis to show specificty of riboprobes and to determine RNA 
expression by COS-transfected cells.
(A, B, C) 15pg of total mouse RNA from 16.5 day p.c. liver (1) and 14.5 day p.c. mouse 
RNA (2) was probed with (A) mTGF-(31, or (B) mTGF-p2, or (C) mTGF-£3. The 
mTGF-j31 probe recognised a 2.5Kb band in both the liver and whole mouse samples. 
mTGF-p2 probe hybridised to bands of 4.0 and 5.0Kb in the whole mouse RNA 
sample. The asteroks indicate positions of the rRNA which masked any other bands 
present The mTGF-p3 probe detected the expected 3.5 Kb band in whole mouse 
RNA but detected no RNA in the liver. (D,E) 15pg of RNA extracted from COS-7 cells 
which had been untreated (1) or transfected with either 6133 construct (4) or 62 
construct (5) were subjected to Northern analysis. (D) Northern probed with nTGF-p1. 
A 2.4Kb band was detected in the COS cells transfected with 6133 (E) Northern 
probed with hTGF-[32. A band was detected in the RNA transfected with p2 at 3.0Kb.

perichondrial layer becomes vascularised and forms periosteum, while the 
inner perichondrial cells become osteogenic. Osteoblasts differentiate from 
mesenchymal cells, and deposit matrix that is subsequently mineralised. 
Bone is initially laid down as a network of immature trabeculae, the primary 
spongiosa; the primary spongiosa is replaced by secondary bone, or 
removed to form bone marrow, or converted into primary cortical bone by 
the filling of spaces between the trabeculae (Hamilton et al 1978)).
In previous studies (Lehnert and Akhurst, 1988), TGF-|31 RNA expression 
was observed in areas of ossification, including osteoblasts and 
osteoclasts. Neither TGF-p2 RNA nor TGF-p3 RNA were seen at high 
levels within these cell types. The earliest abundant expression of any 
TGF-p isoform was that of TGF-p3 RNA, seen at 10.5 days p.c. in the 
intervertebral disc anlagen (Figure 13 A,C.). This expression pattern of 
TGF p3 RNA persisted up to at least 16.5 days p.c.. TGF-p3 RNA was also 
present, in abundance, in mesenchyme within, and adjacent to, the 
perichondria of non-ossifying cartilage. This included tracheal cartilage 
(Figure 13. E,G), nasal septum (Figure 19. C, D), the otic capsule (Fig 5 E) 
and sclerotic coat. Transcripts of TGF-p3 RNA were also seen in the 
perichondria of cartilage models of the vertebrae, ribs and the presumptive 
long bones and digits (Figure 13, I, J and O). The TGF-p3 riboprobe also 
hybridised to the perichondria of jaw bone and Meckel’s cartilage. 
Hypertrophic chondrocytes no longer express this gene.
TGF-p2 RNA was seen in the pre-chondrogenic blastemae of the limb 
buds at 12.5 days p.c., before there is any morphological distinction 
between these cells and the surrounding mesenchyme (Figure 13 K). 
Adjacent sections containing pre-chondrogenic blastemae were analysed 
to determine if there was any difference between the cells which made up 
the blastema and the surrounding mesenchyme. The stain, alcian green, 
picks up cells expressing proteo-lycans which would be expected in the 
pre-chondrogenic blastemae but not surrounding mesenchyme if they have 
begun to differentiate. However, it is quite clear that the pre-chondrogenic 
blastemae are apparently identical to their neighbouring cells (Figure 14 
A). TGF-p3 RNA was not detected in the pre-chondrogenic blastemae or 
elsewhere in the developing limb until much later when the bones were 
being laid down (Figure 13,L). As development of the long bones proceeds
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Figure 13
Expression of TGF (3 isoforms during chondrogenesis and osteogenesis.
Bright field sections hybridised with either TGF 62 (K, M) or TGF 63 (A, E, I, L); Dark 
field of sections hybridised with TGF 02 (B, F, N) or TGF 63 (C, G, J, O) or control 
probe (D, H, P). (A, B, C, D) serial sections through tip of 14.5 day p.c. embryo tail.
(A) light field of section hybridised with antisense TGF (33 riboprobe. (C) 
corresponding dark field section to (A) showing hybridisation of TGF p3 riboprobe to 
intervertebral discs. TGF (32 RNA was not expressed in the IV discs (B). (E, F, G, H) 
serial sections of trachea of 16.5 day p.c. embryo. (E and G) light field and 
corresponding darkfield image of section hybridised with antisense TGF p3 probe 
shows expression of TGF 03 RNA in the mesenchyme surrounding the tracheal 
cartilage but no expression in tracheal epithelium. (F) parallel section to (E) showing 
hybridisation of TGF (32 riboprobe to mesenchyme directly underlying tracheal 
epithelium. Also signal from cartilage of tracheal discs. (I, J) Light and dark field 
showing hybridisation of TGF (33 to the perichondria of ribs, also expression in the 
diaphragm and slight expression in mesothelia of heart of 14.5 day p.c. embryo. (K 
and L) Light fields of parallel sections of 12.5 day p.c. embryo showing intense 
hybridisation of TGF (32 riboprobe to prechondrogenic blastemas. (L) No expression 
was seen with TGF (33 riboprobe to these regions. (M, N, O, P) serial section of 16.5 
day p.c. forelimb. (M, N) Light and corresponding darkfield demonstrating hybridisation 
of TGF p2 probe to growth zone of digits and also tendons. The fingers are bent over 
giving the impression that the growth zone is more central than it really is. (O) parallel 
section probed with TGF (33 showing expression in the perichondrium. (D, H, P) dark 
fields of sections hybridised with sense TGF £2 probe demonstrating no hybridisation. 
Numbers in top right of photographs correspond to which riboprobe was hybridised to 
section: 1=TGF-(31,2=TGF-(32, 3=TGF-63 and 4«sense riboprobe. b=blood vessel, n= 
notochord, iv=intervertebral discs, t*tracneal cartilage, v«ventricle, r=rib, 
p=prechondrogenic blastema, gz=growth zone. Scale bars represents 200pm.

Figure 14.
Alcian green staining of prechondrogenic blastemae.
(A) Transverse section through limb bud of 12.5 day p.c. embryo stained with Alcian 
green. No green staining is visible at the prechondrogenic blastemae (p).
(B) Sagittal section through a 14.5 day p.c. embryo to show staining of rib cartilage (r), 
with alcian green. h=heart. Scale bar represents 200pm-
¥  f
TGF-p2 RNA becomes restricted to the proliferating chondroblast zone of 
the growth plate at the termini of the long bones and digits (Figure 13, M, 
N). No expression of TGF-p2 RNA is seen in areas of intramembranous or 
endochondral ossification.
TGF-|33 RNA is seen in a number of areas of condensing mesenchyme 
which were part of the developing neurocranium. These areas included the 
optic and otic capsules as well as the nasal cartilage (Figures 18 and 19).
3.2.2 Expression in the Pulmonary system
The lungs are derivatives of the digestive tube and are formed from two 
endodermal outgrowths, which invade the splanchnic mesoderm at about
11.5 days p.c.. These simple endodermal tubes are then induced to branch 
distally, and the lung expands as rapid growth occurs at the terminal end 
buds and in the surrounding mesenchyme. The epithelial cells which line 
the respiratory tubes change in morphology at defined points. In the 
trachea the lining is made up of columnar epithelial cells, this type of 
epithelial cell is also seen in the bronchii and bronchioles. However in the 
more distal branches of the respiratory tract there is a change to a simple 
cuboidal epithelial. Furthermore, the fully differentiated alveolar epithelial 
cells (which begin to appear at about 16.5 days p.c.) are flattened in 
shape. These morphological rearrangements correspond chronologically to 
events in pulmonary epithelial cell differentiation such that primitive 
columnar epithelial cells transform/differentiate into simple cuboidal 
phenotype (Joyce-Brady and Brody, 1990). Expression of TGF-p isoforms 
in the pulmonary epithelial cells depends upon the stage and type of 
epithelial cell. At no stage of the development of the lung were either TGF- 
p2 RNA nor TGF-p3 RNA expressed in the mesenchyme of the lung.
TGF-p3 RNA is seen submucosally in the trachea and proximal bronchii at
12.5 days p.c. (Figure 15 A,B). Simultaneously, intense expression was 
seen in the immature columnar epithelial cells of the growing bronchioles 
(Figure 15 A,B) and in the mesothelium which surrounds the lung at this 
stage (Figure 15 A, B). TGF-p3 RNA is also expressed in the mesothelial 
cells which are opposite the lung buds on the dorsal wall adjacent to the 
lung bud (Figure 15 A, B). As lung growth proceeds and the distal
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Figure 15.
Expression in the developing lung. Bright field of section hybridised with either TGF 
62 (E, G) or TGF (33 (A, D, F, H, I). Dark field sections hybridised with TGF 02 (J) or 
TGF p3 (B, K) or control probe (C and L). (A and B) Sagital section through 12.5 day 
p.c. lung buds showing expression of TGF (33 RNA in bronchiolar epithelium and 
underlying tracheal epithelium. Expression also seen in mesothelium of lung buds and 
IV discs. (C) parallel section hybridised with sense TGF (32 probe showing no 
hybridisation. (D) Transverse section through 14.5 days p.c. lung probed with TGF (33. 
(E and F) High power of terminal end buds showing expression of TGF (32 in simple 
cuboidal epithelium (E). No silver grains are seen over epithelium of parallel section 
probed with TGF p3 (F). (G and H) High power of bronchioles showing no expression 
of TGF (32 in columnar epithelium (G). Parallel section probed with TGF (33 
demonstrating specific expression in columnar epithelium of bronchioles (H). (I, J, K,
L) Sagital sections of 16.5 day p.c. lung. Expression of TGF 62 is in all terminal end 
sacs, but no expression around bronchi (J). TGF 63 is limitea to the mesothelia of the 
lung and the mesenchyme underlying bronchi epithelium (I, K). (L) Parallel section to 
(I) probed with sense TGF (32. 1=t GF-(31, 2=TGF-(32, 3=TGF-(33 and 4=sense 
riboprobe. t=trachea, m=mesothelium, iv=intervertebral discs, c=columnar epithelium, 
cu=cuboidal epithelium, b=bronchi, a=developing alveoli. Scale bars represents 200um 
(A, B, C, D, I, J, K, L) or 50pm (E, F, G, H).

branches of the respiratory tract differentiate to a cuboidal epithelium 
TGF-p3 RNA expression remains restricted to the columnar epithelial cells 
of the proximal respiratory tract (Figure 15 F,H). No TGF-p3 RNA 
expression was seen in simple cuboidal epithelia of the terminal end buds 
(Figure 15 F K). By 16.5 days p.c., when differentiation of most bronchiolar 
epithelium has occurred and alveolar epithelium is widespread, expression 
of TGF-|33 RNA in the lung is negligible (Figure 15 K), being restricted to 
the mesenchyme surrounding the epithelial cells of the bronchi. At this 
stage TGF-p3 RNA is still expressed in the mesothelium.
TGF-|32 RNA expression is wholly restricted to the more distal cuboidal 
epithelia of the terminal end buds at 12.5 days p.c up to 14.5 days p.c. 
(Figure 15 E,G). By 16.5 days p.c., as the lung is nearly fully differentiated 
to alveoli, there is widespread expression of TGF-p2 RNA in the flattened 
squamous epithelial cells (Figure 15 J). By 16.5 days p.c., neither TGF-p2 
RNA nor TGF-|33 RNA is detected in the epithelial cells which line the 
trachea or the bronchi (Figure 15 F and Figure 15 K).
3.2.3 Expression in the heart
Organogenesis begins at about 7.5 days p.c. in the mouse embryo. 
Between the ectoderm of the head process and the related endoderm 
appears the notochord. As the head process extends anteriorly, the 
underlying endoderm is carried with it. This will constitute the lining of the 
foregut. Directly beneath the foregut, loose mesenchymal cells are found. 
At this stage of development these cells form the heart primordia. As 
development proceeds the loose mesenchymal cells between the 
splanchnic mesoderm and the floor of the foregut form the endocardium. 
This is at first a straight tube which will, over the next 48-72 hours, twist 
and coil, due to the limited space available to growth in the pericardial 
cavity, to form the various chambers of the heart. Prior to the formation of 
the heart tube, which occurs at about 8.0 days p.c., TGF-p2 RNA is 
present in the cells of the splanchnipleuric mesoderm arranged at the 
ventral side of the primitive foregut. However it is at the next stage that the 
expression pattern of TGF-(32 becomes more interesting. At about 8.0 days 
p.c. the heart begins to turn and twist back upon itself. This is caused by 
unequal growth down one side of the heart tube but also because of the
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Figure 16.
Expression of TGF ps In the heart from 8.5 days p.c. to 9.5 days p.c.. Bright field 
of sections hybridised with TGF (32 (A, D). Dark field sections hybridised with either 
TGF p2 (B, E) or TGF 61 (C, F). (A, B, C) Transverse sections throuoh an 8.5 day p.c. 
embryo. Expression of TGF-p2 is found in all the ventricular and outflow tract 
myocardium but not in the atrial myocardium. Intense expression is also noted in the 
body wall and beside the foregut (A, B). TGF-61 is restricted to the cells which make 
up tne endothelial inner tube of the heart. (D, t ,  F) TRansverse sections through 9.5 
day p.c. embryo. The expression of TGF-p2 appears more intense at this time and is 
limited to the portion of the ventricular myocardium where the valves will form. Note 
the lack of expression of TGF-p2 in the myocardium of the heart coming from the 
outflow tract (m) (D,E). Intense expression is still observed in the region of the foregut 
(D, E). TGF-pi is expressed in the endothelial cells but is beginning to be limited to 
those endothelial cells which lie over the regions where heart valves will form (F). 
1»TGF-pi, 2=TGF-p2, 3=TGF-p3 and 4=sense riboprobe. a=primitive atrium, 
e=endothelium, j=cardiac jelly, o= outflow tract, m*myocardium. Scale bars represents 
200^m

Figure 17.
Expression of TGF 0s in heart at 10.5 days p.c. and 14.5 days p.c. Bright field of 
sections hybridised with TGF 62 (A, D) or TGF-63 (F); Dark field of sections hybridised 
with TGF 02 (B, E), or TGF (G) or TGF 61 (C). (A, B) sagittal section through 
atrioventricular region and outflow tract of 10.5 day p.c. heart (A, B) Specialised 
myocardium overlying AV valve region expressing TGF 02 RNA. Note also slight 
expression in cushion tissue but no expression in myocardium of ventricle. TGF 02 
also expressed in the myocardium and cushion tissue of outflow tract (B). (C) 
corresponding parallel section probed with TGF 61 demonstrating RNA expression in 
endothelial cells of AV region and outflow tract. (D, E, F, G) Sagittal section through 
14.5 day p.c. heart Expression of TGF 02 is limited to the cells of the cushion tissue 
at the valves (D, E). TGF 63 RNA is expressed in small condensations below valves 
(*) (F, G). 1=TGF-01,2=TGF-02,3=TGF-03 and 4=sense riboprobe. m=specialised 
myocardial cells, av=atrioventricular valve, v=ventricle, o=outflow tract, va=valves. 
Scale bars represents 200pm

limited space in the coelomic cavity. As the heart begins to form the 
various chambers associated with a normal adult heart, a number of 
constrictions begin to appear. These are the primitive valves which 
regulate the flow of blood through the heart. The endocardial cells become 
more intimate with the atrial myocardium, while in the ventricle they form 
attachments with the myocardial wall. At the junction between the atrium 
and ventricle the atrioventricular valve anlage forms. At the same time 
TGF-|31 becomes restricted to the endocardial cells which cover the 
primitive AV valve (Akhurst et al 1990, Lehnert and Akhurst 1988). In this 
study, no expression of either TGF-|32 RNA or TGF-p3 RNA was seen in 
the heart earlier than 8.5 days p.c.. At 8.5 days p.c. the first expression of 
TGF-p2 RNA was seen in the myocardium of the heart, the ventral 
endoderm of the foregut, and the mesenchyme which corresponds to 
splanchnic mesoderm derivatives (Fig 16 A, B). Later, at 9.5 days p.c. the 
expression in the foregut region is localised to the dorsal mesocardium (Fig 
16 E). The early expression of TGF-p2 RNA appears to be associated with 
all myocardial tissue (Fig 16 A, B). However by 9.5 days p.c. the pattern of 
TGF-p2 RNA expression is restricted to that myocardium associated with 
the presumptive heart valve regions (Fig 16 D, E). TGF-p2 RNA is also 
seen in the myocardium of the bulbous arteriosus from day 8.5 p.c. up to
10.5 days p.c. (Figure 16 and 17). At 8.5 days p.c. TGF-pi RNA is seen in 
the endothelial cells of the heart particularly in the region of the cushion 
tissue as described by (Akhurst et al 1990) which was confirmed by this 
investigation (Figure 15 C, F). This pattern of expression persists until after 
birth (Akhurst etal 1990). During this developmental stage TGF-p3 RNA is 
not expressed in any region of the heart.
At about 10.5 days p.c. in the region of the atrio-ventricular canal the 
dorsal atrial myocardial wall splits into two cell layers. The inner 
specialised cell layer adjacent to the dorsal endocardial cushion (which is 
about 2 to 3 cells thick) is continuous with the ventricular trabecular 
system. The outer cell layer underneath the epicardium (1 to 2 cells thick), 
which is degenerate and necrotic, is in continuity with the outer ventricular 
wall (DeRuiter et al 1992). By 10.5 days p.c. the expression pattern of 
TGF-p2 RNA is restricted entirely to the specialised cell layer, which forms 
a band of myocardium facing the dorsal endocardial cushion surrounding
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the atrioventricular canal. TGF-p2 RNA is also expressed in the 
myocardium of the outflow tract (Figure 17 A, B). Expression of this gene is 
not seen in the atrial nor the ventricular myocardium per se, although slight 
expression is seen in the cushion tissue. TGF-pi RNA is localised to the 
endothelial cells overlying the cushion tissue at this developmental stage 
(Fig 17, C). TGF-p2 RNA was not observed in the endothelial or epicardial 
cells in any part of the heart. At 12.5 days p.c the expression of TGF-p2 
RNA has diminished considerably and by 14.5 days p.c the only area of 
expression was in the mesenchyme of the atrioventricular valve itself 
(Figure 17 D, E). At 14.5 day p.c. TGF-p3 RNA was observed to be 
expressed for the one and only time in the heart in a small localised spot 
just below the atrioventricular valve (Figure 17 F, G). By 16.5 days p.c. 
expression of TGF-p2 RNA and TGF-p3 RNA could be detected in the 
mesenchyme of the heart valves and TGF-p3 RNA in the wall of the sinus 
venosus. No expression of either RNA could be detected in the adult heart 
(data not shown).
TGF-p3 RNA was expressed in the tunica media and tunica intima of blood 
vessels at 14.5 days p.c. (Figure 13 C).
3.2.4 Expression of TGF-p genes in epithelial cells
All three TGF-p isoforms are expressed in epithelial cells during 
embryogenesis. In section 3.2.2, expression of TGF-p2 RNA and TGF-|53 
RNA in epithelial cells of the pulmonary system, and the expression of 
TGF-pi RNA in endothelial cells has already been reported.
3.2.5 Expression in sensory epithelia
Neither TGF-p1 RNA nor TGF-p3 RNA were seen to be expressed at any 
time in the sensory components of the developing olfactory, visual or 
auditory apparatus. TGF-p3 RNA was localised in areas of chondrification 
within the otic capsule and nasal septum (see section 3.2.1). Hybridisation 
with the TGF-p2 probe was seen in specific epithelial structures of all three 
of these organs.
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3.2.5.1 Otic epithelia
The inner ear begins to develop from 8.0 days p.c. when the otic 
invagination is seen on the surface of the head, lateral to the 
myelencephalon. At 8.5 days p.c. the vesicle is completely formed and 
goes on to deepen and close over. At 11 days p.c. the endolymphatic 
cavities elongate mesio-ventrally to form the cochlear duct. The dorsal part 
of the otocyst consists largely of simple epithelium, the nuclei of the ventral 
part are stratified in two or three layers. The ganglion of the eigth acoustic 
nerve lies medio-rostral to the thicker, ventral part of the otocyst (Sher, 
1971). Twelve hours later the otic vesicles are surrounded by mesenchyme 
with both the utricle and saccule parts visible. At 12 days p.c. the semi­
circular canals begin to form from the utricle and are lined with epithelium 
(Rugh, 1990). By 14 days p.c. all three semi-circular canals have formed. 
Their walls are made up of simple cuboidal epithelium except on their 
convex sides, where there appears to be pseudostratified cuboidal 
epithelium with two or three levels of nuclei (Sher, 1971).
Prior to 10.5 days p.c. no TGF-p2 RNA was localised to the otic vesicle or 
the surrounding mesenchyme. At 10.5 days p.c. the first expression of 
TGF-p2 RNA was observed in a restricted pattern to one side of the otic 
vesicle adjacent to acoustic ganglion (VIII) (Fig 18, A, B). As development 
progresses TGF-p2 RNA was localised to the thickened epithelia on the 
convex side of the semi-circular canals from 12.5 days p.c.. This pattern of 
expression persists until at least 16.5 days p.c. (Figure 18 A,B and D). No 
TGF-p2 RNA expression was seen in the simple cuboidal epithelium 
opposite (Fig 18 F). TGF-p3 RNA was localised to the auditory capsule as 
described in section 3.2.1 (Figure 18 E). The continuation of the 
development of the inner ear was not followed beyond 16.5 days p.c..
3.2.5.2 Nasal epithelia
The olfactory apparatus develops as two ectodermal thickenings above the 
stomatodaeum below and lateral to the forebrain. By proliferation of the 
surrounding mesoderm these placodes become depressed to form the 
olfactory pits. Further growth causes the epithelium of each nasal placode 
to come to lie in the medial and lateral walls of the nasal cavity. Expression
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of TGF-|32 RNA is seen in the pseudostratified epithelium of the olfactory 
organ at 14.5 days p.c. and persists up to 16.5 days p.c. (Figure 19 A, B). 
The epithelium at this stage is quite thick, up to as many as 6 cells in depth 
and it is clear that the TGF-(32 RNA is localised to that part of the epithelia 
adjacent to the nasal cavity (Figure 19 E). TGF-|32 RNA also hybridises to 
Jacobson’s organ, which is destined to become the glandular and sensitive 
olfactory epithelia (Fig 19 A, B). TGF-p3 mRNA expression is limited to the 
cartilaginous capsule which surrounds the nasal passages (Figure 19 C, 
D). This pattern of expression of TGF-p3 RNA is first seen at 14.5 days p.c. 
and persists up to at least 16.5 days p.c..
3.2.5.3 Optic epithelial
The eye begins to develop by invagination of the optic vesicle from the wall 
of the forebrain at 8.0 days p.c.. As development proceeds the optic cup 
forms, when the embryonic wall invaginates into the optic vesicle. The 
invaginating embryonic wall forms the lens vesicle which by day 11 will 
have formed a completely circular vesicle which is partially engulfed by the 
optic cup. The optic cup is bilayered. The layer immediately adjacent the 
optic vesicle is destined to become the pigmented layer of retina, while the 
outer layer will become the sensory layer. The formation of the optic 
vesicle generates an optic stalk from which the optic nerve will develop 
(Rugh 1990). As the eye continues to develop the lens becomes seperate 
from the epidermis. Lens fibres are observed at about 13 days p.c. and 
nerve fibres appear in the optic stalk. By 13.5 days other structure 
associated with a adult eye begin to form. These include the iris, and 
various ocular muscles. By 14 days the lens epithelium, adjacent to the 
anterior chamber is cellular and as the lens enlarges the epithelium thins. 
At about this stage the eyelids fuse to cover the eye before birth. At 15 
days p.c. the retina can be defined into two regions, the inner and outer 
nuclear layers. The inner nuclear layer contains the neurones which 
recieve signals from the rods, found in the outer nuclear layer, before 
transmitting that signal via the optic nerve to the brain. The epidermis 
begins to differentiate into the cornea. By 17 days the iris is well 
established and the seperation between the retinal and lenticular zones of 
the eye cup, the ora serrata, can be distinguished. The retina is undergoing
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Figure 18.
Expression in sensory epithelia: the ear. Bright field of sections hybridised with TGF 
62 (A, C, F) and dark field of sections hybridised with either TGF (52 (B, D) or TGF 03 
(E). (A, B) sagittal section through otic vesicle of 10.5 days p.c. embryo. TGF 02 RNA 
is expressed in a localised region of the otic epithelia adjacent to acoustic ganalion 
VIII. (C, D, E) Serial sagittal sections through a 16.5 day p.c. embryo. TGF pz is 
localised to the pseudostratified sensory epithelium rather than the simple cuboidal 
epithelium opposite (C,D). TGF 03 RNA is not expressed in any otic structure but is 
present in the mesenchymal condensations which form the otic capsule (E). (F) High 
power of (C). 1=TGF-01, 2=TGF-02, 3=TGF-03 and 4=sense riboprobe. o=otic vesicle, 
g=ganglion, s=pseudostratified epithelium, c=simple cuboidal epithelium, paperi-otic 
capsule. Scale bars represents 200}im (A, B, C, D, E) or SO^m (F)

Figure 19.
Expression in sensory epithelia: the nose. Bright fields of sections hybridised with 
TGF62 probe (A, E) or TGF 63 (C). Dark field of sections hybridised with TGF 02 (B) 
or TGF 03 (D). (A, B, C, D, E) transverse sections through 14.5 day p.c mouse head. 
TGF 02 RNA is expressed in the nasal epithelium adjacent to the cavity. It is also 
expressed in Jacobson’s organ (A, B). (E) High power of (A) demonstrating 
expression of TGF-02 in the epithelium nearest the nasal cavity. TGF 03 is expressed 
in the mesenchymal condensations which will become cartilage and also in the muscle 
of the tongue (C, D). 1=TGF-p1,2=TGF-p2, 3=TGF-03 and 4=sense riboprobe. 
o=olfactory epitheliumJ=Jacobson’s organ, t=tongue. Scale bars represents 200pm 
(A, B, C, D) or 50pm ( 0

Figure 20.
Expression in sensory epithelia: the eye. Bright field (A, C, D, G) and dark field (B, 
E, H) of sections hybridised with TGF 62. (A, B, C, D, E, F, G, H) Sagittal sections 
through eye of 16.5 day p.c. embryo. TGF (52 RNA is expressed in the anterior side of 
the lens epithelium, and in the ora serata (A, B). (C) High power of (A) showing 
hybridisation of TGF (52 to the outer layer of the neural retina. (D, E, F) A more sagittal 
section through the eye to that of (A) demonstrating TGF-p2 in the neural retina and 
also very intense expression in the region of the eye where the neurones from the 
neural retina leave through the optic nerve. (F) Adjacent section hybridised with TGF- 
p3 riboprobe showing no expression in the pigmented layer of the eye. No expression 
in the optic nerve was seen with this riboprobe demonstrating the specificity of TGF-p2 
expression. TGF 62 RNA was also expressed in the mesenchyme of the eyelides 
behind the eyelid furrow. There was also expression of RNA in the epithelia of the 
eyelid furrow adjacent to the eye (G, H). 1=TGF-(51,2=TGF-(S2, 3=TGF-{53 and 
4=sense riboprobe. os= ora serata, Mens, r=retina, Mnner retina, o=outer neuronal 
retina, p=piamented epithelium, on=optic nerve, e=eyelash follicle. Scale bars 
represents 200pm (A, B, D, E, F, G, H) or 50pm (C)

further differentiation, although it has no cones. By 18 days the eye has 
completed development (Rugh 1990)
The earliest expression of TGF-|32 RNA is seen at 10.5 days p.c around 
the retina of the optic cup. Expresson of TGF-|32 RNA continues to be seen 
in this region but it is not until 16.5 days p.c. that it can be localised to the 
outer retinal layer of neural cells (Fig 20 C). Expression of TGF-p2 RNA is 
also seen over the optic nerve at 12.5 days p.c. and an intense 
hybridisation signal was observed at the point where all the nerves of the 
retina leave the eye (Fig 20 D, E). At 16.5 days p.c. TGF-|32 RNA was also 
seen in the ora serata and in the lens epithelium. The expression in the 
lens epithelium was restricted to the anterior portion of the lens itself and 
also limited to the inner cells of the epithelium (Fig 20 A, B). TGF-p2 RNA 
was also seen in the mesenchyme of the lower and upper eyelids at 16.5 
days p.c. (Fig 20, G, H). TGF-p2 RNA was also expressed in the innermost 
layer of cells at the region of the fused epithelium at 16.5 days p.c. but not 
in the eyelid furrow per se (Fig 20 G, H). Note that TGF-p2 RNA was 
detected in the condensation of cells which are the developing follicles of 
eyelashes of the mouse (Figure 20 G, H). There is also expression in the 
cells along the innermost side of the eyelids which are destined to become 
the conjuctiva (Fig 20, G, H). TGF-p3 RNA was expressed in the sclera, a 
tough mesenchymatous and partially cartilaginous coat, outside of the 
choroid coat of the eye, at 16.5 days p.c. and in the pigmented epithelium 
of the eye at 16.5 days p.c. (Fig 20 F).
3.2.6 Expression of TGF-(3s in developing teeth
Tooth development begins at about 12 gestation days and continues 
beyond birth. The tooth buds of the first molars and incisors appear at the 
same time. The first indication of teeth is the appearance of thickening and 
elongation of the dental lamina within the epithelial lining of the oral cavity, 
the growth of which parallels the growth of the jaw. The dental lamina is an 
invagination and ingrowth of the stratified oral epithelium and consists 
mainly of cuboidal cells with a basal layer made up of low columnar cells. A 
day later the first tooth buds (destined to become molars, other teeth such 
as inscisors follow later) show invagination in the dental lamina. This 
invagination will be filled with mesenchymal cells which becomes the
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Figure 21.
Expression of TGF (3 isoforms in the developing teeth. Bright field (A, D, G) and 
dark field (B, E) of sections hybridised with TGF 132. Brightfield (H) and dark field (C,
F) of sections hybridised with TGF p3. (A, B, C) Serial sagittal section through lower 
jaw of 14.5 day p.c. mouse embryo, with a tooth bud. TGF-(J2 riboprobe hybridised to 
the mesenchyme surrounding the tooth bud but was not expressed within the stuctures 
of the tooth bud at this stage (A, B). TGF-p3 was only expressed in a line of muscle at 
the lower part of the jaw and not in the tooth bud or surrounding area (C). By 16.5 
days p.c. both TGF-p2 and TGF-B3 are expressed in the tooth bud. (D, E, Fj Sagittal 
sections through incisor of 16.5 day p.c. embryo. TGF 62 RNA is expressed in the 
ameloblasts and odontblasts as wells as dental papilla (D, E). TGF p3 RNA is 
localised to the ameloblasts but not the odontoblasts. Expression is also seen in the 
dental papilla but not as extensive as TGF 132 (F). There is also extensive expression 
of both genes around the tooth buds at this time. (G and H) are high power views of 
the incisor hybridised with either TGF-p2 (G) or TGF-(33 (H). Expression of TGF-(32 is 
very intense in the ameloblasts and there is also expression in the odontoblasts. 
TGF-p3 is also expressed in the ameloblasts and although difficult to compare in situs 
quantitatively the expression of TGF-p2 appears to be greater than TGF-|33. Neither
?ene is expressed in the single layer of epithelial cells which overly the ameloblasts. 
=TGF-|31, 2=TGF-(32, 3=TGF-j33 and 4=sense riboprobe. t=tooth bud, i and in=incisor, 
d=dental papilla, b=odontoblasts, a=ameloblasts. Scale bars represents 200um (A, B, 
C, D, E, F) or 50pm (G, H) ^

dental papilla. The stellate reticulum appears between the central cells of 
the tooth bud epithelia which defines the inner and outer enamel 
epithelium. The inner enamel epithelium will differentiate to ameloblasts 
which secrete the enamel cap of the tooth. By 16 days p.c. the enamel 
epithelium cells are continuing to proliferate which increases the volume of 
the dental papilla. The inner enamel epithelium is one cell thick while the 
outer epithelium is a single layer of columnar cells overlying a thick layer of 
squamous cells. At this stage the dental sac which surrounds the 
primordial tooth consists of several layers of flattened cells. As 
development proceeds at 17 days p.c., bone is laid down around the tooth, 
and tooth buds of the second set of molars appears. Development of the 
teeth continues up to 5 days after birth for the first teeth that appeared but 
up to 35 days postpartum for the last teeth to develop.
No expression of any TGF-p isoform was detected in the early tooth buds 
at 14.5 days p.c. or earlier (Fig 21 A,B). Both TGF-p2 RNA and TGF-p3 
RNA were expressed in epithelial and mesenchymal components of 
developing teeth, but not until after 14.5 days p.c.. Prior to this stage only 
TGF-pi RNA was detected in the tooth buds, which had been previously 
reported by Lehnert and Akhurst (1988), and which was confirmed by this 
study.
Both TGF-p2 RNA and TGF-p3 RNA were expressed in mesenchyme 
between the tooth bud and the epithelium of the oral cavity. The 
expression of TGF-p2 RNA was more defined, an intense band of 
expression visible directly underneath the oral epithelium. The expression 
of TGF-p3 RNA was not limited to the mesenchymal cells underlying the 
oral epithelium but appeared to have a low level of expression in all the 
cells surrounding the tooth bud (Figure 21 A, B). There is also a disparity of 
expression patterns between the TGF-p isoforms. TGF-pi, unlike the other 
two, was not expressed in the dental papilla in later stages of tooth 
development. There was some over lap of expression with both TGF-pi 
and TGF-p2 expressed in the inner enamel epithelium. Also TGF-p2 
showed similar expression to that described for TGF-pi in the cervical 
loops of the dental epithelium.
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At 16.5 days p.c. the expression of TGF-p2 RNA appeared to be more 
extensive and intense than TGF-p3 RNA, although it is difficult to compare 
quantitatively the intensity of expression of different probes (Fig 21).
Both TGF-p2 RNA and TGF-p3 RNA were expressed in the ameloblasts 
(Fig 21 D, E, F, G, H). Neither gene was expressed in the outer enamel 
although there was intense expression of TGF-p2 in the ameloblasts at 16.5 
days p.c. (Fig 21 G) there was no expression of TGF-p2 RNA (or TGF-p3 
RNA) in the stratum intermedium, which are the single layer off epithelial 
cells overlying the ameloblasts (Fig 21 G, H). Both were also localised in 
the dental papilla, although with apparently different patterns of expression 
(Fig 21 E, F). TGF-02 RNA was localised in a majority of the ceils which 
make up the dental papilla with a gradient of expression becoming more 
intense towards the anterior portion of the tooth, this could reflect cell 
density. The expression of TGF-p3 RNA was not as widespread as 
compared to TGF-p2 RNA. TGF-|33 RNA expression was localised more 
centrally in the dental papilla (Fig 21 F). The expression of TGF-p3 RNA in 
this region did seem to coincide with cell density. The immediate anterior 
portion of the dental papilla was negative for TGF-p3 RNA.
3.2.7 Expression of TGF-(3s in neural tissue
The central nervous system is one of the first systems to develop and to 
differentiate and one of the last to be completed during embryogenesis. 
The spinal cord begins to appear at about 8.5 days p.c.. At 10 days p.c. the 
neural groove is closed in limited regions, forming a large neural canal with 
a thick layer of surrounding neuroblasts. Neural crests appear 
simultaneously as the neural tube closes (Kaufman, 1992). By 11.0 days 
p.c. the spinal cord has thickened and the ventral horns, spinal ganglia and 
spinal nerves become visible. Sclerotome mesenchyme is distributed 
around the cord and encloses the notochord which is located ventrally. 
This will degenerate as a cartilaginous centrum develops around it.
In this study expression of TGF-p2 RNA and TGF-p3 RNA appeared to be 
very limited in neural tissue of the embryonic mouse. At 10.5 days p.c. 
TGF-p2 probe showed hybridisation to the forebrain in the telenchephalon 
(Figure 23 A, B). Expression in the brain appeared to be very limited, the
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Figure 22.
Expression of TGF |J2 in the ventral horns. Bright field (A, D, G) and dark field 
sections (B, E, F) hybridised with TGF 62. Dark field of sections hybridised with sense 
TGF p2 probe (C, F, I). 9.5 (A, B, C) 11.5 (D, E, F) and 12.5 (G, H. I) day p.c. 
embryos transversely sectioned. TGF 62 RNA is expressed at only 11.5 days p.c. in 
the ventral horns of the spinal cord (D, E). Expression of TGF 62 is not seen prior (A, 
B) or post (G, H) this developmental stage. 1«TGF-pi, 2=TGF-62,3=TGF-fJ3 and 
4*sense riboprobe. n=neural canal, v= ventral horns, na* neural arch. Scale bars 
represents 200pm
A -  2 D 2
Figure 23.
Expression of TGF (3 isoforms in other neural tissue. Bright field (A) and dark field 
(B, E) of sections hybridised with TGF (32 riboprobe. Light field (D) and dark field (C,
F) of sections hybridised with TGF 63 probe. (A, B, C) 10.5 day p.c. embryo sectioned 
sagittally showing expression of TGF |32 RNA in the fronto-nasal mesenchyme and 
developing brain (A, B). At this stage of development expression of TGF-p3 is limited 
to the intervertebral discs. Sagittal section through brain of 16.5 day p.c. embryo 
showing hybridisation of TGF (33 probe to the mitral cells of the developing olfactory 
lobe (D, F). TGF-62 is not expressed in the brain at this stage of development. 
1=TGF-(31,2=TGF-|32,3=TGF-(33 and 4=sense riboprobe. Morebrain, fnm=frontonasal 
mesencnyme, m=mitral cell layer. Scale bars represents 200pm

only other time TGF-p2 RNA being observed was at 16.5 days p.c. in the 
mesencephalon (data not shown). TGF-p2 RNA is transiently expressed at 
comparatively low levels in the ventral horns of the spinal cord at about 
11.0 days p.c. (Figure 22 D,E). The transcripts are not seen prior to 10.5 
days p.c. or after 11.5 days p.c. (Figure 22 A,B, G,H). No expression of 
TGF-|S2 RNA was seen in any other structure of the spinal cord or related 
nervous tissue. TGF-03 RNA is not expressed in any part of the spinal 
cord. TGF-p3 RNA is only found to be expressed at later stages of 
development. At 14.5 days p.c. transcripts of TGF-p3 RNA were seen in 
the mitral cells of the developing olfactory lobes. This expression persists 
up to at least 16.5 days p.c. (Figure 23 D, F). Apart from this expression of 
TGF-|J2 RNA and TGF-p3 RNA in the regions described, the presence of 
TGF-(32 RNA during the epithelial differentiation of various sense organs 
was the only other potential site of TGF-p RNA isoforms expression in the 
nervous system.
3.2.8 Expression of TGF-p isoforms in epidermis and 
whisker follicles
Although the embryo has an ectodermal covering from an early stage of 
embryogenesis, it is not until about 14 days p.c. that differentiation of the 
epidermis begins. At this time congregations of cells, hair follicle primordia, 
appear in the single layer of ectoderm. At 15 days p.c. a second skin layer, 
the stratum germanitum arises, and between it and the first layer a basal 
layer develops. In between these two events the vibrissae papilla have 
invaginated. Prior to 14.5 p.c. days no expression of either TGF-p2 RNA 
nor TGF-p3 RNA was seen on the surface of the embryo. At 14.5 days p.c. 
the TGF-p2 riboprobe was seen to hybridise to the congregation of cells 
which are the forerunners of the hair follicles. At this stage TGF-p3 RNA is 
not localised in either the epidermis nor the primordia of the hair follicles.
At 14.5 days p.c. expression of TGF-p2 RNA is restricted to the hair follicle 
primordia which persist up to 16.5 days p.c. (Fig 24 A, B). By 18.5 days 
p.c. the skin is almost fully developed. The hair follicles have differentiated 
rapidly and are abundant. By this stage the hair bulb, core and inner and 
outer sheaths all project deeply into the dermis. Again TGF-|32 RNA was
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Figure 24.
Expression of TGF p isoforms in the skin and vibrissae. Light fields (A, C, F, H, J)
and dark fields (B and D) of sections probed with TGF 62. Light fields (G, I and K) and 
dark field (E) of sections hybridised with TGF p3. (A, B) Sagittal sections through 16.5 
day p.c. skin. No hybridisation is seen in the ectoderm by either TGF 62 or TGF p3 
probes (A,B). TGFjB2 probe hybridises to the condensation of cells which will develop 
into hair follicles. (C, D, E) sections through skin of 18.5 day p.c. embryo. Neither 
TGF-p2 nor TGF-p3 is expressed at levels of detection in the dermis or epidermis. 
TGF-62 is expressed in the hair follicles (C, D). There is slight expression of TGF-p3 
RNA in the hair follicle at this stage (E). (F,G) Sagittal section through snout of 16.5 
day p.c. embryo showing expression of TGF (32 and TGF p3 in the hair follicles. There 
is still no expression in the skin. The expression of TGF-62 is more intense in the hair 
follicles than that of TGF-63. (H, I) High power of hair follicles demonstrating 
expression of TGF-p2 in tne outer root sheath (H). TGF-p3 RNA also appears to be 
expressed in the outer root sheath (I). The hair follicle in (I) is from the adjacent 
section to that in (H) and is giving the impression that TGF-p3 is expressed in the inner 
root sheath. (J, K) High power transverse sections through whisker follicles at 16.5 
days p.c. hybridised with TGF-p2 (J) and TGF-p3 (K). TGF-p2 RNA is expressed in 
Henle’s layer and outer root sheath (J). (K) deeper transverse section than in (J), 
TGF-p3 RNA is expressed in the outer root sheath. Sagittal section through skin of 
18.5 day p.c. embiyo. Neither TGF p2 nor TGF p3 is expressed at a high level in the 
epidermis or dermis. Both are expressed in the condensation of cells which are 
developing hair follicles and in the sub basal mucosa. (J, K, L, M) Sagittal section 
through head of 16.5 day p.c. embryo which has cut vibrissae in transverse sections. 
TGF p2 RNA is expressed in the inner and outer epithelium of the hair follicle (J, K). (L) 
high power of (J). (M) high power of vibrissae showing hybridisation of TGF p3 probe 
to inner epithelium of whisker follicle. 1=TGF-pi, 2=TGF-p2,3=TGF-p3 and 4=sense 
riboprobe. h^hair follicle, d= dermis, e= epidermis, u=upper iaw, Mower jaw, x and r 
«=outer root sheath. Scale bars represents 200pm (A, B, C, D, E, F, G) or 50pm (H, I,
J, K)

only found in the hair follicles with no expression seen in the dermis or 
epidermis (Fig 24 Ct D). TGF-p3 RNA was not expressed at this stage of 
skin development but was expressed, although to a lesser extent in the 
hair follicles (Fig 24 E). The expression of both genes in the hair follicles 
appeared to be associated within different cell types. TGF-p2 RNA was 
restricted to the outer hair sheath while TGF-p3 RNA was localised to the 
cells which would form the mesenchymal sheath (Fig 24 F, G, H, I).
The expression of TGF-p2 and p3 RNA in the whisker follicles was noted 
as early as 14.5 days p.c. when the vibrissae have invaginated. TGF-p2 
RNA and TGF-p3 RNA were expressed in the whisker follicles at 16.5 days 
p.c. (Fig 24 J, K). TGF-p2 RNA was expressed in the inner or outer root 
sheaths at this stage in development (Fig 24 J). TGF-p3 RNA was 
restricted to the inner root sheath (Fig 24 K). Expression of TGF-p2 RNA in 
the mesenchyme of the snout was restricted around the vibrissae. No 
expression of TGF-p2 RNA was observed immediately adjacent to the 
skin.
3.2.9 Extraembryonic expression of TGF-p isoforms
All three TGF-ps are expressed in extraembryonic membranes although all 
have a distinct pattern of expression. The expression of the TGF-ps was 
only followed up to 9.5 days p.c. as after this time the embryo was 
dissected from the decidua.
The earliest embryos investigated were 6.5 days p.c. No expression of 
either TGF-p2 or (33 RNA was seen in any embryonic stucture at 6.5 or 7.5 
days p.c.. However, there was expression of both genes in extraembryonic 
membranes. This expression continued up to 9.5 days p.c.. At 10.5 days 
p.c., and after, the embryo was dissected from the decidua, which was 
discarded.
At 6.5 days p.c. TGF-p2 RNA was RNA was present in the decidua 
capsularis although the expression was not seen at the surface of the 
decidua (Fig 25, A, B). TGF-p3 RNA was also seen in the decidua 
capsularis but the expression pattern was in direct contrast to that 
observed for TGF-p2 RNA, and was possibly located in the uterine
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Figure 25.
Expression of TGF 6 isoforms in extraembryonic membranes. Bright field (A, D,
G) and dark field (B, E, H) of sections hybridised to TGF 02 probe or TGF p3 (C, F, I). 
(A, B, C) section through 6.5 day p.c. decidua. TGF 62 is expressed in a wide band of 
cells around the outside of the decidua (A, B). TGF p3 is expressed in a tighter band 
around the edge of the decidua (C). (D, E, F) Section through 8.5 day p.c. decidua. 
TGF p2 is intensely expressed in the uterine epithelium (D, E). TGF (J3 probe 
hybridised to the decidua. No expression of TGF-03 was seen in the uterine epithelium 
(F). (G, H, I) Section through decidua at 9.5 days p.c. TGF (S2 is intensely expressed 
in the giant cells of the decidua (I, J). TGF 63 is limited to a tight band of cells on the 
outer limits of the decidua (K). 1*TGF-01,2*TGF-p2, 3*TGF-p3 and 4*sense 
riboprobe. d=decidua, e*uterine epithelium, m=mesometrial decidua. Scale bars 
represents 200pm

TABLE 1
Summary of TGF-p RNA expression during embryogenesfs
+ denotes that RNA is abundant at some stage between 6.5 days p.c. and birth, though 
expression may be transient. is below the detection level of in situ hybridisation.
* Data from Lehnert and Akhurst (1988) and Akhurst et al (1990)
1. Data taken from (Sandberg et al 1988a; Sandberg et al 1988b), (Wilcox and 
Derynck, 1988), (Lehnert and Akhurst, 1988), and (Akhurst et al 1990b; Akhurst etal 
1990a).
2. Data taken from (Fitzpatrick et al 1990; Pelton et al 1990)
3. Data taken from (Pelton et al 1989)
c-cuboidal, s=squamous, iv=intervertebral disc anlagen
Cell type p i* £2 p3
Haematopoietic tissue + -  -
Endothelia + -  -
Thyroid +
Parathyroid +
Thymus + -  -
Kidney -  -  -
Intestine -  -  -
Stomach -  -  -
Eplthelia
Whisker follicles 
Salivary gland 
Tooth bud 
Secondary palate 
Bronchiole epithelium 
Otic epithelium 
Olfactory epithelium 
Lens epithelium 
Neural retina 
Hyperplastic nodules 
Suprabasal keratinocytes
Cartilage and bone
Precartilaginous blastema- 
Growth zone of long bone 
Perichondria 
Hypertrophic cartilage 
Osteoblasts,osteoclasts
Cardiac tissue
Pre-valvular endothelium +
Pre-valvular myocardium +
Neuronal tissue
Ventral spinal cord +
Ventral forebrain +
Olfactory lobe +
Extraembryonic membranes + + +
Muscle -  + +
+ + +
+  +  -
+ + +
+ - +
+(s) +(c)
—  +  —
—  +  —
-  +  -
-  +  -
+1
+(limb) +(iv)
Mesothelia +
longitudinal muscle (Fig 25, C, F). TGF-p2 mRNA was also present, in 
considerable quantities, in the uterine epithelium at this stage of 
development (Fig 25, D, E). The expression of TGF-p2 RNA and TGF-p3 
RNA at 8.5 days p.c. was seen in identical patterns to that described for 
6.5 days p.c.. However the level of TGF-p2 RNA expression seemed to 
have increased (Fig 25 G, H), whilst the level of TGF-p3 expression had 
dropped (Fig 25 I). TGF-pi RNA appeared to have an overall low level of 
expression in the extra-embryonic structures (data not shown).
3.3 Generation and analysis of mutant TGF-|32 
constructs
A functional approach to investigate the potential role(s) of TGF-p isoforms 
during embryogenesis was undertaken. Mutations of one isoform were 
generated with the objective of producing a dominant-negative mutant. The 
mutant proteins produced were analysed, in vitro, to determine their 
potential biological activities. Human TGF-p2 (hTGF-p2) was chosen as a 
starting point for the generation of two mutants.
Human TGF-p2 is 414 amino acids long. There are two constitutive parts 
to the polypeptide, these are the latency-associated peptide (LAP) which 
constitutes the first 302 amino acids, followed directly by 112 amino acids 
which make up the mature TGF-p2 protein (see figure 11). Two mutant 
hTGF-p2 genes were made:
(a) In the first mutant, 36bp of the region coding for the signal 
peptide sequence was removed from the cDNA.
(b) The second mutant hTGF-p2 was generated by targeted 
mutagenesis of cDNA sequence encoding the amino acids which are 
recognised as the proteolytic cleavage site sequence of hTGF-p2.
A detailed description of the strategy for mutant generation is given in the 
previous chapter and figure 10. Prior to analysing their biological effects, 
the mutants were sequenced across the areas that had been altered to 
confirm the expected sequence change and to ensure the maintainance of 
the correct reading frame.
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3.3.1 Generation of the signal peptide sequence mutation 
of human TGF-(32
The signal peptide sequence of human TGF-p2 is encoded by the first fifty 
seven nucleotides (19 amino acids) including the initiation codon. Thirty six 
base pairs of this sequence were removed to disrupt the amino acid 
sequence, but leaving the sequence in the correct reading frame. This 
resulted in the removal of twelve of the nineteen amino acids which make 
up the signal sequence (see figure 7). Of the original nineteen amino acids 
the first five codons were left intact as was the last codon. Between these 
original codons one new codon was generated by the ligation of the two 
blunt ends. This codon (ATC) translates to isoleucine. These changes 
maintained the correct reading frame, and if translated should generate a 
shorter TGF-p2 polypeptide of 401 amino acids. The lack of the signal 
peptide sequence would hopefully prevent the secretion of the mutant 
TGF-p molecule.
The generation of the signal peptide sequence mutant was facilitated by 
the fact that the restriction endonuclease Espl (with a heptanucleotide 
recognition sequence) was found to cut hTGF-p2 at two sites. These were 
at positions 225 and 265 of the cDNA. Espl does not cut the vector jiH3M. 
The construct *H3M-TGF-p2 (6.070Kb) was digested with Espl which 
generated two linear pieces of DNA (6.031Kb and 39bp). The digested 
construct was analysed to check for complete digestion and run on a 1 % 
gel to seperate the two fragments. The larger fragment was excised from 
the gel and purified. The Espl restriction endonuclease can in some cases 
generate compatible Hsticky ends.” In this case this was not so and the 
termini had to be end-filled to create blunt ends. Even if the digest had 
produced compatible ends they would have had to be end filled in order to 
maintain the correct reading frame (see fig”^ ). Once the termini were end 
filled they were ligated to generate the first mutant (called p2e). The ligation 
mix was transfected into competent MC1061/P3 bacterial cells. DNA was 
extracted from colonies by the small scale isolation method. To determine 
which of the colonies contained the mutated construct, with the expected 
39bp deleted, DNA was digested with two enzymes, EcoRI and Pstl. EcoRI 
cut the construct at the immediate junction between the vector and the
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cDNA insert at position 0. Pstl cut the construct at position 248 in the 
hTGF-(52 cDNA. A double digest of the mutant construct with these two 
restriction endonucleases should generate two bands; a 5.8Kb and a 
209bp. This was compared to *H3M-hTGF-p2 construct which had also 
been digested with these two enzymes which would generate bands of; 
5.8Kb and 248bp. The digested samples were run on a 2-3% agarose gel 
and the DNA visualised by staining with ethidium bromide.
To check the restriction endonuclease digestion, end filling and ligation had 
generated, precisely, the expected changes, the mutant construct was 
sequenced over the area of interest. Sequence data was generated using 
oligonucleotide primer P6 which was 41 nucleotides upstream of the end of 
the coding region for the signal peptide sequence (see figure 10).
The first time that this cloning procedure was completed, the generated 
mutant, p2e, did not produce the expected sequence. This was confirmed 
by sequence analysis of the alternate DNA strand using primer P1 as the 
sequencing template. P1 anneals to the sequence 200bp upstream of the 
region which encodes the signal peptide sequence.
It was determined that one of the nucleotides from the 5’ terminal end of 
the coding sequence, produced by restriction endonuclease digestion with 
Esp I had been removed (see Fig 8). This was thought to have occurred 
during the reaction to endfill the. recessed termini prior to ligation. It is 
known that the Klenow fragment, which is utilised for the end filling step, 
does have 3’ exonuclease activity, especially if the concentration of dNTPs 
is too low. The removal of this single nucleotide resulted in the sequence 
moving out of frame after the sixth codon (see Fig 8). A stop codon was 
present in this reading frame 24 codons further upstream, which would 
result in a polypeptide of 32 amino acids being generated from the original 
ATG site.
This mutant was not discarded immediately, as an ATG site, normally 28 
amino acids beyond the original initiation site, could possibly provide an 
alternative startpoint for initiation of translation. A protein produced from 
this initiation site would be 28 amino acids short of the wild type TGF-p2 at 
386 amino acids long. If this protein was produced then it would lack the
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whole signal peptide sequence, and could have unusual biological activity. 
This mutant was designated as p2e.
The signal peptide mutation was generated again in order to produce the 
original defined mutant and was called |52f. This mutant was also 
sequenced to confirm the maintainance of the reading frame.
3.3.2 Generation of cleavage site mutation of hTGF-|32
The second mutant hTGF-p2 molecule, (p2c,) was produced by altering the 
sequence which coded for the proteolytic cleavage site. The proteolytic 
cleavage site is required to allow the mature TGF-p polypetide to escape 
from the LAP and become activeted.
The hTGF-|32 polypeptide cleavage site is a five amino acid recognition 
sequence (Arg-Arg-Lys-Lys-Arg) at position 298aa to 302aa. The mature 
hTGF-|52 protein is cleaved from the latency-associated peptide directly 
after the last arginine residue in the above sequence. The cleavage site 
mutant was generated by altering the DNA sequence from which the 
cleavage site is encoded. This resulted in a change in three of the five 
amino acids which make up the cleavage site sequence, and 
simultaneously introducing two new restriction endonuclease recognition 
sequences into the cDNA.
This was achieved by using a 26 base long oligonucleotide (P4) (Fig 3), 
which contained three mismatches compared to the wild type sequence, in 
a PCR-site directed mutagenesis (PCR-SDM) reaction (described in detail 
in section sdm). The incorporation of this mismatch oligonucleotide into 
hTGF-p2 cDNA would alter three codons in the cleavage site sequence. 
This would result in the replacement of the three arginine residues with two 
leucines and a glutamine residue respectively to give a new sequence of 
amino acids (Leu-Gln-Lys-Lys-Leu). The new sequence would not be 
recognised as a site for proteolytic cleavage and would therefore prevent 
the cleavage of the mature TGF-02 molecule from the LAP.
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3.3.2.1 Identification of PCR products and clones which carried the 
mutant sequence
The mismatch oligonucleotide, P4, was also designed to generate new 
restriction sites which could be used to quickly analyse clones. The two 
new restriction sites were a Pstl site introduced at position 1155, of the 
cDNA, and an Hindlll site at position 1169 of the cDNA. The PCR-SDM 
products were produced as described in Materials and Methods. Amongst 
the PCR products there were, potentially, a variety of double stranded 
products. These were:
(a) wild-type products
(b) heteroduplexes (either strand contains mutation)
(c) products which contained the mutation in both DNA strands
(Fig 4).
The introduction of the restriction endonuclease recognition sites for Pstl 
and Hindlll, meant that a PCR-SDM product containing these two new 
sites would, after digestion with these restriction endonucleases, generate 
different fragments of DNA that were compared to wild-type hTGF-|32 
which had been subjected to normal PCR (Fig 26 B).
The PCR-SDM product which contained both mutated strands was sub­
cloned into the *H3M vector after appropriate digestion with restriction 
endonucleases.
The PCR-SDM product was digested with Notl and Sphl which have 
recognition sequences at positions 730 and 1300 of the hTGF-p2 cDNA 
respectively (Fig 10). This double digest generated an 872bp fragment that 
contained the potential mutant cleavage site (position 1155-1169 of hTGF- 
p2 cDNA). The ^H3M-hTGF-p2 construct was also digested with Notl and 
Sphl and the comparable 872bp fragment containing the wild-type 
cleavage site coding sequence removed (see Fig 10). The 872bp fragment 
of cDNA generated from the PCR-SDM was ligated into the linearised 
3tH3M-hTGF-p2 construct.
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Figure 26.
Sequence analysis of mutant construct generated by SDM-PCR.
(A) Sequence across wild-type and mutant strand using primer P5. The asteriks 
beside the bases on the mutant side indicate the changed nucleotides. (B) The wild 
type and mutant constucts were subjected to PCR using primers P1 and P2. The PCR 
products were digested with Hind III and Pst I. The wild type samples gave the 
expected fragments of DNA 1039 and 927 bp, when digested with Hind III and 1718 
and 248 when digested with Pst I (3 and 6). Samples 1 and 2 were two products of the 
SDM-PCR which were suspected to have the mismatched base pairs introduced.
When digested with Hind III and Pst / they generated DNA fragments of (Hind III) 927, 
797, and 242bp; and (Pst I) 907, 811 and 248bp. This indicated that the correct base 
pair mutations had been introduced.
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The construct was transfected into MC1061/p3 and the clones analysed. 
24 colonies were picked and subjected to small scale DNA preparation. 
The plasmid DNA was analysed by digestion with restiction endonucleases 
Pstl and Hindlll. Of the 24 colonies picked 12 were found to contain these 
two new restriction sites and therefore the mutated cleavage site 
sequence.
Conformation that the base pair changes had occurred was achieved by 
sequence analysis of this region with primer P5 (See Fig 26).
3.4 Analysis of the biological activity of 
polypeptides generated from the mutant and wild 
type constructs
3.4.1 Optimization of COS-7 cell transfection and 
collection of conditioned media
The mutant constructs were transfected into COS-7 cells as described in 
materials and methods. To confirm that the predicted proteins could be 
expressed from the mutant genes, conditioned media was collected and 
treated and assayed as described in materials and methods.
Each transfection was assayed for efficiency using a vector which 
contained a bacterial reporter gene. COS-7 cells were transfected with 
pIRV (2.5un'its), a construct containing the bacterial gene p-galactosidase 
driven by actin promoters (Beddington et al 1989). The transfection of this 
construct into COS-7 cells provided an indication of the efficiency of 
transfection. After conditioned media had been collected from cells which 
had been transfected with pIRV they were fixed and stained. 
Approximately 80% of cells were stained blue after a 24-36 hour 
incubation. Cells which had not been transfected with any DNA, but had 
undergone the complete transfection protocol, were also fixed and stained. 
No staining was observed.
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The three mutant hTGF-p2 constructs, p2®, p2c, p2f, as well as p i33, p2 
and the 3iH3M vector were transfected Into COS-7 cells.
p i33 was generated by Brunner et al (1989). They described the mutation 
of simian cDNA by SDM, causing amino acid 33 in the LAP to change from 
a cysteine to a serine residue. This resulted in normal levels of biological 
activity. However, p i33 does not require acid activation, unlike other TGF-p 
polypeptides. For the purpose of these experiments it was considered to 
give wild-type activity.
One flask of cells underwent the transfection protocol but without the 
presence of any DNA, to act as a negative control. Media was conditioned 
for 24, 48 and 72 hours. Conditioned media collected after 48 hours was 
determined to have the highest level of TGF-p expression from the 
constructs. At 72 hours cell death was quite extensive and the cells looked 
very poorly. The level of TGF-p expression at this time was equivalent to 
that seen at 24 hours. All biological activity from the various constructs 
described below was from conditioned media collected at 48 hours. The 
potential instability of TGF-p polypeptides in the conditioned media was 
investigated by incubating rTGF-pi in media collected from COS cells 
transfected with no DNA. The conditioned media was treated as normal 
and assayed. No loss in biological activity of the rTGF-p1 was detected. 
The effect of protease inhibitors on TGF-p polypeptides and CCL64 assay 
was determined. Conditioned media from COS cells transfected with p i33 
had either all three protease inhibitors added (see Materials and Methods), 
or no protease inhibitors added and the media assayed. The protease 
inhibitors did not effect the biological activity of p i33. The three protease 
inhibitors were also added seperately to CCL64 cells during a biological 
assay. The presence of protease inhibitors did not influence the 
incorporation of 3H-thymidine by the CCL64 cells. Conditioned media, 
which was stored at 4°C or at room temperature, did show considerable 
loss of biological activity. For this reason conditioned media was either 
stored frozen or dialysed immediately after collection. The dialysed 
conditioned media was also stored frozen in aliquots and lyophilised when 
required.
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3.4.2 Western blot analysis of TGF-p
Conditioned media from various transfections were dialysed, lyophilised 
and resuspended in sample buffer. Detection of (10-200pl conditioned 
media) TGF-p was carried out as described in Materials and Methods. The 
antibody detected 5ng rTGF-p1 which had been run simultaneously. No 
p i33, p2, p2e, p2c or p2f protein was detected. The limit of detection with 
this antibody is 5ng (British Biotechnology).
3.4.3 Growth inhibition of CCL64 cells by rTGF-(31
Dilutions of rTGF-p1 were freshly prepared in assay media and analysed 
each time a CCL64 assay was performed. A representative titration curve 
is shown in figure 27. Maximum inhibition was observed at a rTGF-p1 
concentration of 285pg/ml with 50% inhibition at between 5-15pg/ml. The 
inhibition by rTGF-pi (and conditioned medias) was comparable to the 
level of inhibition described by Danielpour et al (1989). They described 
50% inhibition occuring at a concentration of between 12.5-17.5pg/ml of 
rTGF-pi. Maximum inhibition was observed at 250pg/ml TGF-pi by 
(Danielpour eta! 1989) (Figure 27).
The inhibition of CCL64 cells by rTGF-p1 could be blocked by pre­
incubation of the rTGF-p1 with an anti-TGF-p neutralising antibody (British 
Biotechnology). CCL64 cells which were treated with the antibody-blocked 
rTGF-pi protein (200pg/ml) showed 96% incorporation of 3H-thymidine 
compared to less than 3% incorporation if the rTGF-p1 protein had not 
been blocked. This demonstrated that TGF-p was responsible for the 
growth inhibitory effects on CCL64 cells. Comparable results were seen 
with conditioned media from the constructs p133 and p2, which had been 
pre-incubated with anti-TGF-p neutralising antibody (Figure 28).
3.4.4 Biological activity of sTGF-pi33 and hTGF-|32
Conditioned media from COS-7 cells which had been transfected with the 
constructs p i33, p2, pIRV, jtH3M alone and also conditioned media from 
cells which had been through the transfection protocol but with no DNA 
present in the transfection mix were assayed for biological activity. The
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biological activity determined from 4 independent transfections of the 
constructs using the equivalent of 10pl of conditioned media in each assay 
is presented in Table 2. The biological assay was carried out at least twice 
for each transfection (Figure 29).
The figures generated for p i33 and p2 compared to the results generated 
using rTGF-pi suggest that the two wild type constructs are producing 
280pg/ml and 140pg/ml respectively. Conditioned media from COS cells 
transfected with the control constructs or no DNA also showed some 
biological activity. The average incorporation of 3H-thymidine by CCL64 
cells treated with 200pl conditioned media was 46% (±4%). This suggests 
that the COS cells are producing approximately 35pg/ml. The absolute 
concentration of recombinant TGF-pi33 and TGF-p2 is approximately 
245pg/ml and 105pg/ml (Table 3). This does not compare well with the 
reported production of 60-90ng/ml from the p i33 construct by Brunner et al 
(1989) (Table 3).
3.4.5 Biological assay of conditioned media from COS-7 
cells transfected with mutant constructs
The three mutant constructs had the proteins they generated assayed for 
biological activity exactly as described above (Table 2). Figured shows the 
average biological activity of 10pl of conditioned media collected from 
COS-7 cells transfected with 4 units (40pg) of each individual mutant. p2e 
showed 83.0% (±40.6%) growth as determined by 3H-thymidine 
incorporation into CCL64 cells. p2c showed 66.0% (±31.3%) incorporation 
and p2f showed 63% (±31.2%) incorporation. Biological activity of 
conditioned media collected from COS-7 cells which had been transfected 
with 1 unit of each mutant all showed >90% incorporation (Fig 30).
3.4.6 Biological assay of conditioned media from COS-7 
cells co-transfected with hTGF-|32 and mutant constructs
Co-transfections, into COS-7 cells, were carried out such that the wild 
type:mutant molar ratios were 1:1, 1:2 and 1:4. Transfections and 
collection of conditioned media was carried out in an identical manner as 
described above. 10pl of conditioned media was assayed against CCL64
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Figure 27.
Standard curve of percentage 3H-thymkJine incorporation by CCL64 ceils 
against known concentrations of rTGF-p1.
Known concentrations of rTGF-j31 were assayed and a standard curve plotted. The 
half maximal incorporation was between 5-15pg/ml. Total inhibition of CCL64 growth 
was achieved at a concentration of about 285pg/ml.
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Figure 28.
Standard curve of 3H-thymidine incorporation by CCL64 ceils assayed against 
conditioned media from COS-7 cells transfected with p i33 and p2 constructs.
Different volumes of conditioned media from COS-7 cells which had been transfected 
with 1 unit (10pg) of 6133 and p2 constructs were assayed for biological activity. The 
concentration of each was determined in relation to the standard curve generated 
using rTGF-pi. The half maximal incorporation of 3H-thymidine was achieved at a 
concentration of 12pg/ml and 15pg/ml for p i33 and p2 respectively. This is within the 
range expected as determined for the rTGF-pi. Total inhibition was observed at 
200pg/ml for both construct The dip in the curve between 15 and 100pg/ml may 
refelect errors in the assay.
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Figure 29.
Biological activity of conditioned media from COS-7 cells transfected with wild- 
type and mutant constructs.
Histogram showing percentage 3H-thymidine incorporation by CCL64 cells when 
assayed with 10jxl of conditioned media from various transfections.
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Figure 30.
Biological activity of conditioned media from COS-7 cells co-transfected with (32 
and three mutant constructs.
1. (32 (1 unit)
2. p2 (1 unit)/(32° (1 unit)
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9. (32 (1 unit)/|32° (4 unit)
10. (32 (1 unit)/(32f (4 unit)
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Figure 32.
Biological activity of conditioned media from COS-7 cells co-transfected with 
p i33 and p2« orp2c.
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5. p i33 (1 unit)/p2c (2 unit)
6. p i33 (1 unit)/p2® (4 unit)
7. p i33 (1 unit)/p2c (4 unit)
Bi
ol
og
ica
l a
cti
vit
y 
of 
co
nd
itio
ne
d 
me
dia
 
from
 
co
-tr
an
sf
ec
te
d 
ce
lls
<o
in
to
CM
8 Q O O Q Q O O O O O  C f t c o s f f i w ^ n c M T -
uoijBJOdioou! 9 U!P!UjAj u
w
I 1 I I I I I I ■ 1 I " "I1 " ■ I ■ I 11
■— i /  /  /  /  /  /  v / y  / / / / .
■—izzzzzzzzz 
■— izzzzzzzzzzzz
.— 1ZZZZZZZZZZZZ2
HZZZZZZZZZZZZ2 
1—IZZZZZZZ
HZZZZZZZZZ
J ^  < . 1 . I . . . J . 1 > « , 1 >
cells. The average percent Inhibition of 3H-thymidine was determined for at 
least two independent transfections which were assayed twice, each time 
in triplicate (Table 2).
Figure 29 shows a the average incorporation of 3H-thymidine incorporation 
into CCL64 cells treated with conditioned media from the various co­
transfections and also the average incorporation assayed for expression of 
hTGF-p2 (61.0%). The average percentage incorporation of 3H-thymidine 
was between 50 and 62% at a 1:1 ratio of wild-type:mutant construct, 
between 58 and 77% when in a 1:2 ratio, wild-type:mutant and between 44 
and 58% when wild-type:mutant ratio was 1:4 (Table 2 and Figure 31).
3.4.7 Co-transfection of mutant constructs with sTGF-pi33 
construct
In order to determine whether the TGF-p2 mutants would form 
heterodimers with TGF-p1, the mutant constructs were co-transfected with 
the p i33 construct in the same ratios described above. The conditioned 
media was also treated and assayed in an identical manner as described 
above. The p i33 construct was not transfected with the mutant construct 
p2f.
The incorporation of 3H-thymidine by CCL64 cells was 62%, 74% and 55% 
when, assaying conditioned media from COS cells transfected with p i33 
and p2e constructs in a 1:1, 1:2 and 1:4 ratio respectively. COS cells 
transfected with p133 and p2c in a 1:1, 1:2 and 1:4 ratio produced 73%, 
68% and 77.3% incorporation of 3H-thymidine resepectively (Table 2 and 
Figure 32)
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TABLE 2 Percentage of 3H-thymidine incorporation by CCL64 cells assayed with 
conditioned media from COS-7 cells transfected with wild-type and mutant 
constructs.
Four independent transfections were completed and 10pl of conditioned media which 
had been treated as described in Materials and methods were tested for biological 
activity in a CCL64 assay. Incorporation of 3H-thymidine by CCL64 cells was 
determined as a percentage of conditioned media from COS-7 cells which had been 
through the transfection procedure but with no DNA in the transfection mix. u=unit
% 3H-thymkJine incorporation
TRANSFECTION T1 T2 T3 T4 X SD
p i33 (1 unit) 62 47 37 67 57 50 59 — 54.1 9.4
p2 (1 unit) 72 52 53 63 47 87 54 58 60.6 12.2
p2® (4 units) 80 151 8 65 82 126 59 96 83.3 40.6
p2° (4 units) 83 109 7 48 49 104 54 72 65.8 31.3
p2f (4 units) — — 41 57 37 115 — — 62.5 31.2
Co-transfection (1unit: 1unit)
02/02® 25 59 47 15 76 63 42 103 53.8 26.3
02/02° 16 39 35 32 33 106 45 96 50.3 30.4
02/02f — — 79 48 35 87 — — 62.3 21.4
01/02° 56 7 — — — — 57 49 42.2 20.6
01/02° 56 89 — — — — 64 86 73.8 14.1
01/02f
Co-transfection (1 unit:2 units)
02/02® 101 82 31 87 36 114 79 93 77.9 27.7
02/02° 70 34 70 72 68 102 71 79 70.8 17.3
02/02f — — 41 50 42 102 — — 58.8 25.2
01/02° 99 28 — — — — 82 88 74.3 27.4
01/02° 95 16 — — — — 84 80 68.8 31.0
01/02f
Co-transfection (1 unit:4 units)
02/02® 67 51 — — 26 80 49 68 56.8 17.4
02/02° 63 50 — — — — 30 91 58.5 22.1
02/02f — — — — 28 61 — — 44.5 16.5
01/02® 73 7 — — — — 63 77 55.0 28.2
01/02° 109 40 — — — — 52 108 77.3 31.5
01/02f
pIRV (2.5u) 70 125 90 79 64 104 — 45 82.4 24.6
jcH3M (5u) 74 102 83 50 88 79 — 77 79.0 14.6
TABLE 3
Estimation of concentration of protein produced by transfected COS-7 cells
The approximate amount of TGF-0 polypeptide being produced from the COS cells 
after transfection with 0133 and 02, was determined by assaying 200pl of conditioned 
media. The concentrations of both 0133 and 02 polypeptide was estimated using the 
standard curve generated by known concentrations of rTGF-01. A basal level of TGF- 
0 polypeptide production by COS cells was produced by averaging the biological 
activity of 200pl of conditioned media from control samples. The basal concentration 
of TGF-0 production by COS cells was subtracted from the estimated concentrations of 
0133 and 02 transfections to give a final concentration of 0133 and 02 polypeptide.
Samples
0133C20CVO
02(200^0
controls(200ul)
% incorporation 
of 3H-thymidine
13%
27%
46%
♦ blocking antibody 
% incorporation of 3H 
thymidine
96%
97%
— '%
concentration
TGF-0
280pg/ml
140pg/ml
35pg/ml
3.5 Statistical analysis of biological activities
3.5.1 Student’s t test on difference between mean of two 
samples
To test the null hypothesis that there is no difference between the means of 
two samples, Student’s t test was applied to the results (see Appendix B 
for statistical equations).
The means of the 3H-thymidine incorporation of the conditioned media 
from co-transfections were compared against the mean generated by the 
analysis of the conditioned media from cells transfected with the 
appropriate wild-type construct.
The values of t are presented in Table 4. The majority of the results gave
0.1<p<0.5 or p>0.5 indicating that the null hypothesis is correct. Only one 
co-transfection, p133/p2° at a 1:1 ratio gave 0.1<p<0.05 which is still not 
significant (Table 4).
TABLE 4
Values of t and their associated probabilities
The difference between the means of biological activity produced from the co­
transfections of wild-type and mutants was compared to the means of the transfections 
of wild-type constructs alone, using Student’s “t-test” to examine the null hypothesis 
that: There is no difference between the means. The values of t and their associated 
probabilities indicate that the null hypothesis is correct and there is no difference 
between the means, 
d of f = degrees of freedom
t(1:1)
£2/£2® 0.61
£2/(52® 0.79
£2/£2f 0.12
p i33/ ^ ' 1.055
p i33^ ® 2.218
(1:2)
£2/(52® 1.395
£2/£2® 1.160
£2/£2f 0.154
p i33^ ® 1.421
£133/£2® 0.930
(1:4)
£2/£2® 0.449
£2/£2® 0.190
£2/£2f 1.034
p i33^ ® 0.062
p i33^ ® 1.450
d of f probability
14 p<0.5
14 0.5<p<0.1
10 p<0.5
9 0.5<p<0.1
9 0.1<p<0.05
14 0.5<p<0.1
14 0.5<p<0.1
10 p<0.5
3 0.5<p<0.1
3 0.5<p<0.1
13 p<0.5
10 p<0.5
8 0.5<p<0.1
3 p<0.5
3 0.5<p<0.1
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Chapter 4 
DISCUSSION
4.1 Introduction
This thesis presents data concerning the expression of three members of 
the transforming growth factor type beta (TGF-p) family, TGF-p1, TGF-p2 
and TGF-p3, during murine embryogenesis. TGF-pi expression has 
previously been reported extensively in both mouse (Lehnert and Akhurst 
1988, Akhurst et ai 1990a, b) and human (Gatherer et al 1990) but 
investigation of the expression of this gene along with the other two family 
members provides an opportunity to compare their respective expression 
patterns.
These genes are members of the TGF-p family of genes which is itself just 
one group of a larger, TGF-p super-family of over 20 related genes. The 
various members of the super-family are expressed during embryogenesis 
and are thought to be vital for normal development. It has previously been 
demonstrated that both mouse TGF-p2 and TGF-p3 mRNA are expressed 
during embryogenesis, as determined by Northern analysis, and that there 
was variable expression during gestation. In order to determine the exact 
spatial and temporal localisation of these two genes, in situ hybridisation 
studies were performed on serial mouse sections from 6.5 days p.c. to 
16.5 days p.c..
The latter part of the thesis presents data which begins to assess the 
biological function of TGF-p2 by the generation of mutants and their 
investigation in vitro.
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4.1.1 In  situ hybridisation: Limitations of the current study 
and discrepancies in the literature
There are a number of points which have to be considered when carrying 
out any technique which involves nucleic acid hybridisation. These 
considerations are multiplied when examining stages of development.
1. When working with genes which are members of large gene 
families it is vital to minimise the extent of cross-hybridisation of probes to 
homologues within the gene family. The problem of cross-hybridisation 
was easily overcome by prudent choice of template from which to generate 
riboprobes. In the case of the TGF-p family this usually means that the 
template is from the sequence of the gene which codes for the latency 
associated peptide (LAP) or, from the 5’ or 3’ untranslated regions.
2. Although embryo age was calculated from the day the plug 
was found, variation in embryonic age within the litter will occur. Also the 
embryo’s actual developmental age can appear either more or less 
advanced than expected. This is particularly true of outbred strains which 
develop at a faster rate than inbred strains. Investigation of developmental 
stages at 24 hour intervals can result in morphogenetic events being 
missed. The only method to ensure complete coverage of any particular 
developmental stage is to harvest embryos at close time intervals.
3. The interpretation of RNA localisation studies often makes an 
assumption that RNA transcripts are translated into a biologically active 
protein at the site of manufacture. This is probably a simplification of the 
process, especially when considering TGF-p genes. It is well established 
that the TGF-ps are under considerable post-translational control 
(Miyazono et al 1991; Gentry et al 1987) and that TGF-p isoforms are 
secreted in an inactive form, and only activated when removed from the 
cell or tissue of origin.
Data produced from early investigations, via the in situ hybridisation 
technique, used full length TGF-p probes or probes based on homologous 
genes from a different species (Lehnert and Akhurst, 1988; Pelton et al 
1989). Lehnert and Akhurst (1988), although having used a full length
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mouse cDNA TGF-pi as a template on mouse material, commented that 
under the stringent conditions they employed for the hybridisation and 
washes, there was no difference between the results they obtained initially 
with the full length TGF-p1 riboprobe, and data generated from a template 
which was based on the latency-associated peptide region and therefore 
specific (Akhurst et al 1990b). Their results were confirmed during this 
investigation which used the same specific TGF-pi template as a positive 
control (See materials and methods). Pelton et al (1989) described the 
temporal and spatial localisation of TGF-p2 during murine embryogenesis. 
Throughout their investigation they utilised a 750bp of the human TGF-p2 
cDNA, which encodes a region of the LAP, as a template. Due to the 
expected difference in sequence homology between man and mouse the 
stringency under which they carried out the in situ hybridisation was lower 
than that described in this study or by (Lehnert and Akhurst, 1988; 
Gatherer et al 1990; Fitzpatrick et al 1990; Schmid et al 1991), and 
therefore more likely to lead to non-specific hybridisations of the human 
TGF-p2 riboprobe to the mouse TGF-p gene family. The mouse TGF-p2 
homologue which was subsequently cloned was found to be 85% 
homologous in the region chosen by Pelton and coworkers as a template. 
Previously Lehnert and Akhurst (1988) described a different pattern of 
TGF-p1 expression when they reduced the stringency of their hybridisation 
conditions, observing a signal in the ventral horns and dorsal root ganglia. 
Data presented in this thesis shows that this expression was, probably, 
due to TGF-p2. However, the less stringent conditions employed in that 
experiment were still higher than those employed by Pelton et al (1989).
One possible explanation for the differences in expression patterns 
observed by different groups is due to mouse strain. Fowlis et al (1992) 
described a novel finding in that some mouse strains show a different 
response to TPA induction of TGF-pi. Previously a strong and rapid 
induction of TGF-pi mRNA and protein had been observed when treating 
an inbred colony of NIH-Beatson mice (Akhurst et al 1988). Fowlis et al 
(1992) examined outbred and inbred mice of a fresh stock (NIH-Olac) and 
did not observe the the same strong induction of TGF-p1 mRNA which had 
previously been described. They suggested that their results demonstrated 
that elevated TGF-pi protein production is a consistent response to TPA
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treatment, but that the mechanism by which this is achieved can vary 
between strains. This may go some way to explaining the discrepencies 
between the work presented in this thesis and data published by Pelton et 
at (1989). However, this cannot be the complete explanation, as it is 
argued that the TGF-p genes are of fundamental importance in 
development, so much so, that there is conservation of them throughout a 
variety of species. To then suggest that mouse strain differences can 
produce different localisation patterns is maybe pushing that explanation 
too far.
4.1.2 Reported expression patterns of TGF-|32 and TGF-|33 
RNA in the literature
Pelton et al (1989) investigated the temporal and spatial patterns of 
expression of TGF-p2 RNA in mouse embryos from 10.5 days p.c. to 3 
days post partum. They described the expression of TGF-p2 RNA in a 
variety of tissues including bone, cartilage, tendon, gut, blood vessels, skin 
and foetal placenta. They noted that the expression of TGF-p2 RNA in 
these tissues was generally mesenchymal. FitzPatrick et al (1990) and 
Pelton et al (1990) simultaneously published the localisation of the three 
murine TGF-p gene transcripts in the developing palate. Both groups 
reported essentially identical patterns of expression of the three TGF-p 
genes although there were some minor discrepencies. Both described 
intense expression of TGF-p3 in the medial edge epithelium both before 
and after palatal shelf fusion. TGF-pi RNA was also localised to the medial 
edge epithelium but only after shelf elevation. TGF-p2 RNA was described 
by FitzPatrick et al (1990) as localised in the palate mesenchyme 
underlying the medial edge epithelium when the shelves were elevated 
and after fusion. Pelton et al (1990) described a similar pattern of 
expression but also suggested that there was localisation of TGF-p2 RNA 
transcripts in the medial edge epithelium. Gatherer et al (1990) described 
the localisation of all three human TGF-p gene transcripts in human 
embryos from 32 to 57 days p.c.. The pattern of expression for the three 
murine TGF-p RNAs were described by Schmid et al (1991) and were 
identical to that reported here, in this thesis, and by Gatherer et al (1990). 
Neither of these reports described patterns of TGF-p2 RNA expression
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previously described by Pelton etal (1989). However, the reported pattern 
of expression of TGF-pi, 2 and 3 RNA by both Gatherer et al (1990) and 
Schmid et a /(1991) were identical.
A comparison of data produced from this study, which employed specific 
mouse cDNAs as templates, and that reported by Pelton et al (1989) 
demonstrates a clear difference in the temporal and spatial pattern 
encountered. The results generated from this investigation have been 
confirmed independently by others who have also used specific mouse 
probes under comparable stringent hybridisation conditions (Schmid et al 
1991). Furthermore the temporal and spatial pattern of human TGF-p 
isoforms has been examined in comparable gestational age human 
fetuses, using specific human TGF-p probes under identical stringent 
conditions as employed in this investigation (Gatherer et al 1990), and 
have described identical patterns of expression to that described in this 
thesis and by Schmid et al (1991). More recently both Vaahtokari et al 
(1991) and Manova et al (1992) have also described data concerning 
expression of TGF-p RNAs which is in agreement with data presented in 
this thesis. A final point which indicates that the data presented here 
represents specific hybridisation is the fact that each gene does have a 
unique pattern of expression both temporally and spatially with very few 
areas of overlap.
To further minimise the chance that the in situ hybridisation might give 
spurious results each stage of development described was investigated at 
least three times. At all times a mouse specific TGF-pi template was used 
as a positive control, which produced the expected pattern of expression 
previously described by Lehnert and Akhurst (1988). As a negative control 
a full length sense human TGF-p2 template was employed. At no time of 
the developmental stages investigated was there any indication of specific 
hybridisation using this probe.
4.1.3 Antibodies to TGF-(32 and TGF-|33
The TGF-p2 and TGF-p3 antibodies described were raised against 
different epitopes of the isoforms (Pelton et al 1991, Flanders et al 1990 
and van den Eijnden-van Raaij et al 1990). Pelton and coworkers made
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antibodies to TGF-p2 and TGF-p3 against amino acids 4-19 and 9-20 of 
the LAP, respectively. Flanders and coworkers raised antibodies to TGF- 
(52 against amino acids 50-75 of the mature protein, and two antibodies to 
TGF-p3 raised against amino acids 50-60 of the mature region and 81-100 
of the LAP. The TGF-p2 antibody employed by Slager et al (1991) had 
been raised against the first 29 amino acids of the mature TGF-p2 protein 
and was previously described by van den Eijnden-van Raaij eta! (1990).
Pelton et al (1991) described the expression of the TGF-p2 polypeptide in 
cartilage, including chondrocytes; bone, pulp and odontoblasts of teeth, 
muscle, kidney, adrenal cortex, basement membrane of the gut and inner 
ear, in the meninges and extensive expression in the skin. The expression 
of TGF-p3 protein, described by Pelton and coworkers was different to that 
described for TGF-p2 protein although there were areas of overlap. These 
included cartilage, bone, muscle, gut and skin. Areas of unique TGF-p3 
protein expression included periosteum of bone, ameloblasts, basal 
epithelia of the bronchi, endothelium of blood vessels, and the liver 
capsule. Flanders et al (1991) described the localisation of TGF-p2 and 
TGF-p3 protein in the developing nervous system. They described the 
localisation of TGF-p2 and TGF-p3 protein to neuronal perikarya and 
axons as well as radial glial cells. In the central nervous system, they 
commented that staining for the two isoforms was most prominent in zones 
where neuronal differentiation occurred and less intense in zones of active 
proliferation. They also described strong staining in many nerve fibres of 
the peripheral nervous system. The antibody to TGF-p2 described by Van 
den Eijnden-van Raaij et al (1990) was employed in a study of heart 
development (Dickson,M,C. et a /1992 submitted).
Protein localisation studies of TGF-p isoforms, as with most other proteins, 
has limitations concerning the interpretation of the data produced. The first 
limitation is the specificity of the antibody. As antibodies described by 
Pelton ef a/ (1991), Flanders et a /(1991) and Van den Eijnden-van Raaij et 
al (1990), were raised against synthetic peptides chosen from only a 
portion of the whole protein, there is no guarantee that this polypeptide is 
an epitope on the surface of the protein in vivo. Recently the three- 
dimensional structure of mature human TGF-p2 has been elucidated 
(Schlunegger and Grutter, 1992). A comparison of their data and the
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antibodies raised against portions of the mature TGF-p2 by Flanders et al 
(1991) and Van den Eijnden-van Raaij (1990) demonstrates the difficulty 
encountered when trying to produce antibodies. Of the first 29 amino acids, 
of the mature TGF-p2 region, used by Van den Eijnden-van Raaij (1990) to 
generate antibodies, only 5 are exposed and 10 buried within the three 
dimensional structure of the protein. The synthetic peptide described by 
Flanders and coworkers has only one amino acid exposed and 14 buried. 
The specificity of the antibodies raised against the synthetic peptides 
described are usually determined by Western blot analysis. However, the 
structure of the protein on such gels has been altered by the conditions 
and probably does not reflect the structure which will be encountered in 
vivo.
Furthermore, the detection of TGF-p isoforms by antibodies is limited by 
the fact that it is not known whether the protein detected is in a latent, 
active or spent form. Also, the localisation to a particular cell type indicates 
nothing concerning the relation of the cell to the protein. That is; is the cell 
a producer or a responder to the protein? The questions raised by the 
localisation of the protein can only be resolved by the interpretation of that 
data alongside RNA localisation data and knowledge of receptor 
distribution.
4.2 Expression of TGF-p isoforms during murine 
embryogenesis
Although much of the data presented in this thesis is analysed without 
reference to comparable data concerning the localisation of the specific 
proteins. This was beyond the scope of the study as the antibodies to 
TGF-p2 and TGF-p3 protein were unavailable. Recently, however other 
workers have reported data concerning TGF-p2 and TGF-p3 protein 
localisations in specific cells and organs (Slager et al 1991, Pelton et al 
1991, Flanders eta! 1992), and where possible, the expression patterns of 
RNA and protein will be compared and the role of the gene considered.
- 1 1 9 -
4.2.1 The role of TGF-p isoforms during chondrification 
and ossification
In vitro TGF-ps are potent inducers of chondrogenesis in appropriately 
responsive mesenchyme (Seyedin efa/1987; Kulyk efa/1989). Kulyk etal
(1989) demonstrated that exposure of cells cultured from chick limbs to 
TGF-pi and TGF-p2 for as little as two hours was enough to stimulate 
chondrogenesis. They observed an increase in Alcian blue positive 
cartilage matrix plus an increase in glycosaminoglycans. They also noted 
an increase in the steady state levels of cartilage-characteristic type II 
collagen. Previously TGF-p1 and TGF-p2 had been termed cartilage 
inducing factors A and B respectively (Seyedin etal 1985). Both had been 
shown to induce fibroblastic, mesenchymal cells to synthesize cartilage 
matrix proteins in vitro (Seyedin et al 1987).
Lyons et al (1989) proposed a simple model to explain the role of the 
TGF-p family of genes in determining the cartilage model of bone 
formation, from condensing mesenchyme to hypertrophic cartilage. Their 
model suggested that BMP2-A and TGF-p2 was involved in the formation 
of the precartilaginous blastema and induced the differentiation of 
mesenchyme into actively proliferating chondroblasts and chondrocytes. 
They suggested that this would in turn induce TGF-p2 in the more 
terminally differentiated cells in an autocrine and paracrine manner. This 
would ensure the coordinate progression through the cell lineage to 
hypertrophic cartilage where Vgr-1 gene is expressed possibly promoting 
differentiation of these cells in an autocrine manner, as well as stimulating 
chondrocytes in a paracrine way. However, this model seems to over 
complicate the process and some of its data is not consistent with that 
produced in this thesis and by others (Gatherer et al 1990; Schmid et al 
1991). No evidence of TGF-p2 RNA expression in chondroblasts was seen 
during the course of this thesis, nor was it observed in these cells by 
Gatherer et al 1991 or Schmid et al (1991).
To describe the process of bone formation in more detail, the developing 
long bones provide a useful model. In the developing limb, the formation of 
the skeleton involves a sequence of events which includes the 
accumulation of the extracellular glycoproteins including fibronectin, the
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formation of clusters of mesenchymal cells (precartilaginous blastema) and 
the cytodifferentiation of cartilage at these sites of condensation (Rugh 
1990). Leonard et al (1991) demonstrated, by analysis of the mechanism 
of enhancement of chondrogenesis in chick wing bud mesenchyme in vitro, 
that exogenous TGF-p1 could cause the accumulation of ECM and raised 
levels of fibronectin mRNA. This coincided with an acceleration and an 
increase in the extent of precartilaginous blastema (PCB) formation 
determined microscopically. They also detected endogenous TGF-p like 
activity in limb mesenchyme. This correlates with the time of expression of 
TGF-p2 RNA observed in the PCBs of embryos seen during this 
investigation and others (Gatherer et al 1990, Schmid et al 1991). It 
therefore seems likely that the endogenous TGF-p like molecule found in 
chick limbs is the chicken TGF-p2 homologue (Leonard etal 1991). These 
data combined, suggest that TGF-p2 is a major factor in the histogenesis 
of the cartilage model. In later stages of long bone development, TGF-p2 
was limited to the growth zone with TGF-p3 mRNA present in the 
perichondrium. The expression of TGF-p2 in the growth zones is probably 
related to its involvment in the continued proliferation of chondroblasts in 
that area. The expression of TGF-pi mRNA and protein in the 
development of the long bone has previously been described (Heine et al 
1987; Sandberg et al 1988a; Lehnert and Akhurst, 1988; Gatherer et al 
1990). TGF-p1 RNA was localised in osteogenic cells, osteoblasts, 
osteocytes and osteoclasts, of the zone of ossification (Lehnert and 
Akhurst 1988, Sanberg et al 1988, Gatherer et al 1990). TGF-pi protein 
was present in calcifying parts of long bones (Heine et al 1987).
The expression of TGF-p3 mRNA in the perichondrium of developing ribs 
is similar to that described for TGF-pi by Lehnert and Akhurst (1988). 
However, there is a dissimilarity in that TGF-p1 is expressed on the 
innermost chondrogenic cell layer of the perichondrium (Lehnert 1989) 
whereas TGF-p3 mRNA is found in the outermost fibrous layer. The cells 
expressing TGF-pi may have a similar function to that seen in vitro 
systems of chondrogenesis, where TGF-pi stimulates chondrogenic 
differentiation of fibroblasts. The role of TGF-p3 in the perichondrium is 
more of a problem as it seems unlikely that it would be required to perform 
the same function as TGF-pi, and, if they were acting synergistically, it
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might seem reasonable for them to be expressed in the same cell layer 
unless they were operating in a paracrine manner. Data concerning protein 
localisation presented by (Pelton et al 1991) did show that an antibody 
specific for TGF-p3 was staining in the perichondrium. Although Pelton and 
coworkers did not specify which cell type, the fact that it was not present in 
the hypertrophic cartilage may suggest that it is operating in an autocrine 
manner. The action of TGF-p3 in a paracrine manner upon the innermost 
chondrogenic layer of the perichondrium cannot be discounted. 
Immunohistochemical data, also from Pelton and coworkers, showed 
TGF-pi protein present in the perichondrium as well as in mature cartilage, 
as previously described by Heine et al (1987), suggesting that TGF-pi may 
act in a paracrine fashion, for example to inhibit proliferation and induce 
ECM production by mature chondrocytes. Both these functions have been 
observed in vitro (Rosen et al 1988; O Keefe et al 1988). Thorp et al (1992) 
described the localisation of TGF-p1, 2 and 3 protein in 3 week old chicken 
long bones using specific antibodies raised against human TGF-p 
isoforms. They observed staining in chondrocytes recently derived from the 
perichondrium.
If TGF-p3 has an alternative function to that of TGF-p1 it may be that it 
promotes vascularisation of the fibrous layer of the perichondrium which 
occurs prior to the formation of the periosteum. This conforms with in vitro 
analysis which demonstrated that TGF-p can induce angiogenesis (Yang 
and Moses 1990). Alternatively TGF-p3 could be cooperating with TGF-pi 
to maintain the perichondrium at this stage.
TGF-p3 mRNA was also observed in the perichondria of cartilage capsules 
of the ear and nose and also tracheal cartilage. TGF-p3 RNA is also 
present in the condensations of the optic capsule however this, unlike 
other cartilage models, will not under chondrogenesis. It apppears only to 
be associated with precartilage condensations. Neither TGF-p1 nor TGF- 
p2 were observed in these condensations. The expression of TGF-p3 in 
the condensations which are destined to become cartilage capsules of the 
ear and nose, but also in condensations around the eye which does not 
form cartilage (Hamilton et al 1978) seems to suggest that TGF-p3 may be 
necessary, but not sufficient, for cartilage formation. What role TGF-p3 is 
playing in these condensations is unclear. It seems that TGF-p3 is
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expressed in many fibrous capsules, e.g. mesothelium, perichondrium, 
pericardium. This might suggest that TGF-p3 is inducing specialised 
fibrous connective tissue elements necessary for structral integrity.
TGF-p3 RNA was also detected in the prechondrogenic blastemas which 
will ultimately form the intervertebral discs. The gene Pax 1, a member of 
the paired box family, is also expressed in this area and is thought to be 
playing a role in the formation of segmented structures of the mouse 
embryo (Deutsch etal 1988). The timing of expression of both these genes 
in the intervertebral discs anlagen correlates well although it appears that 
Pax1 gene transcripts may appear slightly before TGF-p3 gene transcripts. 
There is a fundamental difference between the expression pattern of Pax1 
and murine homeobox genes. The Hox gene 1.3 is region specific for 
thoracic prevertebrate at 12 days p.c.(Dony and Gruss, 1987). It has been 
speculated that Hox genes specify positional information whereas Pax1 
gene is expressed, independent of position, and may mediate a process 
required for the entire axis. This process may involve the initiation of TGF- 
p3 transcription in the region of the intervertebral discs.
4.2.2 The role of TGF-p isoforms in pulmonary system
Both TGF-p2 and TGF-p3 mRNA were expressed in the developing 
pulmonary system. Both were restricted to the epithelial component of the 
lung but with distinct patterns of expression which reflected a change in 
epithelial morphology which is part of the developmental process of lung 
formation. Lehnert and Akhurst (1988) have previously reported the 
expression of TGF-p1 RNA in the lung, however the pattern of expression 
was limited to the mesenchyme, and was at no time seen in any epithelial 
cells of the pulmonary system.
Although a lung bud is first seen at 9.5 days p.c. in the mouse embryo, no 
expression of any TGF-p isoform was detected until 3 days later. It is from 
this point that the primordial system will develop with columnar epithelia 
lining the primitive tubes of the lung. During this stage only TGF-p3 RNA is 
expressed in the epithelial component of the lung. Not until later, at about 
14 days, will there be a demarcation in the lining of the lung tubes, when 
there is a change in morphology from columnar epithelia in the proximal
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lung tubes to the cuboidal epithelia in the distal lung tubes. The expression 
of TGF-p2 RNA correlates with the change in epithelial morphology, and is 
expressed only in the simple cuboidal epithelium, while TGF-p3 is still 
expressed in the columnar epithelia of the bronchioles. TGF-p2 expression 
remains in the epithelia of the distal portion of the lung even as they 
become more flattened in shape as the alveoli are formed. The correlation 
of expression of TGF-p2 and TGF-p3 RNA with the change in epithelial 
morphology leads to the speculation that these two genes are in some way 
responsible for the differentiation to a simple cuboidal epithelium in the 
distal part of the lung. However, the expression of TGF-p3 RNA cannot 
induce a differentiation to a columnar epithelial cell in the lung tubes, as 
the columnar morphology appears before TGF-p3 RNA expression. As the 
tubular system continues to divide there comes a point when there is a 
change in epithelial cell morphology, from columnar to simple cuboidal. 
The simple cuboidal cells are found at the ends of the lung tubes at the 
point where they terminate. TGF-p3 RNA was not expressed in any of 
these cells. This means that TGF-p3 RNA transcription is switched off as 
TGF-p2 RNA transcription is switched on. During no stage investigated 
was TGF-p2 or TGF-p3 RNA localised in the same epithelial cell type of 
the lung. However, it was very difficult to distinguish the exact expression 
pattern at the points where epithelial morphology changed.
The continual growth of the lung and branching of the tubes to form the 
alveoli, ultimately leads to an almost total epithelial expression of TGF-p2 
RNA towards the end of gestation. At this stage there has once again been 
a change in epithelial morphology with the simple cuboidal epithelium 
becoming flattened. This flattening has no effect upon TGF-p2 RNA 
expression.
As described above, all three TGF-p isoforms are expressed in developing 
lung, each with a unique pattern and each presumably with a unique role. 
The RNA expression pattern of the TGF-p isoforms in the lung was 
identical to that described by Gatherer et al (1990) when they investigated 
human embryogenesis, except that they described the localisation of 
TGF-p2 RNA to the epithelium of bronchioles, but only at the terminal 
portion. The stage of human lung development when this was seen was 
probably equivalent to a 14.5 day p.c. mouse and could reflect the time
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when there is the change in epithelial morphology. This might suggest that 
TGF-p2 RNA expression takes over from TGF-p3 in the terminal portion of 
the bronchiolar epithelium before there is any morphological change to the 
simple cuboidal epithelium.
The role of TGF-p2 and TGF-p3 at this time could be associated with the 
epithelial change at about 14 days p.c.. Pelton et al (1991) observed that 
the three TGF-p proteins had identical patterns of localisation in the 
embryonic lung. They did describe slight expression of TGF-p3 (and TGF- 
p i) in epithelium of 17.5 day bronchioles, but in general, staining for TGF-p 
isoforms was seen mainly just below the respiratory epithelium. Pelton and 
coworkers did not distinguish between the epithelial cell types. It is known 
that all three TGF-p isoforms inhibit growth of lung epithelial cells. In fact 
the inhibition of a mink lung epithelial cell line, (CCL64), forms the basis of 
a standard biological assay for TGF-p isoforms (Danielpour et al 1989). 
However, the fact that the expression of TGF-p2 RNA and TGF-p3 RNA 
are quite specific to distinct epithelial cell types would imply that these 
isoforms are differentially utilised by different epithelial cells. Masui et al
(1986) demonstrated that TGF-p was responsible for inducing normal 
human bronchial epithelial (NHBE) cells to undergo squamous 
differentiation. It seems that the switch from TGF-p3 expression in the 
columnar epithelial cells of the bronchioles to TGF-p2 expression is 
coincident with this change in epithelial cell morphology and could be 
implicated in controlling this event. The question as to whether it is the 
change to TGF-p2 expression that causes a change in cell morphology or 
the change in cell morphology that causes a change in TGF-p isoform 
expression is very interesting. Since the application of serum containing 
TGF-p can induce NHBE cells to differentiate to a more squamous 
morphology, Masui et al (1986), it would seem that it was the TGF-ps 
which brought about the change.
TGF-pi protein expression has been investigated during lung development 
(Heine et al 1990). They demonstrated that TGF-pi protein was present at 
the epithelial-mesenchymal interfaces of stalks and clefts and suggested 
that TGF-pi was having a direct effect upon lung branching. Heine et al 
(1990) also described the localisation of collagen III, fibronectin, collagen I 
and glycosaminoglycan I using immunohistochemistry on parallel sections.
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They found that these four ECM proteins co-localised with the expression 
of TGF-p1 protein in the clefts of the tubes and in a sheath around the 
bronchioles. The closer localisation of TGF-pi protein in smooth muscle 
cells under the bronchiolar epithelium at later stages was thought to be 
stabilising the epithelia above through an intermediate such as tenascin. 
Tenascin is also expressed in smooth muscle cells underlying bronchiolar 
epithelia in chicken lung, (Crossin eta11986) and is known to be induced 
by TGF-pi (Pearson et al 1988). Heine et al (1990) also pointed out that 
there was an enhanced expression of TGF-pi protein at about 13 days p.c. 
a time when there is massive vascularisation and innervation of the lung.
Epithelial-mesenchymal interactions are required for normal lung 
morphogenesis. A variety of ECM proteins are found in the area of the 
interactions, these include types I, III and IV collagen, laminin, heparan 
sulphate, proteoglycans, fibronectin, chondroitin sulphate and enactin 
(Timpl and Martin, 1982; Hay, 1981). Blum etaU 1987), demonstrated that 
the role of one ECM protein, laminin, was intimately involved in 
epithelial/mesenchymal interactions. Laminin is known to regulate cell 
differentiation in vitro, in part by influencing gene expression (Blum et al 
1987). They suggested that epithelial cell interactions with laminin might 
result in the expression of specific genes. That these genes, which are 
influenced by laminin, may be the TGF-ps could be investigated by 
examining the effect of blocking antibodies to laminin on TGF-p 
expression.
4.2.3 The role of TGF-p isoforms in heart development
The embryonic heart is an extremely complex organ which develops very 
rapidly thus presenting a problem in a study such as this when embryos of 
limited stages were investigated. From a period starting at about 7.5 days 
p.c. up to 9.0 days p.c. the heart undergoes an amazing evolution, from a 
simple two layered tube, to an elaborate structure. The results described in 
this thesis can only be considered a crude analysis of TGF-p isoform 
expression during this complicated morphogenetic event.
The expression of TGF-p2 RNA in the heart, described in this thesis, is 
transient and specific. The low level expression of TGF-p2 RNA localised
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in most myocardial cells at early stages of heart development changes to a 
more elevated expression pattern in a specific subset of myocardial cells 
which underly the region of the heart at the region which will become the 
atrio-ventricular (AV) and outflow tract cushion tissue, which later contribute 
to septation and valve formation. TGF-p2 is not the only growth factor 
which has been found to be expressed in the heart, or indeed in this 
specific pattern. The expression of these other factors will be discussed 
later.
The first cells of the embryo to contain detectable amounts of TGF-pi RNA 
are cardiac precursor cells, at 7.0 days p.c., which arise from the splachnic 
mesoderm overlying the pharyngeal endoderm (Akhurst et al 1990a). As 
the early heart develops into a myocardial tube with an endocardial lining, 
separated by “cardiac jelly,” the expression of TGF-pi is restricted to the 
endocardial cells.
As development proceeds there is an invasion of the cardiac jelly at the AV 
valve by mesenchymal cells which are known to arise from the endocardial 
“epithelial” cells, as demonstrated in chicken heart cultures (Krug et al 
1985). Krug et al (1985) also showed that the signal which is required to 
induce the epithelial/mesenchymal transformation, of the endocardial cells, 
arises from the myocardium, specifically from the same myocardium region 
that has been shown to express TGF-p2 RNA.
A considerable amount of work has been carried out on chick hearts. Krug 
et al (1985) demonstrated that a signal emanating from the myocardium at 
the AV valve causes the adjacent endothelial cells to transform and migrate 
towards the myocardium thus forming the AV cushion tissue. In an effort to 
determine whether one of the TGF-p isoforms was providing the signal, 
(Potts and Runyan, 1989) applied blocking antibodies to disaggregated 
chick heart, in vitro. The application of antibodies to the TGF-ps blocked 
the epithelial/mesenchymal transformation implicating one or more of the 
TGF-ps as the signal molecule. They continued their investigations using 
modified specific antisense oligonucleotides in an attempt to knock out the 
individual TGF-p isoforms to determine which was providing the signal 
(Potts et al 1991). The oligonucleotides were modified in the sense that 
they had phosphoramadite linkages at their 5’ and 3’ ends which minimises
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nucleolytic degradation. They discovered that a modified antisense 
oligonucleotide to TGF-p3 inhibited normal cell invasion by 84% in vitro but 
failed to inhibit normal epithelial activation in the same in vitro heart 
cultures. Other modified oligonucleotides specific for the other two TGF-ps 
failed to inhibit the cell invasion. This result indicated that the 
epithelial/mesenchymal transformation, and subsequent invasion of the AV 
region, is a two step process, and that TGF-p3 is required for the 
mesenchymal cells to invade.
The results of Potts et al (1991), are at odds with the data described in this 
thesis in that no evidence of TGF-p3 was found in the heart at these stages 
of development. There are a variety of reasons why this may be so. Firstly, 
the level of TGF-p3 in the mouse hearts may be low, such that it is beyond 
the limit of detection by in situ hybridisation. If the TGF-p3 RNA level is low 
there may, still, be very efficient translation. This question will be easily 
resolved by the use of specific TGF-p3 antibodies when they become 
available. The antibody can be used in two different ways, either as a 
blocking antibody in a similar experiment as described by Potts and 
Runyan, or in immunohistochemistry. The second possibility is that heart 
development in mouse and chicken, although proceeding in a similar 
fashion, is controlled by different genes of the same family. This arguement 
must be wrong if the TGF-ps are supposed to be conserved in a variety of 
species due to their fundamental importance during embryogenesis. The 
third possibility is that the data is not valid. The interpretation of a positive 
result in this system involves counting the number of cells which have 
invaded the collagen gel-matrix upon which the chick heart disaggregates 
have been cultured. The number of cells required to have "invaded” to 
provide a positive result was very low.
Other members of the TGF-p superfamily are also expressed in the heart 
at about these stages of development. Gatherer et al (1990) described the 
expression of TGF-p3 RNA in the mesenchyme of the human AV valve 
cushion tissue at a low level. At no time during this stage of development 
were transcripts of TGF-p3 RNA detected during this investigation, in 
mouse, although later TGF-p3 RNA was detected in a slight condensation 
underneath the AV valve. Vgr-1 has also been found in the mesenchymal 
cells of the AV cushion tissue, (Jones et al 1991), and activin B has been
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cloned from 10 day p.c. mouse heart although the spatial localisation of 
this peptide has not been determined. Lyons et al (1990) described the 
expression of the bone morphogenetic protein, BMP-2, in the myocardium 
but not the endocardium of the AV canal at 9.5 days p.c.. This persisted 
until at least 14.5 days p.c.. By contrast BMP-4 appears first in the 
myocardial layer of the AV canal at about 9.0 days p.c. and by 10.0 day 
p.c. is restricted to the ventricular outflow tract (Jones et al 1991). Jones et 
al (1991) suggested that BMP-2 and BMP-4 cooperate during early 
development to influence the differentiation of the AV cushions but that 
later in development BMP-4 alone mediates some process unique to the 
outflow tract. However, it is simplistic to assume that it is just BMP-2 and 
BMP-4 which are cooperating when there are at least three other TGF-p 
superfamily members known to be present at the same developmental 
stages and with similar expression patterns.
A comparison of the various TGF-p superfamily members patterns of 
expression might provide an insight into how they interact. TGF-pi is 
unique in that it alone is expressed in the endothelial cells. BMP-4, BMP-2 
and TGF-p2 RNA are all expressed in the myocardial cells, at 9.5 days 
p.c., in the AV region and the outflow tract. Vgr-1 and TGF-p2 are also 
expressed at low levels in the AV cushion tissue at 10.5 days p.c.. There is 
no evidence, as yet, of interaction of TGF-p superfamily members with 
each other. Although there is evidence that TGF-p genes can induce 
members of their own group. The expression of TGF-p2 RNA and BMP-2 
RNA is also seen in prechondrogenic blastemas. The fact that both genes 
are expressed at similar times and similar locations might indicate that 
these two genes cooperate in developmental functions. How these two 
genes might cooperate is unknown, but both the formation of myocardium 
around the heart valves and formation of prechondrogenic blastemas 
involve the movement of cells.
Recently a mouse antibody to TGF-p2 has been used to detect the protein 
during heart development (Dickson et al submitted). Dickson and 
colleagues described the localisation of protein in the whole myocardium at 
9.0 days p.c. with the broad distribution more obvious at later stages of 
embryogenesis. This pattern of protein expression does not conform with 
what might have been expected if TGF-p2 was involved in providing the
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signal for endothelial cells to transform at the AV region. Dickson and 
colleagues determined that the protein staining occured some 12-24 hours 
after RNA transcript localisation. They suggested that translational control 
of TGF-p2 protein production might regulate some aspects of 
cardiomyogenesis, or the growth factor might play an important role in 
maintainance of the differentiated function of the cardiomyocyte. 
Nevertheless, they did not rule out the possibility that TGF-p2 was 
providing the signal which caused the epithelial/mesenchymal 
transformation.
4.2.4 The role of TGF-p isoforms in epithelia
The results presented in this thesis show that both TGF-p2 and TGF-p3 
RNA were found in a variety of epithelial cells during embryogenesis. The 
expression of TGF-p1 RNA in epithelial cells has previously been reported 
(Lehnert and Akhurst 1988). This was in contrast to the accumulation of 
TGF-p1 polypeptide in the mesenchyme underlying the epithelia (Heine et 
at 1987). This phenomenon was observed in tissue undergoing 
morphogenetic activity such as the whisker follicle, toothbud, 
submandibular gland and heart (Lehnert and Akhurst 1988). A comparison 
of the RNA expression of the three TGF-p isoforms showed that TGF-p2 
was found in the widest variety of epithelia.
Potent growth inhibition by TGF-p on epithelial cells, in vitro, has been well 
established (Graycar et ai 1989). Some have been induced to differentiate 
in the presence of TGF-p (Reiss and Sartorelli, 1987; Moses et al 1990; 
Gehris and Greene, 1992). It is important to know whether epithelially- 
derived TGF-ps are involved in autocrine regulation of growth and/or 
differentiation, or in paracrine interactions with the underlying 
mesenchyme. Lehnert and Akhurst (1988) proposed that TGF-pi acted in 
both a paracrine and autocrine mode. They based this hypothesis on a 
comparison of RNA expression they found and TGF-pi protein 
immunohistochemistry data from Heine and coworkers (Heine et al 1987). 
Lehnert and Akhurst found that TGF-pi RNA was expressed in epithelial 
cells overlying mesenchyme which had previously been shown to contain 
TGF-pi protein. They argued that TGF-pi protein was being produced in 
the epithelial cells and subsequently secreted in to the underlying
- 1 3 0 -
mesenchyme where it would control the ECM and the mesenchymal cells 
themselves in morphogenetic interactions.
Unlike TGF-pi or TGF-p3, TGF-p2 RNA expression was not limited to 
morphogenetically active tissue, but was also found in epithelial cells of 
established structures that are in the process of differentiation. These 
include epithelia of the sense organs, alveolar epithelia (discussed in 
section 4.2.2) and the hyperplastic nodules of palatal epithelium 
(Fitzpatrick et al 1990).
Pelton et al (1991) has described the localisation of TGF-pi, 2 and 3 
proteins in murine embryos from gestational age 12.5 to 18.5 days. They 
described the localisation of TGF-p2 protein in the epithelia of the inner 
ear. However, in contrast to the expression of TGF-p2 RNA in the 
pseudostratified epithelium (described in this thesis and by Pelton et al 
(1990), and Schmid et a /(1991)), immunostaining demonstrated that TGF- 
p2 protein was localised to the basement membrane below the simple 
epithelium, opposite the pseudostratified epithelium. Pelton et a /(1990) did 
describe the localisation of TGF-p3 protein in the pseudostratified 
epithelium, although nobody has described RNA for TGF-p3 in any otic 
structures. The intensity of staining described by Pelton and coworkers for 
TGF-p3 protein seems to match the intensity of expression of TGF-p2 RNA 
in the otic epithelium, this might suggest that the antibody for TGF-|33 is in 
fact detecting TGF-|32. The localisation of TGF-p2 RNA in sensory epithelia 
suggests that it may be playing a role in the innervation of those epithelial 
cells. The expression of TGF-p2 RNA in the neural retina seems to back 
up this arguement.
The investigation of the development of the palate with respect to the 
expression of TGF-p isoforms has been carried out by FitzPatrick et al 
(1990) and Pelton et al (1991). Although this thesis did not attempt such 
an in depth study of palate formation as described by either of these two 
authors and their coworkers, the observations from this study matched 
those described. TGF-p3 RNA is expressed early in the development of 
the palate in the medial edge epithelium (MEE) of the palatal shelves. This 
pattern persists until the palatal shelves have fused. Once the palatal 
shelves have fused the MEE is lost and the expression of TGF-p3 is no
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longer seen. TGF-|31 RNA is also seen in the palatal shelve MEE, but only 
after the shelves have elevated and TGF-p2 RNA is expressed in the 
mesenchyme underlying the MEE both prior to fusion and for some time 
after (FitzPatrick et al 1990). The only difference in expression patterns 
seen by Pelton et al (1991) when compared with FitzPatrick et al (1990) is 
the presence of TGF-|32 RNA transcripts in the MEE seen by Pelton and 
colleagues. This minor discrepency could be due to the differentiative 
status of the MEE cells. FitzPatrick et al (1992) described the localisation 
of TGF-p2 RNA in MEE of mice which had been treated with retinoic acid. 
FitzPatrick and coworkers suggested that both TGF-p1 and TGF-p3 could 
be acting on the underlying mesenchyme. Sharpe et al (1988) claimed that 
TGF-p is inhibitory to palatal mesenchyme growth, although this is at odds 
with other reports of the effect of TGF-ps on mesenchymal cells. The 
induction of a variety of ECM proteins by TGF-ps has already been noted. 
FitzPatrick et al (1990) noted that the high level of TGF-p3 expression in 
the MEE occurred 24 hours prior to shelf elevation. They proposed that a 
possible function of the intense expression of TGF-p3 at this point was to 
induce chondroitin/dermatan proteoglycans which are thought to be 
important in causing the palatal shelfs to rise by mechanical means 
(Brinkley and Morris-Wiman, 1987). The difference in expression pattern of 
TGF-p2, compared to that of the other isoforms led FitzPatrick and 
coworkers to suggest that it was possibly involved in the maintenance of 
the overlying MEE.
4.2.5 Expression of TGF-(3 isoforms during tooth 
development
The expression pattern described in this thesis for TGF-p2 and TGF-p3 
during tooth development, was similar to that described by Pelton et al 
(1990). TGF-pi RNA has previously been localised to the epithelial bud 
and in the condensed mesenchyme (Vaahtokari et al 1991). This group 
also described intense TGF-p1 RNA expression in the morphologically 
active cervical loops of the dental epithelium. Later at about 16.5 days p.c. 
Vaahtokari and coworkers described expression of TGF-pi RNA in the 
inner enamel epithelium where it subsequently dissappeared.
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A number of other genes are expressed in a variety of cell types during 
tooth morphogenesis. Both tenascin, fibronectin and collagen are 
developmental^ regulated during tooth morphogenesis (Thesleff et al 
1979; Thesleff et al 1987). Tenascin was expressed in dental 
mesenchymal cells throughout tooth development. This expression was 
downregulated at one point, the cap stage, during which teeth undergo 
massive morphogenetic changes. Tenascin was also found in the basal 
membrane at the time of odontoblast differentiation (Thesleff et al 1987). 
Fibronectin has also been localised to dental mesenchyme, as well as 
basement membranes but not to epithelial tissues (Thesleff 1979).
Tooth development is not only a complicated event morphologically, but 
also in relation to expression of the TGF-p isoforms and ECM proteins. The 
distribution of all three TGF-p isoforms changes during tooth development. 
It is clear that none of the TGF-ps are involved in the initial events of tooth 
bud formation since no RNA or protein for any of the isoforms has been 
localised to dental lamina which elongates and thickens before 
invaginating to form tooth buds.
Vaahtokari et al (1991) described the regulation of TGF-pi expression in 
epithelial cells by mesenchyme. They demonstrated that when bud-stage 
epithelium was cultured with bud-stage mesenchyme TGF-p1 RNA was 
detected. However, if the bud-stage epithelium was cultured with jaw 
mesenchyme then no expression of TGF-p1 RNA was seen. They also 
demonstrated that dental mesenchyme induced TGF-pi RNA expression 
in oral epithelium where normally it is not found. They concluded that the 
bud stage mesenchyme regulates expression of epithelial TGF-pi.
Hox7.1, a homeobox gene, has been found to be expressed in dental 
mesenchyme some time before any of the TGF-p isoforms are detected 
(Mackenzie et al 1992). Vaahtokari et al (1991) argued that since it has 
been shown that a member of the TGF-p superfamily can be regulated by 
homeotic genes, ie dpp (Reuter et al 1990), then it could be possible that 
Hox7.1 is regulating expression of some or all the TGF-ps.
- 1 3 3 -
4.2.6 Neuronal expression of TGF-p isoforms
TGF-p isoforms affects on a variety of nerve cells in vitro. These include 
mitogenic activity with respect to Schwann cells (Ridley et al 1989), and a 
response by neuronal accessory cells to TGF-p treatment (Eccleston et al 
1989). In astroglial cells application of TGF-p delays the peak of DNA 
synthesis induced by serum (Toru-Delbauffe et al 1990). Martinou et al 
(1990) reported that TGF-p1 can increase the survival of embryonic spinal 
cord neurons in vitro. Rogers et al (1992) demonstrated that TGF-p alters 
differentiation of avian neural crest cells having an effect on morphology, 
proliferation, fibronectin expression and melanogenesis.
The data presented in this thesis represents the first global RNA 
localisation of TGF-p RNA isoforms in the developing nervous system. No 
TGF-p isoform was detected in the developing nervous system prior to 
10.5 days p.c.. Both TGF-p2 and TGF-p3 RNAs were expressed in 
neuronal cells at later stages in development but in temporally and spatially 
unique patterns. The expression of TGF-p3 at 14.5-16.5 days p.c. in the 
mitral cell layer, described in this thesis, was also observed by Pelton eta! 
(1990), however this was the only neuronal expression pattern of TGF-p3 
which was observed. Pelton et al (1990) also described expression of 
TGF-p3 RNA in developing olfactory bulbs at 14.5 days p.c.. They 
described the expression of TGF-p3 RNA along the entire periphery of the 
olfactory bulb at later stages of development. They suggested that 
expression of TGF-p3 in the developing olfactory bulbs, at a time when 
complex cell interactions between the the olfactory bulb and innervating 
afferent axons, may be playing a role in proliferation and/or differentiation 
of neuronal or glial cells within the mitral cell layer. Pelton et a /(1990) also 
described the localisation of TGF-p3 transcripts in the meningeal layers 
surrounding the brain and in the spinal cord. At no time was TGF-p3 RNA 
detected in the olfactory bulbs, or in the meningeal layers surrounding 
either the brain or the spinal cord.
The first detection of any TGF-p isoform in the developing nervous system 
was TGF-p2 in the forebrain at 10.5 days p.c.. TGF-p2 RNA was detected 
in the ventral horns of the spinal cord but with a very short temporal 
window of expression at 11.5 days p.c.. This compared well to expression
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detected in the spinal cord of an approximately similar age human embryo 
described by Gatherer et al (1990). This transient appearance of TGF-p2 
RNA in the ventral horns does correlate with a period of motor neuron 
differentiation.
Flanders et al (1991) described the localisation of TGF-p protein isoforms 
in the developing mouse nervous system. They examined embryos from 
12 days p.c. to 18 days p.c.. They reported a more extensive localisation 
for both TGF-p2 and TGF-p3 which does not reflect the level of RNA 
transcripts described in this thesis nor the levels reported by Pelton et al
(1990) and Schmid et al (1991). They also noted that the pattern of 
localisation for both TGF-p2 and TGF-p3 were so similar that only one set 
of results was shown. This begs the question as to whether the two 
antibodies were detecting the same species of protein. The localisation of 
protein in areas described by Flanders et al (1991), not found to express 
RNA from either gene may be due to very low transcript levels being very 
effectively translated, thus producing discordant levels of RNA and protein. 
Certainly the in situ hybridisation technique would not be able to distinguish 
low levels of expression from background. Also the choice of stages 
investigated by Flanders and coworkers probably meant that they would 
not have seen expression of TGF-p2 protein in the ventral horns and 
therefore did not report such. This even allows for the time taken from 
transcription to translation (estimated by Fowlis et al (1991) to be in the 
region of 12-24 hours) plus the half-life of the protein. However, they did 
suggest that both TGF-p2 and TGF-p3 might have a role in regulation of 
neuronal migration and differentiation, which correlates well with the 
interpretation of the RNA expression data presented in this thesis.
4.2.7 TGF-(3 isoforms and their role in skin development
TGF-p2 RNA and TGF-p3 RNA transcripts were expressed at a low level in 
the dermis of the developing skin. Both genes transcripts were also seen in 
whisker follicles and TGF-|32 RNA was localised to the primordia of hair 
follicles and in more mature hair follicles at later stages of development. 
Both TGF-p2 and TGF-p3 transcripts were observed in the sub-dermal 
mucosa. Previously, Pelton et a /(1989) described the localisation of TGF- 
p2 in both epidermis and dermis from 13.5 days p.c. at high levels. By 15.5
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days p.c. Pelton et al (1989) found that the TGF-p2 RNA was localised to 
the dermis and not seen in the epidermis or hair follicles. At 18.5 days p.c. 
the expression of TGF-p2 RNA was restricted to the suprabasal layer of 
the epidermis and was now found in the hair follicles. Apart from the hair 
follicle expression at 18.5 days p.c. this pattern of intense expression does 
not compare with that described in this thesis. Pelton et al (1991) have also 
described the protein localisation of TGF-p2 and TGF-p3 in the skin at 
similar stages of development. They found that TGF-p3 RNA was present 
in the epidermis and hair follicles at later stages of development, whereas 
TGF-p2 protein seemed to be ubiquitously expressed in all components of 
the skin. However, Pelton etal (1991) did comment that the highest level of 
staining of TGF-p2 antibody was in the developing hair follicles which 
correlates with the higher levels of expression of TGF-p2 RNA presented in 
this thesis.
Glick et al (1989) found that TGF-p2 could be induced by application of 
retinoic acid to keratinocytes in culture and in intact epidermis. This 
supports the evidence that embryonic skin has the potential to express 
TGF-p2. The proliferation of both mouse and human keratinocytes is 
known to be potently, and reversibly, inhibited by TGF-p (Shipley et al 
1986; Coffey et al 1988). Choi and Fuchs, (1990) described plietropic 
effects of both TGF-p and RA on keratinocytes. They found that TGF-ps 
acted on mitotically active basal cells to retard cell proliferation. Although 
stopping the cell cycle is a prerequisite for terminal differentiation, TGF-ps 
inhibited normal keratinisation and promoted the type of differentiation 
normally seen in wound healing and epidermal hyperproliferation (Choi and 
Fuchs, 1990; Mansbridge et al 1989). Also, treatment of epidermis with 
phorbol esters, which induces differentiation of cultured keratinocytes and 
hyperplasia, in vivo, is known to increase levels of TGF-pi RNA (Akhurst 
et al 1988). Neither TGF-p2 nor TGF-p3 RNA levels are raised in the skin 
on treatment with phorbol esters (Fowlis etal 1992).
The vibrissae and hair follicles, which begin to appear at about 13 and 14 
days p.c. respectively, express RNA from all three isoforms (this thesis, 
and Lehnert and Akhurst 1988). The vibrissae arise by epithelial 
thickenings which invade the primitive epidermis. Lehnert and Akhurst
(1988) described the localisation of TGF-pi RNA, initially in the basal
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keratinocytes of the invaginating whisker follicle and later in the outer root 
sheaths of the more advanced whisker follicle. TGF-pi protein was 
localised in the adjacent mesenchyme (Heine etal 1987).
Tenascin, an ECM protein which is known to be induced by TGF-pi 
(Pearson etal 1988), is also expressed in the mesenchyme underlying the 
epithelia of the developing vibrissae. This would suggest that the 
epithelially synthesised TGF-p1 is directly inducing tenascin accumulation 
in the mesenchyme around the developing vibrissae. However, the exact 
role of tenascin in the development of this structure remains unknown.
The expression of the TGF-p isoforms in the hair follicles seems to be 
similar to that of the vibrissae. Early on in their development both TGF-p2 
and TGF-p3 are expressed to a similar extent in the primordial 
condensations of mesenchymal cells that will become the hair follicles.
4.2.8 Role of TGF-p isoforms in extra-embryonic material
The expression of both TGF-p2 RNA and TGF-p3 RNA in the extra- 
embryonic material suggests that they may play a role in the proliferation 
and maintainance of decidual structures. The expression of TGF-p2 RNA 
in the uterine epithelium was first observed at 8.5 days p.c.. However, it is 
not, limited to this one cell type as it also localises to the myometrium. This 
is similar to the pattern of expression seen by Manova et al (1992). They 
suggested that factors such as TGFp2, which have mesoderm-inducing 
capability, are expressed only within the decidua before and during primary 
period of mesoderm formation. The pattern of expression, described for 
TGF-p2 RNA, was also observed for colony stimulating factor 1 (CSF-1) 
Arceci et al (1989). They suggested that CSF-1 was not only regulating 
the proliferation of macrophages but controlling the formation and 
differentiation of decidual tissue. These genes are not the only ones 
expressed in pre- and post-implantation deciduas suggesting many lelvels 
of control over the maintainance and differentiation of decidual structures.
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4.2.9 Interaction of TGF-p isoforms with other molecules
The TGF-ps are known to regulate and be regulated by a wide variety of 
molecules ranging from other peptide growth factors, homeobox genes, 
transcription factors, phorbol esters, retinoids and each other.
The induction of TGF-p2 by RA in cultured keratinocytes has been 
described above (Glick et al 1989). Glick et al (1991) have also described 
the regulation of TGF-p expression by retinoic acid (RA) in vitamin A 
deficient rats. They showed that systemic RA induces expression of all 
TGF-p isoforms in the epidermis, and of TGF-p2 and TGF-p3 in the 
respiratory epithelium as well as in the intestinal mucosa and lamina 
propria. In contrast they also showed that retinoid deficiency results in 
increased expression of all isoforms in the vaginal epithelium, and 
subsequent addition of RA decreased expression. Vaginal epithelium is 
one of the few epithelial cell types which is stimulated by TGF-p in vivo 
(Takahashi et al 1989). They noted that TGF-p2 was the most sensitive to 
tissue retinoid levels, but the response by all three isoforms was transient 
and expression returned to original levels after a few days. Glick et al 
(1989) indicated that the control of TGF-p2 expression by RA was at the 
post-transcriptional level. The data of (Glick et al 1990) suggest that 
systemic levels of retinoids maintain epithelial homeostasis in part through 
the local regulation of TGF-p expression in responsive epithelia. Previously 
they had shown that TGF-p2 which had been induced by RA is in a 
biologically active form. This suggests that the induction of TGF-p isoforms 
is an important element of the regulation of epithelial differentiation by 
retinoids in vivo, not only in adult tissues but in embryological tissues. This 
is supported by the observation that TGF-p2 is induced by RA in 
embryonal carcinoma and stem cells (Mummery et al 1990). A number of 
investigations of the developmental expression of the RA receptors RNAs 
(RAR), have found that RAR-beta RNA expression is closely parallel to 
that of TGF-p2 in the developing limb (Dolle et al 1989) and that RAR- 
gamma RNA is coordinately expressed with TGF-p3 in the developing 
spinal column (Ruberte et al 1990). Both RAR-gamma and RAR-beta are 
also expressed in the frontonasal mesenchyme at a similar time described 
in this thesis and by Gatherer (1991). The cellular retinol binding protein
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(CRBP) has been localised in the ventral horns at the same stage as 
TGF-p2 RNA in this thesis (Maden et al 1989). It is a well established tact 
that application of exogenous RA to developing embryos can produce 
severe cranio-facial abnormalities (Webster et al (1986). This would seem 
to suggest that RA is acting upon endogenously expressed TGF-ps, 
perturbing the expression and causing the changes. However, FitzPatrick 
et al (1992) have demonstrated that the pattern of expression of RNA of 
the three TGF-p isoforms is unaltered, at least with respect to palate 
formation, after treatment with RA except for TGF-p2 which was expressed 
in the medial edge epithelium. It is possible that RA is regulating the TGF- 
ps as suggested by Glick e ta l(1991). At the same time, very high levels of 
TGF-p2 RNA, compared to non-treated mice, were observed in the 
cuboidal epithelium of the developing lung (D. FitzPatrick unpublished 
observations). This might suggest that there is already a level of 
expression in the MEE of TGF-p2 RNA, which is normally beyond the level 
of detection by in situ hybridisation, or possibly the control of TGF-p2 
expression by RA is dependent upon other factors.
4.3 Generation of mutants as a form of analysis 
of biological function
As has been described above, the TGF-p genes are expressed in 
developmentally specific patterns. All appear to be involved in 
morphogenetic events, interacting with the ECM and other proteins to 
direct growth, either by inhibition, promotion or differentiation. However, the 
mass of data produced by expression studies and in vitro analysis does not 
answer the basic question: What is the role of TGF-p isoforms in vivo? In 
vitro analysis can only provide so much information which is generated in 
an artificial environment which may never be found naturally. Herskowitz,
(1987) described a method by which the role of genes could be 
investigated. He suggested that by the manipulation of cloned genes to 
create the generation of dominant-negative mutations which, when 
overexpressed, disrupt the activity of the wild-type gene, might provide an 
answer to the question above.
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Other strategies available for the disruption of gene function include 
directly knocking the gene out. The advantage to this method is that the 
entire gene function is obliterated. Recently this method has been 
employed to disrupt mouse homeobox genes (Zimmer and Gruss, 1989; 
Chisaka and Capecchi, 1991; Le Mouelic etal 1992; Lufkin etal 1991). As 
might be expected most of the mice carrying these mutations have not 
survived, probably due to the fundemental importance to development of 
the homeobox genes. However, there is an exception, the Hox 3. V1' null 
mutation generated by (Le Mouelic et al 1992) has survived to sexual 
maturity and produced viable offspring. The survival of these null-mutant 
mice is probably indicative of the ability of other Hox family members to 
take over the role of the missing gene. This may not be a direct action of 
the Hox genes but possibly an indirect response to the lack of the missing 
genes signal and a change in the gradient of expression normally observed 
with Hox genes. It is unlikely that this method of gene disruption would be 
applicable to the TGF-p family of genes. There are also many areas of 
morphogenesis where the TGF-p genes are possibly interacting directly or 
indirectly. Whether the other TGF-p genes could replace the function of the 
lost gene, without disrupting the smooth developmental progression is 
doubtful. However, the example of leukaemia inhibitory factor (LIF) which 
is thought to be fundemental to mouse embryo implantation, can be 
knocked out without changing the viability of the mouse, may indicate that 
TGF-ps are not necessary either (Stewart et al 1992). If, however, the 
TGF-p mutated gene, or mutational event, could be targeted to a specific 
tissue at a specific time then this would provide a more useful model for 
examining the role(s) of TGF-p isoforms. Recently, Hasty et a /(1992) have 
described a “hit and run” approach to mutation of Hox genes. This method 
allows the selection of very specific mutations in genes which may 
circumvent the problem associated with previous homologous 
recombination techniques and allow the TGF-p genes to be targeted in a 
more subtle fashion.
The use of antisense RNA as a method of disrupting gene function has 
also been successfully attempted in vitro (Anfossi et al 1989; Becker et al 
1989; Goodchild et al 1988; Wickstrom et al 1988). These authors all 
utilised short antisense oligonucleotides to knock out gene function, though
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there is no known limit on the size of the antisense RNA which could be 
used. This might be particularly significant as the requirement for 
specificity, especially when dealing with genes like the TGF-ps which share 
high sequence homology, is important. Whether an antisense RNA would 
be able to bind and control expression of the targeted gene is not clear. It 
has been demonstrated that Xenopus oocytes contain naturally occurring 
antisense transcripts of bFGF (Kimelman et al 1988). Although the 
antisense RNA produced a protein it was also shown to interact with the 
sense RNA, possibly regulating the expression of the normal gene product. 
If the cell has the ability to cope with antisense RNA molecules and allows 
them to interact with sense RNA then this approach seems to offer 
considerable scope for the generation of dominant-negative mutations. 
Cockayne etal (1991) have employed this approach to knock out the gene, 
granulocyte-macrophage stimulating factor (GM-CSF). They generated 
stable transfected cell lines containing a portion of the GM-CSF coding 
sequence, in the reverse orientation, driven by a B19 parvovirus promoter. 
They were able to show a reduction to 10% of normal levels of GM-CSF 
production. However, Cockayne et al (1991) could not prove conclusively 
that the reduced level of GM-CSF was due to the formation of RNA 
duplexes between the endogenous antisense RNA and their sense RNA, 
due to clonal heterogeneity observed in the transfected cell populations.
The generation of mutants which compete with wild-type gene products 
also offer a method by which to knock out a specific gene function 
(Meeks-Wagner and Hartwell, 1986). The over-expression of the mutant 
gene product might compete with the wild-type gene product at a variety of 
levels, depending on the function of that particular protein. In the case of 
TGF-ps there exists a potential variety of sites which could be mutated. 
These include the areas of the protein which bind to the numerous 
promoters and other active sites. This method of creating a dominant- 
negative mutant is complicated by the fact that no active sites on the TGF- 
p isoforms have as yet been identified. Recently, an analysis of regions of 
mature TGF-p polypeptide, by generation of TGF-pi-2-1 and assessing the 
chimaeras biological activity, has been reported (Qian etal 1992). This sort 
of analysis will provide information useful for determining areas to mutate.
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The approach, to generating a dominant-negative mutation, in this thesis 
concentrated on the genration of a mutant TGF-p protein which would have 
the potential to bind to endogenous wild-type TGF-p protein forming a 
heterodimer. The lack of a particular structure in the mutant protein would 
result in the heterodimer being unable to function at normal levels and 
therefore reduce the bioactivity of TGF-p. The TGF-p protein contains a 
number of sites which are suitable for the introduction of subtle mutations. 
These include the signal peptide sequence, the N-glycosylation sites, the 
proteolytic cleavage site and the cysteine residues. Gross mutations 
including the complete removal of the sequence of DNA which encodes 
either the LAP or the mature region are also possible targets for analysis.
Recently, site-directed mutagenesis of PDGF-A cDNA to disrupt the 
proteolytic cleavage site and substitution of a cysteine residue for a serine 
residue resulted in the succesful generation of stable dominant-negative 
mutations, described by Mercola et al (1990). Mercola et al (1990) 
demonstrated the ability of both types of mutation to inhibit wild-type 
PDGF-A activity but only the protein carrying the Cys to Ser change had 
the ability to disrupt the activity of PDGF-B. Brunner et al (1989) described 
mutagenesis of a simian TGF-p1 cDNA to change cysteine residues to 
serine residues in the translated protein. They chose which cysteine 
residues to mutate based upon the expected function in the formation of 
the 3-D structure of the protein. One cysteine residue was involved in 
inter-subunit disulphide bonds between the LAP and mature region at 
amino acid position 33. The other cysteine residues were involved in 
disulphide bonding within the mature peptide at amino acid positions 
223/225. They generated two mutant TGF-pi cDNAs and subcloned them 
into the jcH3M vector and transiently transfected COS cells. They 
demonstrated that the position 33 had normal biological activity but did not 
require acid activation. The other mutation, at position 223/225, did require 
acid activation but produced the equivalent of five times normal biological 
activity. These mutant TGF-p1 proteins were not generated for their 
potential dominant-negative activity. Instead they have provided valuable 
insights into how the interaction of disulphide bonds between the LAP and 
the mature region act in TGF-p proteins. However, it might be possible to 
take the mutated cDNA which has five times normal activity and use that
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as the basis for generating a dominant-negative mutation which might 
compete with wild-type TGF-p proteins.
4.3.1 Which TGF-p isoform to mutate and where to mutate 
it
In this thesis, human TGF-p2 was chosen as a starting cDNA for the 
attempt to create dominant-negative mutants. The reasons for this choice 
were twofold. Firstly, from the in situ hybridisation analysis, our main 
interest had been the function of TGF-p2. The expression pattern of mouse 
TGF-p2, included many epithelial sites of expression and in particular 
expression in the myocardium of the heart at a time of valve formation. 
From the data presented in this thesis, it had been speculated that TGF-p2 
was the molecule that induced an epithelial/mesenchymal transformation 
at the region of the presumptive heart valve and regulates epithelial 
differentiation. It was hoped that the generation of a dominant-negative 
mutant for TGF-p2 could be used, eventually, to specifically knock out 
wild-type TGF-p2 at that particular developmental stage. Secondly, at the 
initiation of the project this was the only cDNA which was immediately 
available which possessed both 5’ and 3’ untranslated regions.
Two mutations of human TGF-p2 were generated. These were (a) deletion 
of the signal peptide sequence which makes up the first 19 amino acids 
and (b) ablation of the cleavage site sequence by site directed 
mutagenesis. These sites were chosen for mutation rather than either the 
N-glycosylation sites or the other cysteine residues for a variety of reasons. 
Firstly, the N-glycosylation sites were discounted as it had been reported 
that prevention of glycosylation of the LAP by endoglycosidase F had 
resulted in the activation of the TGF-p protein (Miyazono and Heldin 1989). 
Miyazono and Heldin (1989) suggested that removal of carbohydrate 
structures might be a method of activation of the TGF-p protein. Sha et al 
(1989) investigated further the role of glycosylation on the activity of TGF-p 
protein. They described the prevention of secretion, and increase in 
cellular levels of the LAP, when cells expressing TGF-pi were treated with 
tunimyacin, which blocked the glycosylation steps. However, when they 
treated the cells with swainsonine, which inhibits correct glycoprotein 
processing, the abnormal TGF-p1 proteins containing the altered
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carbohydrates were secreted readily by the cells. They suggested that 
oligosaccharide addition, and remodelling, are important for secretory exit 
of TGF-pi, but play no role in the specific proteolysis to activate TGF-pi. 
Sha et al (1989) did not investigate the biological activity of media from the 
cell line expressing TGF-p1, but relied solely on detection of radio-labelled 
protein extracts or Western blots. They did note that the levels of LAP and 
mature protein were at a comparable ratio to each other in the cell lysates, 
which they suggested meant that no active mature protein was released 
from the cell. However, since most TGF-p antibodies can only detect a 
minimum of 1-5ng of TGF-p protein, this analysis does not indicate the 
potential inactivivty, especially when only picogram quantities of TGF-p are 
required for biological activity.
The cysteine residues also offer a target for generation of mutations by site 
directed mutagenesis. However, the number of potential target sites 
available, combined with the lack of knowledge concerning their specific 
role, made the cysteine residues an unappetising target. Brunner et al 
(1989) had already shown that alteration of some of these cysteine 
residues to serine reidues had resulted in activation of the protein. 
Although this had been expected since it was known that the particular 
residues they altered were involved in inter-disulphide bonding (see 
above).
4.3.2 Biological activity of homodimers and heterodimers 
of mutated human TGF-|32
The two wild-type constructs, p i33 and p2, were estimated to be producing 
215pg/ml and 105pg/ml respectively. This does not compare with the 
production of 60-90ng/ml reported by Brunner et al (1989) when using the 
exact same p i33 construct. The only difference between the method 
employed in this thesis and that employed by Brunner et al (1989) was in 
the transfection protocol. Although almost identical, Brunner et al (1989) 
transfected their constructs into the COS cells in NuSerum (In this thesis 
the transfection was carried out in DMEM + 10%FCS). Nuserum, is 
normally used for the growth of primary cultures and was not considered 
ideal for stable cell line growth. The method of Brunner et al (1989) was
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attempted, but during and after cell transfection, cell death was 
considerable with over 80% of cells lost. This technique was not pursued 
further, and although the production of TGF-p polypeptides by the method, 
described in this thesis, was lower than expected, it was producing 
quantities of TGF-p which were detectable in a biological assay.
The transfection efficiency was determined to be in the expected range of 
50-90% by analysing COS cells which had been transfected with the 
construct pIRV (Beddington et al 1989). The problem with lack of 
production does not seem to be poor transfection efficiency, although this 
can only be judged by comparison with the efficiency of the pIRV 
transfection. If the expected number of DNA molecules are getting into the 
cells then maybe there is a breakdown in the replication, transcription or 
translation steps.
Another possibility is the sensitivity of COS-7 cells to TGF-p. Previous 
reports which involved the use of the aH3M vector utilised COS-1 cells, 
although Brunner et al (1989) did not specify which type of COS cell they 
used. Both these cells are derived from the same source and have been 
transformed with an SV40 virus which lacks an origin of replication. Both 
are reported to be able to support vectors such as aH3M. The continuous 
culture of cells can lead to changes in phenotype and the COS-7 cells may 
have developed sensitivity to TGF-p. If this was the case then the COS 
cells might go through a selection procedure killing off many of the cells. 
Cell death was not extensive after 24 or 48 hours although by 72 hours it 
was beginning to increase, although this was, probably, as much to do with 
the fact that the cells were cultured in serum-free medium.
The aH3M vector is designed specifically to give high copy number in COS 
cells, which have been transformed by an origin-defective mutant of SV40. 
The cells support the growth of recombinant SV40 viruses. As the atH3M 
vector has been designed with an SV40 origin of replication, there is a 
massive replication of the aH3M vector to between 10,000 and 100,000 
copies per cell (Kaufman, 1990). Since the constructs were generated from 
a jcH3M-TGF-pi33 construct described and provided by Brunner et al
(1989) which had been proven to generate nanogram quantities of protein, 
then it would be unlikely that there was a mistake in the vector resulting in
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either defective replication or transcription. This is based on the 
assumption that this is indeed the correct construct as determined by 
restriction endonuclease digests. The lack of high copy number in the cell 
lines was not tested at the time although this is possible by re-extracting 
the construct from the cells and possibly estimating the concentration, of 
plasmid DNA, compared with what was initially transfected. However, this 
would not tell you if the lack of copy number was due to defective 
replication caused by a defect in the cell line or a defect in the construct.
The transfections were carried out at least twice and the biological activity 
assayed twice for each transfection, each time in triplicate. This was 
carried out by measuring growth of the epithelial cell line CCL64, in a 
standard biological assay, after they had been incubated with conditioned 
media from COS cells which had undergone transfection with the various 
constructs, either individually or as co-transfections.
The mutant constructs p2c (cleavage site mutant) and p2f (in frame signal 
peptide mutant) had a reduced biological activity compared to p2, although 
it was not completely lost. This suggests that these two mutants were not 
inactivating the effect of TGF-p2 polypeptide, and it was being produced, 
cleaved and secreted normally. This was borne out by the analysis of a 
comparison of these mutants co-transfected in the ratios described with 
wild-type human TGF-p2. All the mean percentages of 3H-thymidine 
incorporation were below the mean produced by hTGF-p2. This probably 
reflects the increase in number of copies of vector, whether mutant or wild 
type being introduced into the COS cells. When the means were compared 
by Student’s t-test, p<0.1 which is not significant and the null hypothesis is 
not rejected.
Mutant p2®, which contained the frame-shift mutation produced a mean of 
incorporation at 83% after 4 units of construct had been transfected. 
Comparison with rTGF-p1 standard curve suggested that this mutant was 
producing between 0-100pg/ml. The pIRV construct which was employed 
to test the efficieny of transfection also provided a mean of 82% which 
might reflect the basal level of activity of COS cells after transfection 
estimated at 35pg/ml. Co-transfection of this mutant with wild-type TGF-p2
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did not significantly alter the mean level of incorporation of 3H-thymidine, 
observed with (32, in the CCL64 cells.
To test the specificity of the mutant (32 constructs they were co-transfected 
with (3133 in the same ratios as described above. Means of ^-thymidine 
incorporation of the various co-transfections were compared to the mean 
generated from (3133 construct transfected alone. This was also done by 
Student’s t-test. The value of p was determined to be: p<0.5 or 0.5<p<0.1 
for most of the co-transfections which is not significant. However, the 
cotransfection of |32c in a 1:1 ratio with (3133, (mean 74% ±14.1%) did 
produce a value of p between 0.1 and 0.05. This level of significance 
probably does not mean rejecting the null hypothesis that there is no 
difference between the means.
4.3.3 Mutations introduced into human TGF-[32 do not alter 
biological activity.
Two of the three hTGF-|32 mutations generated in the latter half of this 
thesis do not produce a slight reduction of biological activity. The other 
mutation, (32°, does not appear to generate detectable levels of activity and 
might either not be stable or be translated.
The likelihood that |32® does not translate to a protein is quite high. The 
most likely reason for this is the requirement of the construct to generate a 
protein from a secondary ATG codon some 87bp downstream of the 
original ATG. The lack of biological activity ascertained from this construct 
probably reflects the inability of the translational machinery to recognise 
anything but the original ATG initiation site. If this is the case, then the 
polypeptide generated from this site enters a frame shift at position 5 and 
hits a stop codon at position 24. The fate of this short polypeptide is 
unknown.
The reason for the other two mutants not behaving in a dominant-negative 
manner obviously stems from the fact that the both produce some level of 
activity.
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The p2f mutant which lacks the DNA sequence encoding the signal peptide 
demonstrates that this structure is not required for TGF-p2 to follow the 
normal secretory pathways, and that it can find it’s own way out of the cell, 
whether by passive means or by attachment to other polypeptides involved 
in a secretory pathway. This would account for the lack of inhibition of 
activity of wild-type forms of TGF-p.
What is the signal peptide for, if it is not required for secretion from the 
cell? Secreted proteins are generally synthesised with an N-terminal 
signal sequence 15-25 residues long, which somehow initiates the export 
process. Several functions have been associated within this short peptide. 
These include mediation of interaction between ribosome and the signal 
recognition peptide which arrests translation until an occupied site on the 
membrane is found (Perlman and Halvorson, 1983). It is also thought that it 
may influence the release of the polypeptide from the ribosome. It also 
contains the information required to remove it from the rest of the 
polypeptide (Von Heijne, 1984). It is quite possible that it is used to secrete 
TGF-p2 across organelle membranes within the cell itself. This would 
suggest that TGF-p2 functions in an intracrine manner, which is supported 
by data from the in situ hybridisation analysis, (presented in this thesis and 
Gatherer eta! 1990, Schmid etal 1991) which described the localisation of 
TGF-p2 RNA in many epithelial cells which were undergoing differentiation. 
This does not preclude TGF-p2 operating in a paracrine manner. Whether 
this is the case for TGF-pi and TGF-p3 could be ascertained by deletion of 
their signal peptide sequences. Cell lines which are known to respond to 
TGF-p2 in an autocrine manner could be transfected with the (52f mutant to 
establish whether this suggestion is true. It is unknown which organelle 
TGF-p2 acts upon in the cell, although recently it has been reported that 
TGF-pi is localised in the mitochondria of rat and mouse cardiomyocytes 
(Heine eta! 1991).
The levels of activity observed with the mutant p2c and it’s lack of effect, 
when co-transfected with p2 and p133, on biological activity was 
disappointing. Complete biological inactivity was not observed. Mercola et 
al (1990) and Lopez et al (1992) have both described the generation of 
dominant-negative mutations based on alteration of cleavage recognition 
site in PDGF-A and TGF-pi respectively.
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Six mutations were generated by Lopez et al (1992) designed to 
specifically knock out TGF-p1. Three of the mutations were generated by 
disruption of the N-glycosylation sites, at amino acid positions 82,136 and 
both (82-136). This was achieved by replacing the asparagine residues 
with glutamine residues. A further two mutants were generated by deletion 
of a small charged peptide sequence (residues 42-63 of the LAP, which is 
found in all three TGF-p isoforms). The final mutation involved the 
alteration of the tetrabasic proteolytic cleavage site which would prevent 
release of the mature protein from the LAP. The mutant TGF-pi genes 
were expressed in human 293S cells, known to secrete very little TGF-p.
Lopez et al (1992) demonstrated that conditioned media from transfected 
cell lines was assessed for presence of TGF-pi by immunoprecipitation. 
The two mutations which carried the single altered N-glycosylation site 
showed reduced levels of TGF-p in the conditioned media. However, the 
mutant TGF-pi which contained both disrupted N-glycosylation sites 
showed no secreted TGF-pi, and was apparently more succesful than the 
constructs carrying the individual N-glycosylation mutations at preventing 
correct processing. The most succesful mutation described by Lopez et al 
(1992) was the construct which had had residues 42-63 of the LAP 
removed. They also described succesful inhibition of secretion of TGF-pi 
generated from the construct which had the proteolytic cleavage site 
altered.
Lopez et al (1992) continued by investigating the specificity of action of the 
dominant-negative mutations. They described co-transfections of the 
mutants with constructs carrying wild-type TGF-pi, 2, and 3 and showed 
that the mutations would inhibit secretion of TGF-p2 and TGF-p3 but that 
they would preferably form dimers with TGF-p1. The mutant constructs 
described by Lopez et al (1992) did not interfere with secretion of protein 
from other members of the TGF-p superfamily or unrelated polypeptides.
However, Lopez et al (1992) did not describe biological activity of the 
various constructs on their own, or from co-transfections with wild-type 
constructs. Even if this mutant only prevented secretion of 99% of the 
wild-type polypeptide the remaining 1 % may still retain enough biological 
activity to elicit a normal response. Mercola et al (1990) demonstrated
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reduced levels of PDGF-A by both biological response assays and 
immunoprecipitation. The effect of the mutant construct was dependent 
upon its concentration against the concentration of the wild-type PDGF 
construct. A ratio of 4:1 in favour of the mutant construct almost obliterating 
the biological activity of the wild-type PDGF-A polypeptide.
Why these mutations, described by Lopez et al (1992) and Mercola et al 
(1989), operated in the expected manner and the mutations generated 
during this project did not, may be due to two reasons. Firstly, the mutation 
of the cleavage site in PDGF polypeptide resulted in the change from four 
basic amino acids to one. Lopez et al (1992) described the complete 
alteration of the TGF-|31 cleavage site leaving no basic residues. The (32° 
mutant generated in this project left two adjacent basic residues intact, 
although the other three were changed (Arg-Arg-Lys-Lys-Arg to Leu- 
Gln-Lys-Lys-Leu). It is known that specific proteases can cut the protein 
when only one basic residue is present, but usually they recognise a 
specific peptide sequence (Schulz and Schirmer 1985). This suggests that 
the two basic Lys residues provided enough of a recognition site for 
proteolytic cleavage. However, it is clear that at least 4 times the amount of 
construct had to be transfected into the COS cells, to produce a 
comparable level of biological activity to that described for COS cells which 
had been transfected with only 1 unit of |32. Secondly, it is possible that 
proteolytic cleavage was occurring at an alternative site. If this was the 
case then an alternative size of mature polypeptide would be produced 
which could possibly be detected by Western analysis. Unfortunately 
Western analysis was precluded in this thesis because of the low levels of 
production of TGF-|3 proteins, (estimated concentrations were based on 
biological assays of rTGF-(31), and the requirement for a minimum of 5ng 
of protein for antibody detection.
4.4 Conclusions and perspectives
One of the most interesting pieces of information to emerge from the 
expression studies of the TGF-(3 isoforms presented here and elsewhere is 
the fact that each has a unique pattern of expression both temporally and
- 1 5 0 -
spatially (Lehnert and Akhurst 1988, Pelton et al 1989, FitzPatrick et al 
1990, Gatherer et al 1990, Pelton eta! 1990, Schmid etal 1991, Millan et 
al 1991). There are occasional areas of overlap, such as whisker follicles, 
tooth buds, but in general the RNA of each isoforms has a specific and 
unique pattern in which it is expressed. It brings to the fore the question of 
why is there a requirement for such identical mature proteins to have these 
unique patterns of expression? One answer is that each TGF-p isoform 
has a unique function, which only that isoform can perform, in vivo. This is 
not necessarily borne out by the accumulation of data concerning the 
biological activities of the three isoforms. In most biological systems they 
are interchangeable, but there are exceptions, for instance only TGF-p2 
can promote mesoderm induction in Xenopus (Rosa et al 1992). A more 
probable explanation might be that the three genes have essentially 
identical functions in vivo (as expected from in vitro data), but that the 
diversity of the promoter regions play a vital role in expression of the three 
genes. To complicate the situation further, the interaction of the isoforms 
with receptors has to be considered. As has been described, there have 
been seven receptor types found which interact with TGF-p. The specificity 
for each of the receptors with respect to the TGF-p isoforms has not been 
fully characterised, but the fact that most cell types, with notable 
exceptions, seem to express at least one receptor indicates another level 
of control of TGF-p activity. An obvious next step in the understanding of 
the role of TGF-p genes in development might be the elucidation of the 
expression patterns of the various receptor genes.
One of the most obvious problems when attempting to interpret RNA 
localisations studies, is that of whether the TGF-p protein is active at the 
site of synthesis, or is it excreted from the cell and activated elsewhere. 
This problem has been answered to a certain extent by the RNA and 
protein data generated concerning TGF-p1 (Heine et al 1987, Lehnert and 
Akhurst 1988). A comparison of the protein and RNA expression patterns 
indicated that TGF-pi could act in a paracrine or autocrine manner. 
Whether the same can be said of TGF-p2 and TGF-p3 has been partially 
resolved by comparison of protein localisation data generated recently 
(Pelton et al 1991, Flanders et al 1991, Akhurst et al 1992 ). The 
localisation of protein for both these genes occurred, like TGF-p1, either in
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cells where RNA had been observed, or in adjacent cells. This suggests 
that both TGF-[32 and TGF-|33, like TGF-pi, are undergoing extensive 
post-transcriptional control and operating in a paracrine or autocrine 
manner.
There is abundant evidence in the literature of the control exerted upon the 
ECM and its constituent parts by TGF-ps. Not only are they known to 
upregulate a variety of proteins they are also known to inhibit the 
production of proteases. An interesting and important question is what 
regulates the TGF-ps? How do the TGF-p genes know when to switch on, 
and just as importantly, off? There is considerable evidence accumulating 
that TGF-p genes, like many other developmentally important genes, 
respond to morphogens. So far only one natural morphogen, retinoic acid, 
has been identified in mammals (Tickle etal 1982). This has been shown 
to regulate the expression of TGF-ps in vitro, especially TGF-p2 (Glick etal 
1991). it may be a possibility that the TGF-ps are regulated by other 
morphogens which are yet to be discovered. Recently TGF-p2 has been 
shown to be activated by the retinoblastoma (pRB) gene product through 
the transcription factor ATF-2 (Manova et al 1992). A full investigation into 
the transcriptional control of the TGF-ps can only provide insights as to 
how cellular mechanisms utilise TGF-p.
The role of TGF-p isoforms has begun to be investigated more directly with 
the attempts to generate mutations which can increase the level of 
expression, act in a dominant-negative manner or have different pieces of 
genes spliced into each other to determine the active sites of the protein 
(Brunner et al 1989a; Lopez-Casillas et al 1991; Qian et al 1992). The 
attempts, presented in this thesis, to generate dominant-negative 
mutations have pointed out the pitfalls in attempting such a course of 
action. The deletion of signal peptide from TGF-p2 apparently has no effect 
on secretion from the cell. What can this suggest as to the function of the 
signal peptide sequence of TGF-p2, and will its function be the same as 
that of the signal peptide sequence of TGF-pi or TGF-p3. The mutation of 
the cleavage sequence, had no discernible effect on the biological activity 
of wild-type polypeptides. There did appear to be limited inhibition of 
proteolysis at the mutated site, but not enough to prevent activation in vitro.
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The investigation into the generation of mutations to analyse the role of 
TGF-p isoforms will eventually move into the realms of transgenic 
technology. However, before this should be embarked upon two important 
areas cannot be overlooked. These are control of expression in the cell or 
tissue of study and, specificity of action.
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Appendix A
Source of chemicals and enzymes 
A.1 Chemicals
agarose Sigma
ampicillin Sigma
bacto Agar Difco
bacto Tryptone Difco
bovine Serum Albumin (BSA) Sigma
BSA, DNase free Gibco
BRL
BSA, DNAse and RNAse free Pharmacia
chloroform BDH
Decon 90 Decon
Labs
a-22? deoxycytodine triphosphate Amersham
deoxyribonucleotides Pharmacia
dextran Sulphate Pharmacia
diethylpyrocarbonate (DEPC) Sigma
dithiothreitol Sigma
Dulbecco’s modified Eagle’s medium Gibco
BRL
EDTA BDH
eosin BDH
ethanol University
store
ethidium bromide Sigma
foetal Calf serum NBL
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ficoll Pharmacia
formamide Fluka
formaldehyde BDH
t - 32?  deoxyadenosine triphosphate Amersham
GeneClean Kit B io
101
glutamine Gibco
BRL
guanidium thiocyante Fluka
Histoclear National
Diagnostics
Harris’ haemotoxylin Sigma
hydroxyquinoline Sigma
IPTG Sigma
isoamylalcohol Sigma
K5 nuclear track emulsion Ilford
MOPS sodium salts Sigma
Panatomic X film Kodak
Pan F film Kodak
paraformaldehyde Sigma
phosphate buffered saline (PBS) Gibco
BRL
PBS without Ca2+ or Mg2+ Gibco
BRL
phenol (Water saturated) Rathburn
Chemicals
phenisol developer Ilford
polyvinylpyrolidine Sigma
proteinase K Sigma
random prime DNA labelling kit Boehringer
Mannheim
Repelcote (2% Silane solution) BDH
ribonucleotides Pharmacia
ribosomal RNA Boehringer
Mannheim
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RNA ladder Gibco
BRL
salmon sperm DNA Sigma
7X detergent Sterilin
Sephadex G50 (medium) Sigma
spermidine Sigma
tetracycline Sigma
tetramethylethylenediamine (TEMED) BDH
TESFA Sigma
3H thymidine Amersham
TGF p antibody detection kit British
Biotec
triethanolamine Sigma
tris base Sigma
a-35S uridine triphosphate Amersham
UTP-S NEN
yeast extract Difco
X-gal NBL
A.2 Enzymes
Alkaline Phosphatase Boehringer
Mannheim
DNAse I (RNAse free) Pharmacia
Klenow fragment (DNA polmerase I) NBL
Restriction endonucleases NBL,
Pharmacia,
Stratagene,
BCL
RNA guard Pharmacia
RNAse A Sigma
T7 RNA polymerase Gibco
BRL
T3 RNA polymerase Gibco
BRL
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T4 DNA ligase Pharmacia
T4 polynucleotide kinase Stratagene
Protease inhibitors Sigma
All other common laboratory chemicals not mentioned above were 
supplied by BDH (Analar grade).
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Appendix B 
Statistical equations for Student’s t test
Zx^ = sum of the squares in observation in sample 1 
Zx22 = sum ° f the squares in observation in sample 2 
(Zx-j)2 ■ square of the total of the observations in sample 1 
(Zx2)2 = square of the total of the observations in sample 2
sum of the squares of the difference from their respective means:
ZCx-j-x-i) ^  Zx^-CZx^/n-,
Z(x2-x2)2= Zx22-(Zx2)2/n2
The variance for the two samples combined is:
(Zbcj-x,)2 -  Z (x2-x2)2)/ OvU+OvU = SD2
The divisors nr 1 and n2-1 represent degrees of freedom.
The standard error of the difference between the means is:
SE diffeVSD^+SD2/^
When the difference between the means is divivded by this standard error 
the result is t.
Thus t=X! -Xg/VSC /^n ^ +SD2/n2
The probability for a given value of t can be looked up in statistical tables, 
with O vD+GvD degrees of freedom.
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